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Summary 
P1-receptors, or adenosine receptors, and P2Y receptors, are G-protein-coupled 
receptors, belonging to the purinergic receptor family. Adenosine is the natural ligand 
of the P1 receptors, while P2Y receptors are activated by nucleotide ligands (ATP, 
ADP, UTP and UDP). The adenosine receptors (P1) consist of 4 receptor subtypes: 
A1, A2A, A2B and A3.  The P2Y receptors are subdivided in 8 subtypes: P2Y1, P2Y2, 
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14. In the first part of this work (chapter 2 and 
3), we present the synthesis and biological evalutation of two series of adenosine A3 
receptor ligands. In the second part (chapter 4), we discuss the synthesis and 
biological evaluation of new P2Y2 receptor ligands. 
Adenosine receptors are not only the major targets of caffeine, the most commonly 
consumed drug in the world, they could also be promising therapeutic targets in a 
wide range of conditions, including cardiovascular, inflammatory and 
neurodegenerative diseases. As a consequence of their numerous therapeutic 
possibilities and the ubiquity of the ARs, synthetic ligands need high selectivity with 
respect to receptor subtype and tissue to be of therapeutic value. The main approach 
for the discovery of selective A3AR ligands, has been the modification of the natural, 
non-selective ligand adenosine. Previous investigations showed that introduction of a 
3’-amino group improved the selectivity for the human A3AR, while enhancing the 
water solubility. By introducing extra modifications, we evaluated the possibility of 
overcoming the A3AR affinity drop caused by this 3’-modification. We synthesized a 
series of hypermodified adenosine derivatives (chapter 2) and demonstrated that 
introduction of a 2-phenylethynyl substituent in concert with a N6-methyl group 
restored the A3AR receptor affinity. 
Based on the good results obtained with the 2-phenylethynyl modification, both on 
A3AR receptor selectivity and affinity, we decided to further explore the modifications 
at the 2-position. Therefore, we synthesized a series of 4-substituted 2-(1,2,3)-triazol-
1-yl N6-methyl adenosine analogues via Huisgen [3+2]cycloaddition (chapter 3). 
Combined with an unmodified ribose moiety, such 2-(1,2,3-triazol-1-yl) substitution 
resulted in very potent and selective A3AR antagonists, for example 2-(4-
cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(β-D-ribofuranosyl)adenine (3.10, Ki 
(A3AR) = 1.3 nM). The reduced efficacy resulting from such modifications at the 2- 
viii 
position were restored by the 4’-ethylcarbamoyl ribose modification, resulting in a 
series of potent an selective A3AR agonists, with 9-(5-ethylcarbamoyl-β-D-
ribofuranosyl)-N6-methyl-2-(4-pyridin-2-yl-1,2,3-triazol-1-yl) adenine as the most 
potent one (3.17b, Ki (A3AR) = 1.8nM). 
P2Y2 agonists are promising potential therapeutics for cystic fibrosis, cancer and dry 
eye syndrome. P2Y2 antagonists exhibit anti-inflammatory and neuroprotective 
effects and have been suggested as potential treatment for coronary vasospastic 
disorders. As for the A3AR receptor ligands, the natural, non-selective ligand uridine 
5’-triphosphate was modified to gain access to more selective P2Y2 receptor ligands. 
Previous investigation demonstrated that the 2-thiouracil modification and the 2’-
amino-2’-deoxy modification enhanced both P2Y2 receptor affinity and selectivity. 
Therefore, we combined these modifications, which resulted in the very potent and 
selective P2Y2 receptor agonist 2’-amino-2’-deoxy-2-thiouridine 5’-triphosphate (4.2, 
EC50 (P2Y2) = 8 nM) (chapter 4).  
UTP and its diverse synthesized analogues are sensitive to enzymatic degradation. 
Replacement of the α-phosphate group by an isosteric phosphonomethyl group 
should enhance the metabolic stability. However, the resulting uridine 5’-
phosphonodiphosphate (4.7) suffered from complete chemical hydrolysis to the 
corresponding 5’-phosphonate (4.50) in the buffer storage solution (chapter 4).  
In summary, in this thesis we succeeded to identify new selective ligands for both 
envisaged receptor subtypes: the A3A and the P2Y2 receptors. 
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Samenvatting 
 
P1-receptoren of adenosine receptoren en P2Y2 receptoren zijn G-proteïne 
gekoppelde receptoren die behoren tot de familie van purinerge receptoren. De P1 
receptoren herkennen adenosine als natuurlijke agonist, terwijl de P2Y receptoren 
geactiveerd worden door de nucleotiden ATP, ADP, UTP of UDP. Tot de adenosine 
receptoren (P1) behoren 4 receptor subtypes: A1, A2A, A2B en A3. De P2Y receptoren 
worden onderverdeeld in 8 subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, 
P2Y14. In het eerste deel van dit werk (hoofdstuk 2 en 3) wordt de synthese en de 
biologische evalutatie van een aantal liganden voor de adenosine A3 receptor 
voorgesteld. In het tweede deel (hoofdstuk 4), wordt de synthese en de biologische 
evalutatie van nieuwe P2Y2 receptor liganden besproken. 
Adenosine receptoren zijn niet enkel verantwoordelijk voor het effect van caffeïne, de 
meest gebruikte drug ter wereld, het zijn eveneens beloftevolle doelwitproteïnen voor 
een brede waaier van therapeutische toepassingen, zoals de behandeling van 
cardiovasculaire, inflammatoire en neurodegeneratieve aandoeningen. Hun ruime 
therapeutische mogelijkheden en de wijdverspreide aanwezigheid van de 
verschillende AR subtypes in ons lichaam zorgen ervoor dat gesynthetiseerde 
liganden subtype- en weefselselectief moeten zijn om therapeutisch bruikbaar te zijn. 
Modificatie van de basistructuur van het natuurlijke, niet-selectieve ligand adenosine 
kan leiden tot A3AR selectieve liganden. Vroeger onderzoek leerde dat introductie 
van een 3’-amino functie zowel de selectiviteit voor de A3AR, als de 
wateroplosbaarheid ten goede komt. Deze 3’-modificatie verminderde echter de 
affintiteit voor de receptor. Om te onderzoeken of extra modificaties dit 
affiniteitsverlies konden compenseren, synthetiseerden we een aantal 
hypergemodificeerde adenosine derivaten (hoofstuk 2). Invoering van een 2-
fenylethynyl substituent, in combinatie met een N6-methyl groep bleek in staat de 
affiniteitsdaling veroorzaakt door de 3’-amino modificatie te herstellen. 
Op basis van de goede resultaten bekomen met de 2-fenylethynyl modificatie, zowel 
wat affiniteit als selectiviteit voor de A3AR betreft, werd besloten de 2-positie verder 
te exploreren. Hiervoor werd via Huisgen [3+2]cycloadditie een reeks 4-
gesubstitueerde 2-(1,2,3-triazol-1-yl) N6-methyl adenosine analogen gesynthetiseerd 
(hoofdstuk 3). Gecombineerd met een ongemodificeerd suikergedeelte, leverde deze 
x 
2-(1,2,3)-triazol-1-yl substitutie zeer potente en selectieve A3AR antagonisten op, 
zoals bv. 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(β-D-ribofuranosyl)- 
adenine (3.10, Ki (A3AR)= 1.3 nM). Door invoering van een 4’-ethylcarbamoyl groep 
kon de intrinsieke activiteit voor de A3AR teruggewonnen worden. Deze ribose 
modificatie resulteerde in een reeks potente en selectieve A3AR agonisten, waarvan 
9-(5-ethylcarbamoyl-β-D-ribofuranosyl)-N6-methyl-2-(4-pyridin-2-yl-1,2,3-triazol-1-yl) 
het meest potente derivaat was (3.17b, Ki (A3AR) = 1.8nM). 
P2Y2 agonisten zijn potentiële geneesmiddelen voor de behandeling van 
mucoviscidose, kanker en het droge ogen-syndroom. P2Y2 antagonisten zijn anti-
inflammatoir, neuroprotectief en worden voorgesteld voor de behandeling van 
coronaire vasospasmen. We onderzochten of modificaties van het natuurlijke, niet 
selectieve P2Y2 receptor ligand uridine 5’-trifosfaat (UTP) aanleiding kan geven tot 
meer selectieve P2Y2 receptor liganden.  Vroeger onderzoek toonde aan dat de 2-
thiouracil modificatie en de 2’-deoxy-2’-amino ribose modificatie elk afzonderlijk de 
affiniteit en selectiviteit voor de P2Y2 receptor verhoogden. Daarom kozen we voor 
de combinatie van beide modificaties, wat aanleiding gaf tot de zeer potente en 
selectieve P2Y2 receptor agonist 2’-amino-2’-deoxy-2-thiouridine 5’-trifosfaat (4.2, 
EC50 (P2Y2) = 8 nM) (hoofdstuk 4).  
UTP, alsook de diverse reeds gesynthetiseerde UTP analogen zijn onderhevig aan 
enzymatische degradatie. Vervanging van de α-fosfaat groep door een isostere 
fosfonomethylgroep werd uitgevoerd om de metabole stabiliteit op te drijven. Het 
resulterende uridine 5’-fosfonodifosfaat (4.7) onderging echter complete chemische 
hydrolyse tot het overeenkomstige 5’-fosfonaat (4.50) in de bufferoplossing voor 
bewaring (hoofdstuk 4).  
Samengevat: tijdens dit onderzoek slaagden we erin om nieuwe selectieve liganden 
te identificeren voor beide beoogde receptor-subtypes: de A3A en de P2Y2 
receptoren. 
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1 INTRODUCTION 
 
1.1 Purinergic Receptors 
Extracellular purines [e.g., adenosine, adenosine 5’-diphosphate (ADP) and 
adenosine 5’-triphosphate (ATP)] and pyrimidines [e.g., uridine 5’-diphosphate (UDP) 
and uridine 5’-triphosphate (UTP)] are important signalling molecules that mediate 
diverse biological effects via cell-surface receptors termed purinergic receptors. 
These receptors were first formally recognized by Burnstock in 1978.1 He proposed 
that these receptors can be divided into two classes termed ‘P1-purinoceptors’, 
recognizing adenosine as principal natural ligand, and ‘P2-purinoceptors’, which are 
activated by ATP and ADP. Although receptor charactarisation is now based on 
distinct molecular structures of the receptors, this major P1/P2 division remains a 
fundamental part of purine receptor classification. In addition, receptors for 
pyrimidines are included within the P2 receptor family.2 
  
 
Figure 1.1 
Classification of the purinergic receptors 
 
The P1 and P2 receptor families (Figure 1.1) are both further subdivided according to 
convergent molecular, biochemical, and pharmacological evidence. The P1 receptors 
P U R I N E R G I C  R E C E P T O R S 
P 2 
P 2 Y 
P 1 
P 2 X 
a d e n o s i n e A T P 
i o n  c h a n n e l G P C R 
U T P 
A 3 A 2 B A 2 A A 1 
P 2 Y 1 P 2 Y 2 P 2 Y 4 P 2 Y 1 1 P 2 Y 1 2 P 2 Y 6 
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or adenosine receptors consist of 4 subtypes classified as A1, A2A, A2B and A3. P2 
receptors have broad natural ligand specificity, recognizing ATP, ADP, UTP, UDP, 
and some dinucleotides. The P2 receptors are divided naturally into two separate 
classes, based on whether they are ligand-gated ion channels3 (P2X receptors4,5) or 
coupled to G-proteins6 (P2Y receptors4,5). Seven mammalian P2X receptors have 
been cloned (P2X1-P2X7).7  At least seven different P2Y subtypes are observed, 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13, all of which have been cloned.8 
The recently cloned UDP-glucose (UDPG) receptor appears to belong to the same 
family and is designated as the P2Y14 receptor.9 In this thesis the synthesis and 
biological evaluation of a series of A3 adenosine receptor ligands and P2Y2 receptor 
ligands will be discussed. 
 
1.2 Adenosine Analogues and the Adenosine A3 
Receptor 
1.2.1   Adenosine 
Adenosine (1.1) is a nucleoside that consists of a sugar part, D-ribofuranose, which is 
linked to the purine base adenine via a β-glycosidic bond. Adenosine is metabolically 
and structurally related to the bioactive nucleotides adenosine 5’-monophosphate 
(AMP), ADP, ATP, and cyclic adenosine monophosphate (cAMP) and to the 
biochemical methylating agent S-adenosyl-L-methionine (SAM). The structures of 
ribonucleic acid (RNA) and the coenzymes nicotinamide adenine dinucleotide (NAD), 
flavin adenine dinucleotide (FAD) and coenzyme A are also derived from adenosine. 
N
NN
N
NH2
O
OHOH
HO
1'
2'3'
4'
5'
2
3
4
5 6 1
9
8
7
1.1
 
Figure 1.2 
Structure of Adenosine (1.1) 
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Adenosine is continuously formed intracellulary as well as extracellulary (Figure 1.3).   
Intracellular adenosine is formed by  
- dephosphorylation of AMP mediated by 5’-endonucleotidases, 10 , 11  which 
catalyse the enzymatic breakdown of intracellular ATP to adenosine  
- hydrolysis of S-adenosyl-homocysteine.12  
Extracellulary, adenosine formation  
- by dephosphorylation of ATP is catalysed by 5’-ectonucleotidases.13  
- from cAMP, released from neurons, occurs through its conversion to AMP by 
extracellular phosphodiesterases, followed by 5’-ectonucleotidase catalyzed 
AMP dephosphorylation.14  
- can be increased by N-methyl-D-aspartic acid (NMDA) receptor stimulation 
and by activation of the dopamine D1 receptors via a NMDA receptor 
dependent mechanism.15  
- can also be controlled by nitric oxide.16 
When extracellular adenosine levels are high, adenosine is deaminated by 
adenosine deaminase to inosine or transported into the cells either by active 
transport or by facilitated diffusion.  
Intracellular adenosine is either deaminated to inosine or phosphorylated to AMP by 
adenosine kinase (Figure 1.3).17 
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Figure 1.3 
Intracellular and extracellular formation of adenosine and adenosine metabolism.18 AC = adenylate cyclase; 
AMPD: adenosine monophosphate deaminase; AK = adenosine kinase, AMPK = adenosine monophosphate 
kinase; ADPK = adenosine diphosphate kinase; AL = adenylosuccinate lyase; AS = adenylosuccinate synthase; 
HGPRT = hypoxanthine guanine phosphoribosyl transferase; 5’N = 5’-endonucleotidase; PDE = 
phosphodiesterase; PNP = purine nucleoside phosphorylase; SAHase = S-adenosylhomocysteinase; XO = 
xanthine oxidase 
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1.2.2  The Adenosine Receptors: G-protein-Coupled 
Receptors 
G-protein-coupled receptors (GPCRs) constitute a large family of heptahelical, 
integral membrane proteins that mediate a wide variety of physiological processes, 
ranging from the transmission of light and odorant signals to the mediation of 
neurotransmission and hormonal action.19 Based on amino acid sequence similarity, 
the superfamily of GPCRs can be subdivided into five main families of receptors, 
named the glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin family 
(GRAFS classification). The adenosine receptors, as well as the majority of GPCRs 
identified to date, belong to the rhodopsin family (family A), which is also the best 
studied family, both structurally and functionally. The rhodopsin family consists of 
four main groups with 13 subbranches.20 
The different GPCR families are characterized by seven transmembrane (TM) 
domains of hydrophobic amino acids, constituting an α-helix of 21 to 28 amino acids. 
The N-terminal of the protein lies on the extracellular side and the C-terminal on the 
cytoplasmic side of the membrane. The TM domains are connected by three 
extracellular (EL1, EL2 and EL3) and three cytoplasmic hydrophilic loops (IL1, IL2 
and IL3). Two cysteine residues, one in TM3 and one in EL3, which are conserved in 
most GPCRs, form an essential disulfide link responsible for the packing and 
stabilization of a restricted number of conformations of these seven TM domains. A 
pocket for the ligand binding site is formed by the three-dimensional arrangement of 
the α-helical TM domains, and in the rhodopsin family the ligand is believed to bind 
with the upper half of this pore.2 An experimentally determined 3D-structure is still 
lacking for most GPCRs, due to the technical difficulties regarding X-ray 
crystallography and NMR experiments on membrane associated receptors. The best 
known GPCR structure, the high resolution X-ray structure of bovine rhodopsin has 
proven to be a suitable template for the resting state (resembling an antagonist-like 
state) of most family A GPCRs, including the A3AR. However, it is questionable 
whether this rhodopsin structure also represents an appropriate template for the 
active state (agonist-like state). 21,22  
Recently, Stevens et al.23 reported the crystal structure of a human β2-adrenergic 
receptor–T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 
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2.4 Å resolution. The engineered β2-adrenergic receptor included lysozyme in place 
of one of the intracellular loops, which reduced conformational heterogeneity and 
facilitated crystal nucleation. Although the location of carazolol in the β2-adrenergic 
receptor is very similar to that of retinal in rhodopsin, structural differences in the 
ligand binding site and other regions highlight the challenges in using rhodopsin as a 
template model for the large GPCR receptor family. 
G proteins initiate the receptor signalling cascade, responsible for the receptor 
mediated effect. There are two main classes of G proteins: heterotrimeric G proteins 
and small cytoplasmic G proteins. Heterotrimeric G proteins associate with G protein 
coupled receptors (GPCRs) and consist of an α-subunit and a tightly associated βγ-
complex (Figure 1.4). In the inactive state, the α-subunit is associated with the βγ-
complex and guanosine diphosphate (GDP) is bound to the α-subunit. Agonist 
binding on the GPCR results in coupling of the receptor to one or more G proteins 
followed by exchange of GDP for guanosine triphosphate (GTP) on the α-subunit. 
This results in conformational changes and subsequent dissociation of the subunits. 
Both the α-GTP and βγ subunits interact with downstream effectors and regulate their 
activity. The intrinsic GTP hydrolase activity of the α-subunit returns the protein to the 
GDP-bound state and thereby restores the association of the subunits. Gα subunits 
are commonly classified into four subfamilies based on their amino acid sequence 
and function: Gs, Gi, Gq and G12 family.22,24  
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Figure 1.4  
Structure of a GPCR and its coupled heterotrimeric G-protein25 
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1.2.3  Adenosine Receptor Subtypes and Their Signalling 
Adenosine receptors (AR) consist of four subtypes classified as A1, A2A, A2B and A3. 
Receptors from each of these four distinct subtypes have been cloned from a variety 
of species and characterized following functional expression in mammalian cells or 
Xenopus oocytes.2  
The adenosine A1/A2 receptor classification was initially based on their inhibiting and 
stimulating activity on adenylate cyclase.26,27 The A1 and A2AR (both A2A and A2BAR) 
are indeed coupled to Gi (inhibiting) and Gs (stimulating) proteins, respectively. The 
A3AR is the most recently identified adenosine receptor28  and is also Gi protein-
coupled. As further described, the adenosine receptor signalling pathways also 
include other G proteins. After the activation of the G proteins, enzymes and ion 
channels are affected and the resulting signalling cascade produces the specific 
receptor-mediated effect (Figure 1.5).  
 
 
Figure 1.5 
Signal transduction pathways associated with the human adenosine receptors22 
 
Activation of A1 receptors by adenosine inhibits adenylate cyclase activity through 
activation of pertussis toxin-sensitive Gi proteins.27 In cardiac muscles and neurons, 
A1AR activation leads to activation of the G0 family, which leads directly to the 
stabilisation of the neuronal membrane potential by activating the K+ efflux from 
inside to outside the cell.22 Coupling to K+ channels in supraventricular tissue is 
responsible for the brachycardic effect of adenosine on heart function.29 Activation of 
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the A1AR results also in increased activity of phospholipase C (PLC)30, 31 and in 
inhibiting Q, P and N-type Ca2+ channels.5                      
A2AARs seem to be mainly associated with Gs proteins whereby A2AAR activation 
increases adenylate cyclase activity. A2AAR stimulation also induces formation of 
inositol phosphates under certain circumstances.32 In the heart, A1AR and A2AAR 
agonist induced preconditioning has been suggested to occur via modulation of 
p44/42 extracellular signal-regulated protein kinase (ERK) signalling.33   
The A2BAR is positively coupled to both adenylate cyclase and PLC. The PLC 
activation, through Gq proteins, possibly mediates many of the important A2BAR 
functions.34 
A3 receptors couple negatively to adenylate cyclase through Gi2,3, and couple to Gq/11 
family, leading to stimulation of PLC.28, 35 In cardiac cells, A3AR agonists induce 
protection through the activation of KATP channels.36 A3AR stimulation can also lead 
to activation of phospholipase D. 
PLC catalyses the formation of diacylglycerol (DAG) and inositol (1,4,5)-triphosphate 
(IP3) from phosphatidylinositol-4-5-biphosphate (PIP2). DAG is implicated in the 
regulation of protein kinase C activity and IP3 increases the intracellular concentration 
of Ca2+ ions. In the brain, by inhibiting neuronal Ca2+ influx (through inhibition of 
adenylate cyclase), adenosine counteracts the presynaptic release of the potentially 
excitotoxic neurotransmitters glutamate and aspartate, which can impair intracellular 
Ca2+ homeostasis.22  
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1.2.4  The Adenosine A3 Receptor 
The adenosine A3 receptor is the most recently identified adenosine receptor and 
was first cloned, expressed and functionally characterised from rat striatum by Zhou 
et al. in 1992.28 The receptor was previously isolated from a rat testis cDNA library by 
Meyerhof et al.,37  but without ligand identification. Homologs of the rat striatal A3AR 
have been cloned from sheep part tuberalis (pituitary tissue),38 human heart39 and 
striatum.40 The interspecies differences in A3 receptor structure are large. There is 
only 74% homology of the rat A3 receptor with both the sheep and human A3 receptor. 
Sheep and human A3 receptors show 85% homology. This is reflected in the very 
different pharmacological profiles of the species homologs, particulary with respect to 
antagonist binding. 
  
1.2.4.1  Adenosine A3 Receptor Agonists 
Adenosine itself is a useful therapeutic agent when a short acting response is 
sufficient to achieve the desired tissue state. It is used clinically in the treatment of 
paroxysmal supraventricular tachycardia (Adenocard®).17 The adverse effects are 
rapidly self-limiting because the half-life of adenosine in blood after peripheral 
intravenous injection is only 10 seconds. Adenosine is translocated by nucleoside 
transporters and degraded by adenosine deaminase located on the extracellular 
surface of endothelial cells of small coronary arteries.41 The main approach for the 
discovery of more stable and more selective AR agonists has been modification of 
adenosine. Most of the useful analogues are modified in the N6- or 2-position of the 
adenine moiety and in the 3’-, 4’- or 5’- position of the ribose moiety.  A summary of 
the performed adenosine modifications is given in Figure 1.6 
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HO
substituted benzyl group: increased affinity
                                         increased selectivity
phenylethynyl, 2-pyrazol-1-yl: increased affinity
                                               increased selectivity
no bulk tolerated
5'-Methylcarbamoyl (MeNHCO),
5'-Ethylcarbamoyl (EtNHCO):
increased affinity
5'-alkylthio:increased selectivity
replacement by S: increased affinity
                              increased selectivity
(N)-Methanocarba 5'-carbamoyl:
increased affinity
increased selectivity replacement by NH2: increased solubility
                                  increased selectivity
                                  decreased affinity
no substitution tolerated
combination of 2 large substituents 
not tolerated
 
Figure 1.6 
Summary of the adenosine modifications, resulting in A3AR agonists 
 
Ribose Modifications 
The most potent adenosine agonists with modified ribose moiety are depicted in 
Figure 1.7. 5’-Methyl- and 5’-ethylcarbamoyl modifications usually lead to an increase 
in A3AR affinity.42 For example, 5’-N-ethylcarbamoyladenosine (NECA, 1.2), a non-
selective AR agonist, which was the first high-affinity ligand for the A2AAR (Ki = 20 
nM), displayed even higher affinity for the A3AR (Ki = 14 nM). 43  5’-N-
propylcarbamoyladenosine showed good A3AR affinity and selectivity (Ki = 44 nM).44 
N-cyclopentyl-carbamoyl substitution reduced the A3AR affinity,42 suggesting there is 
only limited space in the ribose binding domain of the A3 adenosine receptor.   
Bioisosteric replacement of the alkylcarbamoyl moiety by a vinyl group in 
combination with N6-methoxy adenine substitution resulted in the highly active and 
selective A3AR ligand 1.3. 45  5’-Alkylthio substitution led to an increase in A3 
selectivity. 5’-alkylthioadenosine derivatives with N6-benzyl substituents showed high 
A3AR affinity and partial agonist activity, with 5’-methylthio analogue 1.4 as the best 
analogue in this series (Ki = 8.8 nM).46 
Substitution of the 5’-hydroxylgroup by a chlorine atom is tolerated by A1 as well as 
A3ARs,45 while 2’- and 3’- hydroxyl groups are generally required for affinity and/or 
ability to fully activate the receptor.47  Replacement of the 3’-hydroxyl with 3’-amino 
caused decreased A3AR affinity, but improved the A3AR selectivity and water 
solubility. By combining 3’-amino modification with large the N6-substituents as in 1.5 
the A3AR affinity could be restored.48 
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Replacement of the ribose furane ring by the corresponding tetrahydrothiophene ring 
yielded several highly potent and selective A3AR agonists, such as 1.6 (Ki = 0.38 
nM).49 Conformational studies of the ribose moiety and its equivalents indicated that 
the ring oxygen is not required. However, replacement of the ribose furane ring by a 
cyclopentane ring resulted in a large decrease in AR affinity.50  That the North (N) 
ring conformation is preferred in binding to the A3AR is illustrated by the highly potent 
and selective A3AR agonists recently reported in the series of (N)-methanocarba-5′-
uronamide derivatives (1.7, Ki = 0.29 nM).51 
In addition to its beneficial effect on the A3AR affinity, 5’-modification of the ribose 
moiety also increases metabolic stability against adenosine deaminase, because the 
5’-hydroxyl group is essential for binding to the enzyme.52 
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Figure 1.7 
Examples of the most potent ribose-modified adenosine A3 agonists 
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Adenine Modifications 
Figure 1.8  includes the most potent adenosine agonists with modified adenine 
moiety. Large N6-substituents, such as substituted benzyl groups, tend to enhance 
the A3AR selectivity, but reduce the maximal efficacy resulting in partial agonists. The 
reduction of efficacy can be overcome by the combination of the large N6-substitution 
with 5’-alkylcarbamoyl ribose modification. The preferred N6-benzyl substituent 
turned out to be a meta-iodine. Only small substituents at C-2, such as 2-Cl and 2-I, 
are tolerated in combination with N6-iodobenzyl. IB-MECA (1.8) and the more A3AR 
selective Cl-IB-MECA (1.9) are very potent A3AR agonists containing a N6-iodobenzyl 
modification. These compounds have been widely used as pharmacological probes 
in the elucidation of the physiological role of the A3AR.53 Introduction of a small N6-
substituent, such as a methyl group, and a large 2-substituent resulted in very potent 
and selective A3AR ligands. Examples of large 2-substituents exhibiting very good 
A3AR affinity and selectivity are 2-phenylethynyl54 (1.10) and some 4-substituted 2-
pyrazol-1-yl derivatives55 (1.11). Combination of both large N6- and 2-substitution 
does not improve the A3AR affinity.54,55 
Substitution at the 8-position of the ring is not well tolerated by any AR subtype.50,56 
Evaluation of the appropriate deaza analogues indicated that the nitrogen atoms at 
positions 3 and 7 are required for high affinity of adenosine at all subtypes. 50,56,57 
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Figure 1.8 
Examples of potent adenine-modified adenosine agonists 
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1.2.4.2  Adenosine A3 Receptor Antagonists 
Purines  
The discovery of A3AR antagonists started with the investigation of xanthines, such 
as caffeine and theophylline (Figure 1.9). These classical A1, A2A and A2B adenosine 
receptor antagonists exhibited low A3AR binding affinities. 28 
 
HN
N
H
N
H
N
O
O
N
N N
H
N
O
O
N
N N
N
O
O
HN
N N
N
O
O
1.12 xanthine 1.13 caffeine 1.14 theophylline 1.15 theobromine
 
 
Figure 1.9 
 
A series of synthetical xanthine derivatives is depicted in Figure 1.10. Cyclization 
between the 7- and 8-position, resulted in A3AR selective pyridopurine-2,4-dione 
derivatives such as 1.16.58 Exploration of 2-phenylimidazolepurin-5-ones as water-
soluble xanthine derivatives yielded the highly potent human A3AR selective PSB-11 
(1.17, Ki = 2.3 nM), that was tritiated for characterization of this receptor.59 The 
corresponding 2,3,5-trichloro derivative PSB-10 (1.18) even showed higher affinity 
and selectivity for the A3AR (Ki = 0.43 nM). Several classes of extended xanthine 
structures (e.g., 1.19 and 1.20) were reported as A3AR antagonists. 60, 61 
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Figure 1.10 
Synthetical xanthine derivatives 
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Numerous adenine derivatives have been studied as selective antagonists for A1 or 
A2AARs, but the adenine derivative 1.21 (Figure 1.11) was reported to be highly 
selective for the human A3AR.62  
N
N NH
N
O
HN
1.21
Ki (A3AR) = 47 nM
 
Figure 1.11 
 
Triazolopurines have been reported as A3 antagonists that are applied topically to the 
eye for use in the treatment of glaucoma. Compound 1.22 (Figure 1.12) displayed a 
Ki = 0.61 nM at the human A3AR and >10,000-fold selectivity in comparison to the 
three other subtypes.63,64  
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Figure 1.12 
 
Nonpurines 
The most potent nonpurine A3AR antagonists are represented in Figure 1.13 and 
Figure 1.14. The triazoloquinazoline derivative CGS15943 (1.23), previously known 
as a nonselective adenosine antagonist at the human subtypes, served as template 
for designed related nonpurine heterocyclic antagonists of the human A3AR. 
Acylation of the N5-amino group led to 1.24, which is potent and selective for human, 
but not rat A3ARs. 65  In a related series of heterocyclic derivatives, the 
pyrazolopyrimidine derivative 1.25 was found to be a highly selective antagonist at 
the human A3 receptor and was radiolabeled to provide a hydrophobic, useful 
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radiotracer with a Kd = 0.80 nM.66 Analogue 1.26 in the same series displayed a Ki of 
0.16 nM at the A3AR.67 A pyridine moiety was introduced to enhance water solubility 
(1.27).68 
In search for other heterocyclic systems, chemical library screening resulted in the 
identification of new high-affinity hits for the human A3AR, including flavonoids (1.28), 
pyridines (1.29) and 1,4-dihydropyridines (1.30), triazoloquinazolines (1.24), 
isoquinolines and quinazolines (1.31), pyrazolo-triazolo-pyrimidines (1.25-1.27), and 
various other classes (1.32), which were then optimized, typically by substitution of 
aromatic rings. The dihydropyridine derivative 1.30 and the pyridinylquinazoline 1.31 
are both releatively potent A3AR antagonists. The pyridine derivative 1.29 is a 
selective A3AR antagonist in both rat and human.69 
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Figure 1.13 
Triazoloquinazolines and pyrazolo-triazolo-pyrimidines as potent nonpurine A3AR agonists 
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Figure 1.14 
Summary of various classes nonpurine A3AR antagonists 
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Adenosine analogues  
Alternatively, antagonists were also obtained starting from high-affinity adenosine 
derivatives that were modified to remove the capacity to activate the receptor without 
compromising obtained binding affinity. Substitution or rigidification of adenosine 
derivatives often reduces their intrinsic affintity. 70  Remarkably, the influence of 
structural modifications on the receptor efficacy is generally larger at the A3AR than it 
is at the other AR subtypes.70, 71  A few examples of adenosine-based A3AR 
antagonists are depicted in Figure 1.15. The large N6-substituents of 2-chloro-N6-
cyclopentyladenosine (CCPA, 1.33, Ki = 38 nM) and N6-[2-(3,5-dimethoxyphenyl)-2-
(2-methylphenyl)ethyl)] adenosine (DPMA, 1.34, Ki = 106 nM) - respectively, full A1 
and A2A AR agonists - resulted in A3AR antagonist activity. This structural insight was 
used advantageously to obtain the conformationally constrained nucleoside 1.35 (Ki 
= 29.3 nM), which proved to be a selective antagonist for both rat and human 
A3AR.70,72 Other adenosine analogues were reported as A3AR antagonists by Cristalli 
et al.,73 with a series of 8-alkynyladenosine derivatives that exhibited A3AR selectivity, 
but suffered from weak A3AR affinity (1.36, Ki = 650 nM). 
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Figure 1.15 
Examples of adenosine-based A3AR antagonists 
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1.2.4.3  Allosteric Modulation 
A3AR activity can also be modulated by certain agents that bind to an allosteric site, 
distinct from adenosine binding site. Pyridinylquinolines (1.37) and 
imidazoloquinolines (1.38) were shown to positively modulate A3 binding and/or 
action of agonists, although both substances retain antagonistic properties as well. 
Compound 1.37 and 1.38 significantly enhanced the agonist response on forskolin-
induced cAMP production and slowed the dissociation of the agonist radioligand 
[125I]I-AB-MECA in a concentration-dependent manner, suggesting an allosteric 
interaction. The compounds had no effect on the dissociation of the radiolabeled 
antagonist [3H]PSB-11 ([3H]1.17) from the A3 adenosine receptor, suggesting a 
selective enhancement of agonist binding. 74, 75    
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1.2.4.4  Molecular Modeling of the Adenosine A3 Receptor 
As we mentioned in 1.2.2, the structure of bovine rhodopsine served as a template to 
construct a homology model of the A3AR receptor in its resting state (antagonist-like 
state). This rhodopsine-based A3AR receptor model was recently refined by Moro et 
al.22 Similar to rhodopsin, the A3 receptor model reveals a seven-helix bundle with a 
central cavity surrounded by helices 1-7 and 5-6. The second extracellular loop (EL2), 
which has been described in bovine rhodopsin to fold back over transmembrane 
helices, limits the size of the recognition cavity. TM4 is not part of the cavity wall and 
makes contacts only with TM3. The hairpin (EL2) between TM4 and TM5 lies 
between the helices, roughly parallel to the membrane surface, and has contacts with 
side-chains of most of the helices. The most prominent contact is a disulfide bridge to 
helix 3 (TM3). Ligand recognition seems to occur in the upper region of the TM 
helical bundle, and TMs 3, 5, 6 and 7 appear to be crucial for the recognition of both 
agonists and antagonists.  
The side-chains of some crucial important residues in proximity (≤ 5Å) to the 
antagonist binding cavity are shown in Figure 1.17. His95 (TM3) and Ser247 (TM6) 
seem crucial for the recognition of the antagonist structures. Another strong 
hydrogen bonding interaction is possible with Asn250 (TM6). This asparagine residue, 
conserved among all adenosine receptor subtypes, was found to be important for 
ligand binding. A hydrophobic pocket, delimited by non-polar amino acids, Leu90 
(TM3), Leu246 (TM6) and Ile268 (TM7) and a highly conserved region, probably 
stabilized by pi-pi interactions, located between Phe168 and Phe182 are important for 
pharmacophore binding. Another crucial region is mostly hydrophobic and 
characterized by three non-polar amino acids: Ile98 (TM3), Ile186 (TM5) and Leu244 
(TM6). 
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Figure 1.17 
Rhodopsin-based homology modeling of the human A3AR. The side-chains of some crucial important residues in 
proximity (≤ 5Å) to the antagonist binding cavity are shown: Leu90 (TM3), Phe185 (TM5), Ile186 (TM5), Trp243 
(TM6), Ser247 (TM6), Asn250 (TM6), Ser271 (TM7), His272 (TM7) and Ser275 (TM7).22 
 
 
1.2.4.5 The Neoceptor concept 
Adenosine receptors are ubiquitously distributed throughout the body, which 
inherently results in nonselective activation. To adress this issue, efforts have been 
made to reengineer the GPCRs and their agonists. Rhodopsine-based molecular 
modeling was used to pinpoint adenosine receptor mutations for selective affinity 
enhancement, while retaining its capacity for signal transduction. Complementary 
modifications of adenosine were performed to design novel agonists (neoligands) 
that activate the reengineered receptor (neoceptor), but are not effective at the native 
receptor.  
The H272E mutant A3 adenosine receptor was found to have decreased affinity for 
classical ligands, such as NECA and Cl-IB-MECA (20-50-fold), but an enhanced 
affinity for N6-(3-iodobenzyl)-3’-ureidoadenosine compared to the wild type A3AR 
(1.39, >100-fold).76 
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Figure 1.18 
 
The neoceptor-neoligand pairs could be important to validate adenosine receptor 
agonists docking models. While theoretically the neoceptor concept could be an 
important therapeutic approach for tissue-specific GPCR activation, given successful 
targeted delivery of the neoceptor gene to a specific organ or tissue. 
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1.2.4.6 Therapeutic Potential of A3AR Agonists 
Cardiac ischemia 
During myocardial ischemia adenosine is released in large amounts, resulting in 
protection of the cardiomyocytes. This protection afforded by a brief hypoxic period is 
termed ‘preconditioning’ and is mediated through the activation of A1 and A3 
ARs.77,78,79,80 The protection mediated by prior activation of A3 receptors exhibits a 
significantly longer duration than that produced by activation of the adenosine A1 
receptor. The A3 receptor-mediated protection persisted for at least 45 min after the 
initial exposure to the A3 receptor agonist while the A1 receptor-mediated effect 
dissipated within 30 minutes. 81 A3AR-mediated cardioprotection is therapeutically 
more promising because it is obtained in the absence of haemodynamic side effects, 
such as hypotensive effects. A second advantage of stimulation of the A3ARs over 
A1AR activation is that A3AR receptor stimulation is less likely to induce 
brachycardia.82  
 
Cerebral Ischemia/Stroke 
Generally, antagonists of A2A and A3AR receptors are protective when given acutely, 
whereas agonists are harmful, but the situation reverses with chronic pre-treatment 
of animals. 83 , 84  Repeated systemic administration of A3AR agonist Cl-IB-MECA 
reduced cerebral infarction in stroke rats85,86 while acute administration of the same 
A3AR agonist during the ischemia exacerbated histological and functional damage.86 
Due its cerebroprotective effects, chronic treatment with A3AR agonists has been 
proposed for the prevention of stroke. 
 
Inflammation, allergies, asthma 
Inhaled adenosine causes bronchoconstriction in asthmatics. A3ARs as well as A1 
and A2B ARs may be involved.87  A3 receptor activation facilitates the release of 
allergic mediators, such as histamine and stimulates mast cell degranulation.88 On 
the other hand, A3AR agonists inhibit lipopolysaccharide-induced stimulation of TNFα 
production 89  and the release of other inflammatory mediators from human 
macrophages and eosinophils.90 , 91 , 92  The A3 receptor agonist IB-MECA showed 
beneficial effects in phase II clinical trials for the treatment of rheumatoid arthritis. IB- 
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MECA resulted in improvement in signs and symptoms of rheumatoid arthritis that 
did not achieve statistical significance, and was safe and well tolerated. 93   
 
Cancer 
A3AR agonists can induce or attenuate apoptosis depending on the range of agonist 
concentrations used. High Cl-IB-MECA concentrations induce apoptosis and 
relatively low concentrations block apoptosis in human leukemia cells.94 This might 
have important implications for therapeutic use in disorders such as cancer, in which 
induction of apoptosis is desired, and such as arthritis, in which the aim is to 
attenuate apoptosis.  
A3AR is more highly expressed in tumour than in normal cells, which justifies the 
A3AR as potential target for tumour growth inhibition. 95  The apoptotic effect of 
adenosine or its analogues takes place at micromolar level, while at low nanomolar 
concentrations reduced cell growth not due to apoptosis was also observed. Cl-IB-
MECA, at nanomolar concentrations, inhibited tumor cell growth through a cytostatic 
pathway, i.e., induced an increase in the number of cells in the G0/G1 phase of the 
cell cycle and decreased the telomeric signal. Interestingly, Cl-IB-MECA stimulates 
murine bone marrow cell proliferation through the induction of granulocyte-colony 
stimulating factor. Thus, the A3 adenosine receptor agonist Cl-IB-MECA exhibits 
systemic anticancer and chemoprotective effects.96 
Recently, Fishman and coworkers proposed the therapeutic treatment of cancer by a 
combined administration of methotrexate and an agonist of the A3AR (Cl-IB-MECA or 
IB-MECA).97 
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1.2.4.7 Therapeutic Potential of A3AR Antagonists 
Cerebroprotection 
Acute treatment with A3AR antagonists after the ischemia event may exhibit 
cerebroprotective effects.86 
 
Inflammation and asthma 
Activation of the A3ARs in rodents results in histamine release from mast cells, and 
also leads to hypotension. Adenosine also plays a role in lung inflammation through 
the adenosine A3 receptor. On the other hand, adenosine also exhibits anti-
inflammatory effects. Therefore, A3AR agonists as well as antagonists have been 
proposed for the treatment of inflammation and asthma. 
 
Cancer 
A3AR antagonists seem to enhance anticancer treatment by counteracting P-
glycoprotein efflux in multidrug resistance
.
98 
 
Glaucoma 
Application of A3AR antagonist externally to the eye lowers intraocular pressure in 
mice and monkeys. Therefore, A3AR antagonists have been proposed for the 
treatment of glaucoma.99,100,101 
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1.3 Pyrimidine Nucleotides And The P2Y2 Receptor 
1.3.1  Uracil And Adenine Nucleotides 
Adenosine 5’-triphosphate (1.40, ATP) and uridine 5’-triphosphate (1.42, UTP) are 
nucleotides consisting of 5’-triphosphorylated D-ribofuranose, which is linked via a β-
glycosidic bond to an adenine or a uridine base, respectively.  
ATP was discovered in 1929 by Lohmann,102 and was proposed to be the main 
energy-transfer molecule in the cell by Lipmann in 1941.103 In signal transduction 
pathways, ATP is used as a substrate by kinases that phosphorylate proteins and 
lipids, as well as by adenylate cyclase, which converts ATP to cAMP. ATP is also 
incorporated into nucleic acids.  
UTP is used as a substrate for the synthesis of RNA during transcription. UTP also 
occurs as energy source or activator of substrates in metabolic reactions. Glucose is 
activated by UTP while inorganic phosphate is released and the resulting UDP-
glucose enters the glycogen synthesis. UDP glucuronate is formed by oxidation of 
UDP-glucose. Hydrophobic molecules such as bilirubin, steroid hormones and many 
drugs are conjugated with glucuronate by UDP glucuronyl transferase to form a 
water-soluble glucuronide derivative before excretion by the kidney.104 
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Figure 1.19 
Structures of the natural P2Y2 receptor ligands ATP and UTP 
 
 
 
 
 
Chapter 1: Introduction 
30 
1.3.2  The P2Y
 
Receptors  
1.3.2.1 The P2 Receptor Family 
Based on whether they are ligand-gated ion channels (P2X receptors) or G-protein-
coupled receptors (P2Y receptors) P2 receptors are subdivided into two main classes. 
The P2X receptors consist of seven subtypes (P2X1 – P2X7) and the P2Y receptors 
include the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 receptors.7,8 
The missing P2Y sequence numbers represent species homologues of other 
receptors, e.g., p2y3,105 or receptors that have been misassigned to the P2Y family, 
e.g., p2y7,106 which was subsequently cloned as a leukotriene B4 receptor.107 
The receptor proteins of the defined P2Y-receptor subtypes contain the typical 
features of G-protein-coupled receptors including 7 predicted hydrophobic 
transmembrane regions (TMs) connected by 3 extracellular loops (ELs) and 3 
intracellular loops. The proteins of the human receptors consist of 328 (P2Y6) to 377 
(P2Y4) amino acids corresponding to a predicted molecular mass of 41–53 kDa of the 
glycosylated proteins. The biochemical analysis of the P2Y-receptor proteins has 
shown that P2Y-receptors expressed at the level of the cell membrane are in fact 
modified by N-linked glycosylation.108,109 For the P2Y12-receptor (Figure 1.20), it has 
recently been demonstrated that N-linked glycosylation is essential for signal 
transduction, but not for ligand binding or cell surface expression.109 All known P2Y-
receptor subtypes possess at their extracellular domains 4 cysteine residues, which 
are likely to form 2 disulfide bridges: the first one between the N-terminal domain and 
EL3 and the second bridge between EL1 and EL2. 110,111  
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Figure 1.20 
Predicted secondary structure of the human P2Y12-receptor. The red lines show predicted disulfide 
bridges.111 Potential sites for N-linked glycosylation are not indicated. TM, transmembrane region; EL, 
extracellular loop. 
 
1.3.2.2 The P2Y Receptor Subtypes and their Signalling 
Most P2Y receptors act via G protein coupling to activate phospholipase C leading to 
the formation of IP3 and the mobilization of intracellular Ca2+, which will directly 
control cellular function. In addition and secondary to the activation of PLC, multiple 
signal transduction pathways including protein kinase C, phospholipase A2, Ca2+-
sensitive ion channels and the formation of endothelium-derived relaxing factors 
have been shown to be involved in the responses to activation of native P2Y-
receptors. Coupling to adenylate cyclase by some P2Y receptors has also been 
described.2  
The specific downstream signal transduction pathway seems to depend not only on 
the P2Y-subtype but also on the cell type expressing the receptor.2 The third 
intracellular loop and the C-terminus, regions implicated in specific G-protein 
coupling in other G-protein-coupled receptors,112 vary greatly between the sequences 
of the cloned and functionally defined P2Y receptors. This suggests a coupling of 
different P2Y-subtypes to diverse subsets of G-proteins.  
 
Chapter 1: Introduction 
32 
On the basis of their structural similarities, P2Y receptors have been divided into two 
distinct groups:  
group I:  
- consists of the P2Y1-, P2Y2-, P2Y4-, P2Y6-, and P2Y11-receptors  
- couple via Gq proteins resulting in phospholipase C stimulation followed by 
increased inositol phosphates and Ca2+ mobilization 
- in addition, the P2Y11-receptor mediates an increase in adenylate cyclase 
activity 
group II: 
- consists of the P2Y13, P2Y12 and P2Y14 receptors113  
- group II receptors couple via Gi-proteins leading to adenylate cyclase 
inhibition followed by a decrease in intracellular cAMP levels114  
The response time of P2Y receptors is longer than that of the rapid responses 
mediated by P2X receptors because it involves second-messenger systems and/or 
ionic conductances mediated by G protein coupling.2  
The P2Y2 receptor couples via Gq proteins to mediate phospholipid breakdown and 
IP3 formation as well as Ca2+ mobilization via PLC.115  The specific downstream 
involvement of a given signalling pathway seems to be partially dependent on the cell 
type in which the P2Y2 receptor is expressed. In airway epithelial cell lines, biliary 
epithelial cell lines, and avian exocrine salt gland cells, P2Y2 receptor activation leads 
to opening of Ca2+-sensitive Cl--channels that are involved in epithelial fluid 
secretion.116  
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1.3.3  The P2Y2 Receptor  
The P2Y2 receptor has been cloned from mouse,117 rodent,118 and human119 tissue or 
cells. P2Y2 mRNA has a wide tissue distribution and is found at highest levels in cells 
in the lung, heart, skeletal muscle, spleen, kidney, liver, and epithelia.119, 120 The 
human receptor exhibits 89% identity in the amino acid sequence to the mouse 
receptor.119 The P2Y2 receptor is activated by both endogenous ligands UTP and 
ATP. Desensitization of P2Y2 receptors occurs after ca. 5 minutes of exposure to 
UTP probably by phosphorylation of their C-terminus by protein kinases. Recovery 
was observed after 5-10 minutes after removal of the agonist.121 
 
1.3.3.1  P2Y2 Receptor Agonists 
UTP and ATP are full agonists at the P2Y2 receptor. UTP also activates the P2Y4 
receptor while ATP acts as a potent competitive antagonist at the human P2Y4 
receptor.122 In several other species, P2Y4 receptors are activated by both UTP, and 
ATP. Consequently to the high selectivity of the human P2Y4 receptor for UTP it is 
difficult to find UTP analogues that are P2Y2 receptor selective. However, in 
controlled clinical studies, UTP is used in preference to ATP as a P2Y2 receptor 
agonist because of the expected higher selectivity of pyrimidine nucleotides versus 
the other P2 receptors and because active ATP metabolites such as adenosine may 
interact with the P1 receptors and lead to unwanted side effects. 
When tested under conditions excluding enzymatic conversion of nucleotides, UDP 
and ADP did not activate the receptor,123 indicating that at least 3 phosphate residues 
are required for the activation of the receptor. It has been suggested that the P2Y2 
receptor is preferentially activated by the fully ionized forms of ATP or UTP. The UTP 
and ATP responses correlated with the concentration of the fully ionized form.124  
In vitro pharmacological data for the most potent P2Y2 receptor agonists currently 
known are represented in Table 1.1. EC50 values represent the half maximal effective 
concentration in an assay of P2Y2 and P2Y4 receptor-stimulated phospholipase C 
activity. 125  The structure-activity relationship of the different ribose, uracil and 
phosphate chain UTP modifications is summarized in Figure 1.21. 
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compound 
 
name 
EC50 (P2Y2) 
(nM) 
EC50 (P2Y4) 
(nM) 
1.40 ATP 85 antagonist 
1.41 UTP 49 73 
1.42 2'-amino-2-'deoxy UTP 62 1200 
1.43 arabinoUTP 87 710 
1.44 (N)-methanocarba-UTP 85 91 
1.45 2-thioUTP 35 350 
1.46 4-thioUTP 26 23 
1.49 UTPγS 240 1600 
1.50 ATPγS 1720 no data 
1.52 Ap4A 180 inactive 
1.53 UP4U (diquafosol) 60 200 
1.54 UP4dC (denufosol) 220 800 
Table 1.1 
In vitro pharmacological data for the most potent P2Y2 receptor agonists currently known 
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Figure 1.21  
Structure-activity relationship of UTP derivatives as P2Y2 agonists 
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Ribose modifications 
2’-Amino-2’-deoxy UTP (1.42) and 1-(β-D-arabinofuranosyl)uracil 5’-triphosphate 
(1.43) are equipotent with ATP at the P2Y2 receptor and show a moderate selectivity 
over the P2Y4 receptor. Other 2’-modifications decreased the P2Y2 receptor potency. 
The only 3’-modification reported is 3’-O-methyluridine-5’-triphosphate, which proved 
inactive at both P2Y2 and P2Y4 receptors.125  (N)-Methanocarba-UTP (1.44) is almost 
equipotent to UTP.126 (Figure 1.22) 
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Figure 1.22 
 
 
Uracil modifications 
The sulphur-containing nucleotides 2-thioUTP (1.45) and 4-thioUTP (1.46) (Figure 
1.23) are very potent P2Y2 receptor agonists, which are moderately selective (2-
thioUTP) or nonselective (4-thioUTP) versus P2Y4 receptors. All other variations in 
the 4-position (methoxy, hexyloxy, methylthio, hexylthio, amino, hexylamino, 
cyclopentylamino, morpholino) caused a significant loss in P2Y2 receptor affinity.125 
Other uracil modifications such as 5-alkyl, 5-Br, 5-I, 5-Me, 6-aza and 3-methyl 
decreased the P2Y2 receptor affinity.125,127  Replacement (zebularine-5’-triphosphate, 
1.47) or reorientation (pseudouridine-5’-triphosphate, 1.48) of the uracil ring also 
resulted in less potent analogues (Figure 1.23).125  
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Figure 1.23 
 
 
Phosphate chain modifications 
The phosphate chain modified nucleotides UTPγS (1.49), and ATPγS (1.50) (Figure 
1.24) are full agonists at the P2Y2 receptor. UTPγS is a relatively potent P2Y2 agonist 
and is more stable against nucleotidases.128 ATPγS is less potent than UTPγS.129 α-
phosphothioate modification, resulting in both stereoisomers of UTPαS, decreased 
the agonist potency.123 The phosphate chain in UTP has been modified by 
replacement of the β,γ-oxygen by NH, CH2 or CF2. All these modifications resulted in 
a decrease in affinity.130,131 β,γ-Dichloromethylene-5-bromo-UTP (1.51, Figure 1.24) 
also showed a decreased P2Y2 receptor affinity, but showed an enhanced P2Y6 
receptor selectivity.132  
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Figure 1.24 
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Dinucleotides 
Mononucleotides are quickly dephosphorylated by cell surface ectonucleotidases. On 
the airway epithelial surface, UTP and UDP exhibit t½ values (at 1 µM nucleotide) of 
14 and 27 min, respectively.133 The more metabolically stable dinucleotides such as 
diadenosinetetraphosphate (1.52, Ap4A),134 Up4U (1.53, diquafosol, INS365)135 and 
dCp4U (1.54, denufosol, INS37217) (Figure 1.25) are more slowly hydrolyzed to 
nucleoside mono- and triphosphosphates. Denufosol shows a 10-fold higher potency 
at the P2Y2-receptor than at the P2Y4-receptor. Moreover, this compound did not 
activate P2Y1- or P2Y6-receptors.136   
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Figure 1.25 
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1.3.3.2  P2Y2 receptor Antagonists 
 
Standard Antagonists 
The standard P2 receptor antagonists are suramin (1.55) and Reactive Blue 2 (1.56, 
RB-2) (Figure 1.26). Suramin is a naphtylsulfonate derivative that acts as a 
competitive antagonist at several P2 receptor subtypes.137 Suramin does not block 
the P2Y4 receptor. Consequently, the previously suggested receptor subpopulations 
defined by suramin sensitivity2 may be the P2Y2 receptor (suramin-sensitive P2U-
purinoceptor) and the P2Y4 receptor (suramin-insensitive P2U-purinoceptor). 138 
Suramin exhibited an IC50 value of ca. 50 µM. RB-2 is one of the most potent P2Y2 
antagonists known to date (IC50 1-5 µM). It is an anthraquinone derivative with a 
relatively high molecular weight (MW = 840 g/mol), containing three negatively 
charged sulfonate groups. RB-2 may be meta- or parasulfonated or a mixture of both 
isomers.  
The usefulness of RB-2 and suramin as pharmacological tools is limited by their poor 
P2Y2 receptor selectivity and their interaction with several other receptors and 
proteins, including P2X receptors,139 ectonucleotidases,140,141  kinases (RB-2),142 and 
G proteins (suramin).143  
 
RB-2 Derivatives 
Müller and coworkers144 recently discovered a simplified RB-2 derivative PSB-716 
(1.57, Figure 1.26), which appeared to be selective versus other P2Y subtypes as 
well as nucleotide-metabolizing enzymes.   
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Figure 1.26 
 
Thiouracil Derivative 
Structural UTP modifications to eliminate efficacy and improve the pharmacokinetic 
properties led to the development of a thiouracil derivative (1.58, Figure 1.27), 
bearing a tricyclic substituent in the 5-position and a ribose triphosphate- mimicking 
substituent at N-1. The compound appeared to be a P2Y2-selective competitive 
antagonist and showed an IC50 value of ca. 1 µM in a model of P2Y2-agonist-induced 
mucin secretion in differentiated human bronchial epithelial cells.145 The incorporation 
of a large heterocyclic substituent in the 5-position was earlier reported to preclude 
receptor activation.146 
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Figure 1.27 
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Flavonoids 
Several flavonoids were also identified as P2Y2 receptor antagonists with IC50 values 
in the low micromolar concentration range. The most potent P2Y2 receptor 
antagonists of the present series, kaempferol (1.59), tangeretin (1.60), and 
heptamethoxyflavon (1.61), with IC50 values between 6-19 µM, are depicted in Figure 
1.28.147  
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Figure 1.28 
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1.3.3.3  Molecular Modeling of the P2Y2 Receptor 
An early model of the P2Y2 receptor was constructed by Erb et al.148 Recently, a 
molecular model was provided by a molecular dynamics (MD) simulation in a 
phospholipidic and aqueous environment.149,150 This model of the P2Y2 receptor is a 
rhodopsin-based homology model containing not only seven TMs, but also all 
extracellular hydrophilic loops, termini and phospholipids. Inclusion of the natural 
environment of the receptor was previously shown to significantly improve the results 
of a MD simulation, providing a more accurate structure of the receptor, especially in 
its loops and terminal regions.  
 
Extracellular Regions 
Recent MD simulation of the P2Y6 receptor revealed that EL2 moved toward TM3 
and further up into the extracellular space, opening the putative nucleotide binding 
cavity.151 However, in the case of the P2Y2 receptor, EL2 did not show a significant 
displacement during the MD simulation. Several electrostatic and disulfide bridges 
were proposed to fix this loop near the TM domain. In addition to the disulfide bridge 
conserved among all GPCRs of the rhodopsin family and formed between two 
cysteine residues located in TM3 and EL2 (C106 and C183 in the P2Y2 receptor), 
several charged residues located in EL2 of the P2Y2 receptor can interact with 
oppositely charged residues located around the loop (Figure 1.29A). Several other 
bridges in the extracellular region of the P2Y2 receptor appeared in de MD simulation 
model.150 
 
Intracellular Regions 
Three possible pairs of charged residues were found in the intracellular region of the 
P2Y2 receptor: D319-R340, R334-D342, and R335-D345 (Figure 1.29B). All these 
residues are located in the C-terminus domain.150 
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Putative Interhelical Disulfide Bridges 
Analysis of the model obtained after MD simulation suggested the formation of two 
interhelical disulfide bridges [C132(3.51) - C212(5.57) and C44(1.43) - C300 
(7.47)].*,150,152 (Figure 1.29B) 
 
 
Figure 1.29  
Putative electrostatic and disulfide bridges found in the extracellular (A) and intracellular (B) regions of the model 
of the P2Y2 receptor 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
*
 Note on the residue indexing in this work 
To facilitate comparison of aligned redidues in related GPCDs, residues are supplemented with an index, 
according to the van Rhee-convention.149 The most conserved residue in a TM region X is given the index 
number (X.50). Residues within the given TM are then indexed relative to the “50” position. Note that the “50” 
position is not necessary the residue in the middle of the TM region.  
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1.3.3.4  Therapeutic Potential of P2Y2 Receptor Agonists 
Cystic Fibrosis 
Cystic fibrosis (CF) is a recessive genetic disease caused by a mutation in the cystic 
fibrosis transmembrane regulator (CFTR) gene resulting in defective chloride 
secretion and excessive sodium absorption. This leads to a reduction of the airway 
surface liquid, causing defective ciliairy function and cough clearance. Subsequently, 
thickened mucus plaques adhere to the airway surface, generate hypoxic regions 
and promote bacterial infection which can finally cause respiratory failure. Cystic 
fibrosis has affected approximately 75 000 individuals worldwide. Their mean life 
expectancy is only about 32 years.153  
Studies on P2Y2-receptor-deficient mice verified the important role of the P2Y2 
receptor in regulating ion transport in epithelial cells. 154 , 155  Receptor activation 
induces an increase in intracellular Ca2+ concentration, which stimulates the Cl-- 
secretion156,157,158  via the Ca2+-activated Cl- channels (CaCC) and inhibits the Na+ 
absorption158, 159, 160 via luminal epithelial Na+ channels (ENaCs). The ENaCs are 
controlled by CFTR proteins, Cl--channels which are activated when the ENaCs are 
blocked.  The net effect of activation of luminal P2Y2 receptors in respiratory 
epithelium is inhibition of Na+ absorption and stimulation of Cl--secretion.  
As shown in the schematic cell model of a secretory respiratory epithelial cell (Figure 
1.30), luminal Cl--extrusion by CFTR or CaCC requires basal Cl--influx mediated by 
the Na+/K+/Cl- cotransporter isoform 1 (NKCC-1). Nucleotide-mediated activation of 
secretion in the airways was also shown to encompass activation of basal K+-
secretion.161 
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Figure 1.30 
Schematic model of luminal P2Y2 receptor-mediated ion transport regulation in respiratory epithelial cells. Cl- 
secretion requires: a) Na+/K+/Cl- cotransporter isoform 1 (NKCC1)-mediated; b) extrusion of Cl- via either luminal 
CFTR or Ca2+-activated Cl- channels. 155  
 
CFTR proteins, Cl--channels that control the ENaC, are immature in CF patients. 
Consequently, the ENaC activity is up-regulated (Na+-influx is increased) and the cell 
depends only on the CaCC for Cl--secretion. The impaired ion transport in the 
bronchi of CF patients can be bypassed by stimulation of P2Y2 receptors to inhibit the 
ENaC and activate the CaCC.162,163(Figure 1.31) 
  
 
Figure 1.31 
Normal – cystic fibrosis cell163 
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P2Y2 receptor activation also stimulates the mucin secretion from goblet cells,164 
increases the ciliary beat frequency,165 and promotes the surfactant release from 
type II alveolar cells.166 A knockout study confirmed previous pharmacological data 
and identified the P2Y2 receptor subtype as the crucial luminal P2 receptor in 
respiratory epithelium.167 Therefore inhaled P2Y2 receptor agonists are proposed for 
the treatment of cystic fibrosis. 
UTP dose-dependently stimulates the mucociliary clearance and sputum 
expectoration in smokers and patients with a variety of airway disorders including CF.  
However, UTP has limited metabolic stability and, hence, a relatively short duration 
of action when administered by inhalation. Newer dinucleotide P2Y2 agonists such as 
diquafosol (1.53) and denufosol (1.54) (Figure 1.25) have enhanced metabolic 
stability in CF sputum. 168 Denufosol as a treatment for CF received fast-track and 
orphan drug status in the U.S. and orphan drug status in Europe. The efficacy results 
of the first of two planned Phase III clinical trials with denufosol for CF are expected 
mid-year 2008. In February 2008, the second Phase III trial was initiated. 169 
 
Dry Eye Syndrome 
A high expression level of P2Y2 receptors is found in different cell types of the eye. 
Activation of P2Y2 receptors appears to regulate ocular surface hydration by 
stimulation of conjunctival mucin and Cl--secretion. P2Y2 agonists, such as diquafosol 
(1.53, Figure 1.25) stimulate chloride secretion and increase tear production.170 To 
date, four Phase III clinical trials of diquafosol (ProlacriaTM) for the treatment of dry 
eye disease are completed.169 
 
Cancer 
ATP inhibits the growth of primary cell cultures of human oesophageal cancer as well 
as the growth of an oesophageal cancer cell line by inducing apoptosis and cell cycle 
arrest. The effect is thought to be mediated by stimulation of P2Y2 receptors. Thus, 
P2Y2 receptor agonists have been suggested as novel therapeutics for oesophageal 
cancer.171 Therapeutically used anticancer and antiviral nucleoside antimetabolites 
are bioactivated by phosphorylation and might exert some of their effects (or side-
effects) by interaction with P2 receptors. 
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1.3.3.5 Therapeutic Potential of P2Y2 Receptor Antagonists 
Inflammation 
P2Y2 receptors are expressed on epithelial cells in high density and are thought to be 
involved in defense mechanisms.172 They are expressed on inflammatory cells, such 
as neutrophils and macrophages. P2Y2 receptor antagonists may be potential 
antiinflammatory drugs, which is in agreement with the observations of Lackie et al. 
on the potential anti-inflammatory effects of chloride channel blockers.173 
 
Coronary Vasospastic Disorders 
Since stimulation of P2Y2 besides P2X receptors mediates contraction of human 
coronary arteries, P2Y2 receptor antagonists have been suggested as potential 
therapeutics for coronary vasospastic disorders.174 
 
Neuroprotective Agents 
P2Y receptor antagonists, including Reactive Blue-2 (1.55), have been reported to 
exhibit neuroprotective properties. 175  They may be useful for the treatment of 
epileptic seizures, stroke and neurodegenerative diseases, such as Alzheimer's and 
Parkinson's disease.176 The P2Y receptor subtype(s) responsible for these effects 
are not known. Since the P2Y2 receptor is expressed in the brain and RB-2 is a 
relatively potent P2Y2 receptor antagonist, P2Y2 antagonism might be involved. 
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1.4 Objectives and Structure of this Thesis 
The synthesis and biological evaluation of a series of A3 adenosine receptor ligands 
(chapter 2 and 3) and P2Y2 receptor ligands (chapter 4) will be discussed. The A3AR 
and the P2Y2 receptor are G-protein-coupled receptors, which belong to the 
purinergic receptors, which consist of 2 classes, termed P1-receptors or adenosine 
receptors and P2-receptors that recognize ATP, ADP, UTP and UDP as natural 
ligands.  
In chapter 2 and 3 of this thesis, we will describe the design of novel ligands for the 
adenosine A3 receptor by modification of the natural, non-selective ligand adenosine 
(Figure 1.32). Based on the known SAR, we aim to enhance A3AR affinity and 
selectivity by introducing selected substitutions, possibly combined with 5’-N-
(m)ethylcarbamoyl or 3’-amino modifications of the ribose moiety.  
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Figure 1.32 
Summary of the performed adenosine modifications (Chapter 2-3) 
 
In chapter 4, we will discuss the design of ligands for the P2Y2 receptor. Toward this 
end, UTP will be used as a preferred template, because it is expected to yield a 
selective ligand and precludes the formation of active metabolites such as adenosine.  
Our work will focus on a 2-or 4-thio modification of the uracil base combined with 
modifications of the 2’-OH group of the ribose moiety. Furthermore, initial 
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modifications to enhance the metabolic stability of the 5’-triphosphate chain will be 
explored (Figure 1.33). 
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Figure 1.33 
Summary of the planned UTP modifications (Chapter 4) 
 
The biological evaluation of the synthesized A3AR receptor ligands, is performed by 
the group of prof. dr. Kenneth A. Jacobson, National Institute of Diabetes and 
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, 
USA. The group of prof. dr. Kendall Harden, Department of Pharmacology, University 
of North Carolina, School of Medicine, North Carolina, USA performed the biological 
evaluation of the synthesized P2Y2 receptor ligands. The molecular modeling of both 
A3A and P2Y2 receptor ligands is performed under the guidance of prof. dr. Kenneth 
A. Jacobson. We intend to explain the observed biological effects of the synthesized 
compounds by means of the modeling results. 
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1.5 Note on the Nucleoside Nomenclature Used in 
this Work 
In nucleosides, the ribofuranose ring numbering can be distinguished from purine 
heterocycle numbering by the use of the prime after the Arabic numerals. Moreover, 
this “generic” nucleoside notation, i.e. not according to IUPAC conventions, is used to 
indicate the positions of the nucleoside that are chemically modified (for example 2’-
amino-2’-deoxyUTP, 1.42, Figure 1.22) or to pinpoint particular regions to the 
nucleoside that interact with the biological (target) system (like the N6-substituents as 
in 1.5, Figure 1.7). 
These conventions can lead to serious misinterpretations when modifications on the 
nucleoside significantly alter the parent nucleoside structure. Such a modification is 
the replacement of the 4’-CH2OH group of adenosine (1.1) by a N-ethylcarbamoyl 
functionality (NECA, 1.2) (Figure 1.34), which is called a 5’-N-ethyluronamide or 5’-N-
ethylcarbamoyl modification. Although the uronamide group can be seen as a 4’-
substituent, the generic name of compound 1.2 is 5’-N-ethylcarbamoyladenosine 
or 9-[5-N-ethylcarbamoyl)-β-D-ribofuranosyl] adenosine. However, the latter can 
easily be mistaken for compound 1.62 (Figure 1.34).  
Similar 5’-uronamide modifications are described throughout this work (chapter 2 and 
3). In fact, to accurately describe the structures their IUPAC-name should be used. 
For example, the IUPAC-name of 1.2 is (2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)- 
N-ethyl-tetrahydro-3,4-dihydroxyfuran-2-carboxamide. Since the IUPAC 
nomenclature does not allow rapid visualisation of the described structures, the 
“generic” nomenclature is generally accepted in the nucleoside (bio)chemistry and 
pharmacology field and will therefore be used throughout this work. 
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Figure 1.34 
The nomenclature in nucleoside chemistry for modifications at the 5’-position
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 2: 
 
HYPERMODIFIED 
ADENOSINE 
ANALOGUES 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter 2: Hypermodified Adenosine Analogues 
53 
2 HYPERMODIFIED ADENOSINE ANALOGUES 
 
2.1 Introduction 
Adenosine receptors are ubiquitously distributed throughout the body. As a 
consequence, ligands need to be highly selective in their action with respect to 
receptor subtype and tissue to be of therapeutic value.177 Numerous structure-activity 
studies of adenosine derivatives as receptor agonists conclude that selectivity may 
be provided by specific substitutions of the adenine ring.178,179 Substitution at the 8-
position of the ring is not well tolerated by any AR subtype.180,181 The nitrogen atoms 
at positions 3 and 7 are required for high affinity of adenosine at all subtypes.179 2-
Alkynyl derivatives of NECA (1.2, Figure 1.7) possess high affinity at the A3 receptor 
subtype. Moreover, the presence of 2-alkyne substituents enhanced the A3AR 
selectivity.182 (see 1.2.4.1 and Figure 1.8) 
DeNinno et al.48 discovered that introduction of an amino group at the 3’-position 
improves the selectivity for the human A3AR, while enhancing the water solubility. 
The affinity drop caused by this 3’-substitution could be overcome by elaborating the 
N6-substituents (1.5, Figure 1.7). The combination of a large N6-subtitituent with a 2-
alkynyl group has proven to be unsuccessful because of the steric hindrance caused 
by the two large substituents, reflected by a decrease in A3AR affinity.48 Therefore, 
the present study investigated the effect of a 2-alkynyl substituent in concert with a 
small N6-substituent on the affinity and selectivity of a series of 3’-azido and 3’-amino 
adenosine derivatives. In addition, we evaluated the effect of the 5’-methylcarbamoyl 
modification on the overall affinity and efficacy of these compounds (Figure 2.1). 
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Figure 2.1 
Overview of the synthesised hypermodified adenosine analogues 
 
 
2.2 Chemistry 
2.2.1 Synthesis of 5’-N-Methyluronamide 2-Phenylacetylene Adenosine 
Derivatives 2.7, 2.9 and 2.20 
2-Iodo derivative 2.7 was prepared from the commercially available 1,2-O-
isopropylidene-α-D-xylofuranose (2.10) as depicted in Scheme 2.1. Selective 5’-p-
toluoyl protection allowed 3’-triflation. 3-Azido intermediate 2.12 was obtained by 
treatment of the resulting 3’-triflate with NaN3 and subsequent 5’-deprotection, 
following a slightly altered literature procedure.183 Periodate oxidation followed by 
esterification of the carboxylic acid and subsequent treatment with methylamine in a 
pressure tube afforded the ribofuranonamide 2.15. One pot deprotection-acetylation 
gave the peracylated 3’,5’-modified sugar 2.16.48 Vorbrüggen-glycosylation184 (see 
also 2.2.4) with silylated 2-amino-6-chloropurine yielded nucleoside 2.17 in 79% yield. 
Classical procedures allowed a straightforward conversion of 2.17 to 2.19. 
Triphenylphosphine reduction of the azido moiety yielded the corresponding amine 
2.7. 
Based on the results of Cristalli et al.,54 we have chosen phenylethynyl as the most 
promising C2-substituent. Reaction conditions used to perform a Sonogashira 
coupling185 of 2.19 with phenylacetylene yielded the 3’-(4-phenyl-1,2,3-triazol-1-yl) 
derivative (2.21) of the 2-alkynylated compound (Scheme 2.1)  This result was due to 
a Cu+-catalysed Huisgen [3+2]cycloaddition186 of the 3’-azide with phenylacetylene. 
Consequently, another strategy was used to gain acces to compound 2.20, starting 
from 6-chloropurine (2.22) (Scheme 2.2). The purine N-9 was protected as the 
tetrahydropyran-2-yl (THP) derivative 2.23 by reacting 2.22 with the carbocation 
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formed in situ from 2,3-dihydro-4H-pyran and catalytic amounts of p-toluenesulfonic 
acid. The regioselectivity of this reaction had been described extensively.187  Purine 
2.23 was obtained as a mixture of enantiomers because of the stereogenicity of THP 
carbon C1’.188 6-chloro-2-iodo-(9-tetrahydropyran-2-yl)purine (2.25) was obtained via 
a lithiation-mediated stannyl transfer process followed by 2-tributylstannyl-iodine 
exchange. 189 , 190 , 191  Treatment of 6-Cl-purine derivative 2.25 with methylamine 
hydrochloride in the presence of DMAP provided N6-methyladenine analogue 2.26. 
Sonogashira coupling of 2.26, followed by deprotection provided 2.28. Unfortunately, 
classical Vorbrüggen coupling,184  as described for the synthesis of 2.17 did not give 
satisfying results. By using N,O-bis(trimethylsilyl)acetamide (BSA) as silylating 
agent, 192  9-(2-O-acetyl-3-azido-3-deoxy-5-methylcarbamoyl-β-D-ribofuranosyl)-N6-
methyl-2-phenylethynyl-adenine (2.20) was obtained in a poor yield. 
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Scheme 2.1 
Synthesis of compound 2.7 and attempted synthesis of compound 2.20. Reagents and conditions: (a) toluoyl 
chloride, pyridine, CH2Cl2, 0 °C (71%); (b) (i) (CF 3SO2)O, pyridine, CH2Cl2, -10 °C (ii) NaN 3, DMF, rt, overnight 
(40%); (c) 0.1 N NaOMe in MeOH, rt (88%); (d) (i) NaIO4, RuCl3, H2O, CHCl3, CH3CN, rt (ii) EDC, DMAP, dry 
MeOH, rt (40%); (e) 2M CH3NH2 in THF (89%);  (f) H2SO4, (CH3CO)2O, CH3COOH, 18h (55%); (g) (i) 2-amino-6-
chloropurine, HMDS, (NH4)2SO4,reflux, 20h, (ii) 2.16, TMSOTf (79%); (h) Isoamyl nitrite, I2, CuI, CH2I2 in THF, 
reflux (79%); (i) (i) CH3NH3Cl, Et3N, EtOH, reflux; (ii) 7N NH3 in MeOH (77%); (j) Ph3P, H2O, THF, 2 days (82%); 
(k) phenylacetylene, (PPh3)2PdCl2,CuI, Et3N, DMF (41%). 
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Scheme 2.2 
Synthesis of compounds 2.20 and 2.9. Reagents and conditions: (a) 2,3-dihydro-4H-pyran, p-toluene sulfonic acid, 
THF, 80 °C, overnight (69%); (b) LiTMP, THF, -78 °C , then (nBu)3SnCl (95%); (c) I2, THF, 24h (75%); (d) 
CH3NH3Cl, DMAP, EtOH, reflux (81%); (e) phenylacetylene, (PPh3)2PdCl2,CuI, Et3N, DMF (91%); (f) TFA, CH2Cl2 
(72%); (g) 2.16, BSA,TMSOTf, CH3CN, reflux (24%); (h) 7N NH3 in MeOH; (i) Ph3P, H2O, THF, 2 days (91%). 
 
During the course of this work it became clear that the 3’-amino-analogues generally 
exhibit much better A3AR affinities than their 3’-azide precursors. Consequently, we 
focussed on only the 3’-amino derivatives for further synthesis. This direction 
permitted us to reduce the 3’-azide to a 3’-amine before the Sonogashira coupling, 
avoiding the unwanted cycloaddition.  
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2.2.2 Synthesis of 2-Alkynylated 3’-Amino-adenosines 2.3-2.5 
9-(3-Amino-3-deoxy-β-D-ribofuranosyl)-N6-methyl-2-iodopurine (2.1) served as a 
suitable synthon for the synthesis of the 2-alkynylated 3’-amino-adenosines 2.3-2.5 
(Scheme 2.3). It was obtained by coupling of sugar 2.30 with 2-amino-6-chloropurine. 
Elaboration of the base moiety was essentially accomplished as for 2.19 to yield 2.34. 
Staudinger reduction allowed the unmasking of the amine group. Finally, 
Sonogashira coupling on amine 2.1 provided the alkynylated analogues 2.3-2.5 in 
80-82% yield. The choice of p-methyl phenylethynyl was based on a preliminary 
study performed in our lab, in which we compared different para-alkyl substituted 
acetylenes with the unsubstituted phenylacetylene at the 2-position of N6-methyl 
adenosine. From this study, it was possible to conclude that a higher A3AR affinity 
was obtained when a methyl group is introduced in para position of the phenyl ring 
(Ki = 1.5 nM compared to Ki = 3.4 nM for 2-phenylethynyl analogue 1.10). Extending 
the size of the alkyl chain (p-propyl and p-pentyl) resulted in a decrease in affinity. 2-
Hexynyl was chosen because it exhibited an excellent A3AR affinity in Cristalli’s study 
(Ki = 1.1 nM).54  
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Scheme 2.3 
Synthesis of compounds 2.3-2.5. Reagents and conditions: (a) (i) 75% HCOOH, 50 °C  (ii) (CH3CO)2O, pyridine, rt 
(90%); (b) 2-amino-6-chloropurine, BSA,TMSOTf, CH3CN, reflux (65%); (c) Isoamylnitrite, I2, CuI, CH2I2 in THF, 
reflux (81%); (d) (i) CH3NH3Cl, Et3N, EtOH, reflux, (ii) 7N NH3 in MeOH (69%); (e) Na° in MeOH (95%); (f) Ph 3P, 
H2O, THF, 2 days (92%); (g) alkyne, (PPh3)2PdCl2,CuI, Et3N, DMF (80-82%).  
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2.2.3 Synthesis of Other 2-Substituted Adenosine Derivatives  
To continue the exploration of the 2-position, we synthesised the 2-I and the 2-NH2 
derivatives of the 5’-OH and the 2-H and the 2-I derivatives of the 5’-methylcarbamoyl 
3’-amino-N6-aminomethyl adenosine analogues (Scheme 2.4).  
3’-Amine 2.6 (Figure 2.1) was prepared by catalytic hydrogenation of the 3’-azide 
precursor which has been described.193  
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Scheme 2.4 
Synthesis of compounds 2.2 and 2.8. Reagents and conditions: (a) (i) CH3NH3Cl, Et3N, EtOH, reflux, (ii) 7N NH3 
in MeOH (68%); (b) Na° in MeOH (91%); (c) Ph 3P, H2O, THF, 2 days (80%). 
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2.2.4 Mechanism of the Vorbrüggen Coupling Reaction 
In the Vorbrüggen coupling method184, the glycosidic bond formation is driven by the 
use of silylated nucleobases and strong Lewis acids. This highly reproducable 
method generally provides nucleoside formation in high yield with reliable and 
predictable stereochemistry. Generally, formation of a β-nucleoside, for which the 
nucleobase attacks from the β-side of the sugar, is desirable. 
Silylation (e. g. with hexamethyldisilazane) converts the polar, often rather insoluble 
bases into lipophilic silyl compounds, which are readily soluble in organic solvents, 
permitting homogeneous reactions. Silylation also provides better nucleophiles 
because of the electron-releasing property of silicon. 
The Vorbrüggen coupling mechanism is depicted in Scheme 2.5. Reaction of the 2’-
acetate group of a 1,2-diacetylated ribofuranosyl sugar I and the Lewis acid catalyst 
(e.g. trimethylsilyl triflate II) results in the conversion of I into a stable 1,2-
acetyloxonium salt III. Under these conditions the nucleophilic silylated base can only 
attack the sugar cation from the β-side, yielding the exclusive formation of β-
nucleoside IV. Simultaneously, trimethylsilyl triflate is regenerated by reaction of the 
triflate anion with the persilylated nucleobase. 
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Scheme 2.5 
The Vorbrüggen coupling reaction for the formation of D-ribonucleosides 
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2.3 Biological Evaluation 
For the adenosine derivatives prepared in this study (2.1- 2.9, 2.19-2.21, 2.34, 2.36, 
2.38) we measured both the binding affinities at the hA1, hA2A and hA3AR and their 
degree of activation of the A3AR subtype. The results are reported in Table 2.1. The 
ability of each of these adenosine derivatives to compete for radioligand binding at 
each of these hARs was evaluated at a fixed concentration of 10 µM, and full 
competition curves were determined at the A3AR. Six different 2-substituents were 
included: H, I, NH2, Ph-C≡C, pMePh-C≡C and nBu-C≡C. The choice of the methyl 
group as a small N6 substituent was based on the results of Cristalli et al. who 
demonstrated that it increased the affinity for the human A3AR and significantly 
enhanced the A3AR selectivity.48  
Results from the competition experiments showed that the A3AR affinities of the 3’-
amines were much higher than those of the 3’-azides. For all derivatives studied, the 
5’-methylcarbamoyl modification in general enhanced the affinity at the A3AR in 
comparison to 5’-CH2OH. Except for 2.34, all evaluated compounds showed a very 
high selectivity for the A3AR compared to the other ARs. The most potent compound 
(2.9) displayed a Ki value of 16 nM at the A3AR. The C-2 subsituent of this compound, 
a phenylethynyl moiety, was previously shown to enhance A3AR affinity and 
selectivity.54 Although the excellent A3AR affinities of the 3’-unmodified p-methyl-
phenylethynyl (Ki = 1.5 nM) and 1-hexynyl (Ki = 1.1 nM) N6-methyladenosine 
analogues, the 2-phenylacetylene substituent of 3’-amino derivative 2.3 proved to 
have a superior contribution to A3AR affinity than a p-methyl-phenylethynyl (2.4) or a 
1-hexynyl (2.5) moiety. Furthermore, the 2-phenylethynyl modification appeared to 
overcome the reduction of affinity caused by the 3’-azide (cf. Ki = 78.9 nM for 2.20 vs. 
1140 nM for 2.38). Consequently, this C-2 substituent was selected to be combined 
with a 3’-amino and a 5’-methylcarbamoyl modification. 
Previous studies48 showed that 3’-amino derivatives exhibit a decreased affinity at 
the A3AR compared to their 3’-hydroxy analogues. The affinity reduction associated 
with this 3’ modification could be overcome by elaborating the N6-substituents, for 
example with a substituted benzyl group.48 The high affinity of compound 2.9 (Ki = 
15.6 nM) demonstrated that a 2-phenylethynyl modification in concert with a small 
N6-substituent was likewise capable to overcome this reduction in affinity. Note that in 
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our experiments the affinity of derivative 2.6 for the A3AR (Ki = 32.3 nM) was 4-fold 
higher than reported by DeNinno et al.48 The 2-I analogue 2.7 also showed 
appreciable A3AR affinity (Ki = 71.4 nM). Conversely, the 2-NH2 analogue 2.8 
exhibited a weak A3AR affinity (Ki = 536 nM). 
The results of the cyclic cAMP-assay (Table 2.1) indicated that all 3’-azides were 
A3AR antagonists, except for compound 2.38 which showed partial agonist activity. 
Also the 3’-(4-phenyl-1,2,3-triazol-1-yl) derivative 2.21 appeared to be an A3AR 
antagonist. All other compounds were partial agonists, except for compound 2.8 that 
manifested full agonist activity. 
N
NN
N
N
O
OHR3
R2
R1
H Me
 
  R1 R2 R3 Ki (nM) or %inh. at 10 µM % Efficacyb 
  
      
hA1 hA2A hA3 hA3 
2.1 I CH2OH NH2 39% 12% 879±346 67±6% 
2.2 NH2 CH2OH NH2 16% 4% 654±42 57±2% 
2.3 Ph-C≡C CH2OH NH2 50% 14% 126±4.3 36±6% 
2.4 pMePh-C≡C CH2OH NH2 33% 0% 145±35 23±3% 
2.5 nBu-C≡C CH2OH NH2 4% 3% 389±112 66±11% 
2.6 H CONHMe NH2 18% 12% 32.3±3.9 72±10% 
2.7 I CONHMe NH2 16% 24% 71.4±12.8 18±10% 
2.8 NH2 CONHMe NH2 -14% 10% 536±247 92±3% 
2.9 Ph-C≡C CONHMe NH2 9% 9% 15.6±3.6 67±11% 
2.19 I CONHMe N3 16% 0% 2530c -8±5% 
2.20 Ph-C≡C CONHMe N3 31% 16% 78.9±12.4 -11±8% 
2.21 Ph-C≡C CONHMe 4-Ph-1,2,3-triazol-1-yl 14% 2% 1820±770 0% 
2.34 I CH2OH N3 85%c,d 27% 6540±320 -3±2% 
2.36 NH2 CH2OH N3 49% 16% 28,800b 0% 
2.38193 H CONHMe N3 12% 10% 1140±300 38±4% 
 
Table 2.1 
Binding affinities of adenosine derivatives at human A1, A2A and A3ARs expressed in CHO cellsa 
(a)  All A3AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding one 
of the human adenosine receptors. Binding at human A1, A2A, and A3ARs in this study was carried out as 
described in Methods using [3H] PIA, [3H]CGS 21680 or [125I]AB-MECA as radioligand. Values from the present 
study are expressed as Ki values (mean±s.e.m., n = 3, unless noted), or as percent displacement of radioligand. 
(b) % Activation at 10 µM, relative to cyclic AMP inhibitory effect of 10 µM NECA = 100%. Cl-IB-MECA was also a 
full agonist (100%) in this assay. 
(c) n=1  
(d) Ki (A1 AR)= 1850 nM 
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2.4 Conclusions 
The 2,3’,5’-trisubstituted and 2,3’-disubstituted N6-methyl adenosine derivatives 
described in the present study were synthesized in good overall yields. All the 
compounds had A3AR affinities in the low micromolar or nanomolar range and 
showed very high A3AR selectivity. The 3’-azides appeared to be A3AR antagonists 
with a moderate A3AR affinity. The 3’-amino modification significantly improved the 
A3AR affinity and resulted in partial A3AR agonists. For both the 3’-azido and the 3’-
amino derivatives, the 5’-methylcarbamoyl modification improved the overall affinity. 
Curiously, the presence of a 5’-uronamide did not restore full A3AR efficacy in 2-
substituted derivatives, as was demonstrated in the case of N6-substituents that 
reduced efficacy. The 2-phenylethynyl derivative 2.9 demonstrated high A3AR 
receptor affinity with a Ki value of 15.6 nM and >1000-fold selectivity. Previous 
studies revealed that 3’-amines exhibit a decreased affinity compared to their 3’-
hydroxy analogues. This study demonstrated that introduction of a 2-phenylethynyl 
substituent in concert with the N6-methyl group is capable of overcoming this affinity 
drop. 
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3    2-TRIAZOLE-SUBSTITUTED ADENOSINE 
ANALOGUES 
 
3.1 Introduction 
As described in 1.2.4.2, adenosine receptor antagonists are diverse in structure. 
Most reported antagonists lack the ribose moiety, which seems to be essential for 
agonist activity.194 However, the A3AR, more than other AR subtypes, is amenable to 
the design of nucleoside-based antagonists. The efficacy of nucleoside derivatives in 
activation of the A3AR is particularly sensitive to molecular substitution of the 
ligand.195 A wide range of adenosine derivatives have been shown to antagonize this 
receptor, including the highly potent A1AR agonist 2-chloro-N6-cyclopentyladenosine 
(1.33, Figure 1.15). N6-Benzyl groups are associated with reduced A3AR efficacy, 
leading to partial agonists and antagonists. However, many of the nucleosides so far 
demonstrated to be antagonists of the A3AR are not highly subtype-selective.196 
Nucleoside-based A3AR antagonists maintaining an intact ribose moiety were 
reported by Volpini et al.,197 with a series of 8-alkynyladenosine derivatives (1.36, 
Figure 1.15) that exhibited A3AR selectivity, but suffered from weak A3AR affinity. A 
spirolactam derivative, in which the 5’-N-alkyluronamide group was cyclized onto the 
4’-carbon (1.35, Figure 1.15), was found to potently and selectively antagonize the 
A3AR. 198, 199  An important advantage of nucleoside-based A3AR antagonists over 
other heterocyclic antagonists is the ability to achieve high affinity at murine species, 
which permits in vivo evaluation using wild-type A3AR mice. 
Recently, researchers from CV Therapeutics described a series of 2-
pyrazolyladenosine analogues (1.11, Figure 1.8). 200  Several representative 
compounds containing a N6-methyl substituent proved to display high affinity and 
selectivity for the A3AR. This study confirms the former finding54 that introduction of a 
methyl group into the N6-position increases the affinity for the human A3AR and 
enhances the selectivity versus A1 and A2AARs. On the basis of these results, we 
explored the versatile “click chemistry” approach201 to synthesize two series of N6-
methyl-2-(1,2,3-triazolyl)adenosine derivatives and evaluated their affinity, selectivity, 
and efficacy at the A3AR. Figure 3.1 presents an overview of the performed 
modifications.  
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Figure 3.1  
Overview of the performed modifications 
 
Although a number of 1,2,3-triazole nucleoside derivatives have been described,202 
most involve the replacement of the nucleobase moiety with with a 1,2,3-triazole or 
introduction of 1,2,3-triazole at C8 or at the sugar moiety. A few examples are 
depicted in Figure 3.2. 
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Figure 3.2 
Examples of 1,2,3-triazole nucleoside derivatives described previously 
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3.2 Chemistry  
3.2.1 Synthesis of 2-[(1,2,3)-Triazol-1-yl]adenosine Derivatives 3.1-3.11 
The synthesis of the 1,2,3-triazol-1-yladenosine derivatives is depicted in Scheme 
3.1. Classical Vorbrüggen coupling184 of silylated 2-amino-6-chloropurine and β-D-
ribofuranose 1,2,3,5-tetraacetate yielded nucleoside 3.21. 2-Iodine substitution was 
followed by treatment of the resulting 2-iodo derivative 3.22203 with 2.0 M CH3NH2 in 
THF, allowing simultaneous introduction of the N6-methylamine and deprotection of 
the acetyl groups to obtain 2-Iodo-N6-methyladenosine 3.23. This one step procedure 
was more convenient and resulted in a higher yield (99%) than our earlier described 
method (e.g. 77% yield for 2.19 from 2.18), in which CH3NH2 was generated in situ 
from its hydrochloride salt by treatment with Et3N. Moreover, further treatment with 
7N NH3 in methanol to complete deacetylation was not necessary.  Since the 
reaction conditions204 for a Cu(I)-catalyzed nucleophilic substitution are very similar 
to those used in the “click” variant of Huisgen’s [3+2]cycloaddition, we initially 
attempted to perform a one-pot conversion of 3.23 to the desired 1,4-disubstituted 
1,2,3-triazoles. The 2-azido derivative 3.24 was isolated as the main reaction product, 
and only a minor amount of the appropriate triazole was formed. This event forced us 
to perform the reaction in two steps. First the azido intermediate 3.24 was prepared 
in 66% yield from 3.23. 1H and 13C NMR in DMSO-d6 proved the presence of a 
tautomeric fused tetrazole form (17%) of the 2-azidoadenosine derivative 3.24, due 
to a spontaneous cyclization (Figure 3.3). Such azido/tetrazole tautomerism has 
been previously reported for 2-azidoadenine and for 2-azidoadenosine.205,206  
Next we applied a Cu(I)-catalyzed [3+2]cycloaddition reaction of azide 3.24 with the 
appropriate alkyne to generate the triazole analogues 3.1-3.11 (Scheme 3.1). 207 
Generally, the use of a water/butanol mixture as a solvent for the [3+2]cycloaddition 
allowed simple isolation of the desired compounds, which precipitated from the 
reaction medium. 
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Scheme 3.1 
Synthesis of 1,2,3-triazol-1-yl analogues of N6-methyl-adenosine 3.1 -3.11. Reagents and conditions: (a) isoamyl 
nitrite, I2, CuI, CH2I2 in THF, reflux (79%); (b) CH3NH2 in THF, 2 days (99%); (c) CuSO4.5H2O, sodium ascorbate, 
L-proline, Na2CO3, NaN3, H2O:t-BuOH 1:1, 60 °C (66%); (d) CuSO 4.5H2O, sodium ascorbate, appropriate alkyne, 
H2O:t-BuOH 3:1, rt (32-82%). 
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Figure 3.3  
Azido/tetrazol tautomerism of a 2-substituted adenosine derivative 3.24.  
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3.2.2 Synthesis of 2-[(1,2,3)-Triazol-4-yl]adenosine Derivatives 3.12-3.14 
Similarly, the 1,2,3-triazol-4-yl analogues 3.12-3.14 (Scheme 3.2) were prepared by a 
Cu+-catalyzed Huisgen [3+2]cycloaddition reaction of 2-ethynyl-N6-methyladenosine 
(3.26) with the appropriate azide. 
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Scheme 3.2 
Synthesis of 1,2,3-triazol-4-yl analogues of N6-methyl-adenosine 3.12-3.14. Reagents and conditions: (a) 
trimethylsilylacetylene, CuI, (Ph3P)3PdCl2, DMF (66%); (b) 7N NH3 in MeOH, 0 °C (65%); (c) CuSO 4.5H2O, 
sodium ascorbate, appropriate azide, H2O:t-BuOH 3:1, rt (73-80%).  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: 2-Triazole-Substituted Adenosine analogues 
74 
3.2.3 Synthesis of 5’-Uronamide-2-[(1,2,3)-triazol-1-yl]adenosine Analogues 
3.15a,b-3.19a,b 
The synthesis of the 5’-N-methylcarbamoyl and 5’-N-ethylcarbamoyl 2-(1,2,3)-triazol-
1-yladenosine analogues 3.15a,b-3.19a,b (Scheme 3.3) started with the 2’,3’-O-
isopropylidene protection of 3.23. Therefore, 3.23 was treated with 2,2-
dimethoxypropane and p-toluene sulfonic acid. The low yield of this reaction (45%) 
was caused by the formation of the important side product 3.27bis (Figure 3.4), by 
reaction of 2,2-dimethoxypropane with the 5’-hydroxyl group. Treatment of 3.27bis 
with 80% trifluoroacetic acid allowed us to recuperate the starting material.  2’,3’-
Protection of 3.23 with H2SO4 and anhydrous CuSO4 in dry acetone allowed to obtain 
3.27 in 68% yield. 
N
NN
N
NH
O
OO
O I
3.27bis
O
 
Figure 3.4 
 
To obtain carboxylic acid 3.28, both permanganate oxidation and 2,2,6,6-
tetramethylpiperidinoxy/[bis(acetoxy)iodo]benzene (TEMPO/BAIB) oxidation of 3.27 
were evaluated. However the yields were equally, the TEMPO/BAIB oxidation was 
much better reproducable. Carboxylic acid 3.28 was converted into its p-nitrophenyl 
ester 3.29. Treatment with methylamine or ethylamine gave methyluronamide 3.30a 
and ethyluronamide 3.30b. Deprotection with 80% trifluoroacetic acid yielded 2-iodo-
adenosine analogues 3.31a and 3.31b,208 which were converted into the 2-azido 
intermediates 3.32a and 3.32b in 79% yield. Also here, the presence of a tautomeric 
fused tetrazole form (20%) of the 2-azidoadenosine derivatives, due to a 
spontaneous cyclization, was observed in the NMR spectrum. Finally we applied the 
Cu(I)-catalyzed [3+2]cycloaddition reaction of azides 3.32a and 3.32b with the 
appropriate alkyne to generate the triazole analogues 3.15a,b-3.19a,b. (Scheme 3.3)    
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Scheme 3.3 
Synthesis of 1,2,3-triazol-1-yl analogues 3.15a,b-3.19a,b. Reagents and conditions: (a) anh. CuSO4, H2SO4, dry 
acetone; (b) TEMPO, BAIB, CH3CN:H2O 1:1 (75%); (c) p-nitrophenol, EDCI, DMF, rt; (d) methylamine or 
ethylamine; (e) 80% TFA/H2O (63% for 3.31a; 78% for 3.31b, overall yield from 3.28); (f) CuSO4.5H2O, sodium 
ascorbate, L-proline, Na2CO3, NaN3, H2O:t-BuOH 1:1, 60 °C ( 3.32a: 68% yield; 3.32b: 79% yield); (g) 
CuSO4.5H2O, sodium ascorbate, alkyne, H2O:t-BuOH 1:1, rt (32-54%). 
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3.2.4 Synthesis of Compound 3.20 
N6-(5-chloro-2-methoxybenzyl)-2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(β-D-
ribofuranosyl)adenine (3.20) was prepared in three steps starting from intermediate 
3.22, as depicted in Scheme 3.4. 
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Scheme 3.4 
Synthesis of compound 3.20, 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-(2-chloro-5-methoxybenzyl)-adenosine. 
Reagents and conditions: (a) (i) 2-chloro-5-methoxy-benzylammonium chloride, Et3N, EtOH, reflux, (ii) 7N NH3 in 
MeOH (80%); (b) CuSO4.5H2O, sodium ascorbate, L-proline, Na2CO3, NaN3, H2O:t-BuOH 1:1, 60 °C (82%); (c) 
CuSO4.5H2O, sodium ascorbate, alkyne, H2O:t-BuOH 1:1, rt (59%). 
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3.2.5 Mechanism of the Cu(I) Catalyzed [3+2]Cycloaddition of Azides and 
Alkynes 
Via a concerted mechanism, the Huisgen [3+2]cycloaddition186 of an organic azide 
and a terminal alkyne usually afforded a mixture of 1,4- and 1,5-disubstituted 
regioisomers (Figure 3.5), unless the acetylene component is attached to an 
electron-withdrawing group such as a carbonyl or perfluoroalkyl.209   
 
N NN t N N N + N
N N
1
4
1
5
 
Figure 3.5 
 
By using Cu(I) to catalyse the reaction, a complete regioselectivity for forming only 
1,4- over 1,5-disubstituted triazoles has been achieved with a very efficient 
procedure.210,211  The non-concerted mechanism of this Cu(I) catalyzed variant is 
depicted in Figure 3.6. The sequence begins with the conversion to the alkyne to the 
acetylide I, by coordination of the alkyne to the Cu(I) species, displacing one of the 
ligands. With acetonitrile as a ligand, this step was slightly endothermic (0.6 kcal/mol), 
while with water as a ligand, the displacement process becomes exothermic (-11.7 
kcal/mol). This is in good agreement with the experimental observation that the 
reaction proceeds much faster in aqueous solutions and does not require an amine 
base. 
In the next step, the azide replaces one of the ligands and binds to the copper atom 
via the nitrogen proximal to carbon, forming intermediate II. After that, the distal 
nitrogen of the azide in II attacks the C-2 carbon of the acetylide, forming the unusual 
six-membered copper metallocycle III. This reactive intermediate III undergoes ring 
contraction with formation of the triazolyl-copper derivative IV. Proteolysis of releases 
the triazole product, thereby completing the catalytic cycle. 
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Figure 3.6 
A mechanistic proposal for the catalytic cycle of the Cu(I) Catalyzed [3+2]Cycloaddition of Azides and Alkynes 
 
Cu(I) salts  (e.g. CuI) can be used directly or be generated in situ by reduction of 
Cu(II) salts (e.g. CuSO4. 5H2O). The in situ Cu(I) formation is preferred, because  
formation of undesired byproducts, primarily diacetylenes, bis-triazoles, and 5-
hydroxytriazoles are observed using Cu(I) salts, and Cu(II) salts are less costly and 
often purer than Cu(I) salts. Ascorbic acid or sodium ascorbate proved to be 
excellent reductants. Reactions with Cu(I) salts require acetonitrile as co-solvent and 
one equivalent of a nitrogen base. Acetonitrile can stabilize the Cu(I) oxidation state 
and can keep the catalytic species in the solution.  
This Cu(I)-catalyzed variant is described as one of the most reliable processes of 
“click chemistry”, and therefore often referred to simply as the "click reaction". The 
concept of click chemistry, launched by Sharpless in 2001, 212  is an approach to 
generate substances by joining small units together with heteroatom links. The 
required click chemistry process characteristics include simply reaction conditions 
(ideally, the process should be insensitive to oxygen and water), readily available 
starting materials and reagents, the use of no solvent or a solvent that is benign 
(such as water) or easily removed, and simple product isolation. Since 2001, the click 
chemistry concept has grown in impact within drug discovery.213,214 Especially the  
Huisgen [3+2]cycloaddition reacting terminal alkynes with azides forming 1,2,3-
triazoles has been a convenient reaction. The reaction is chemoselective, it accepts 
almost all other functional groups, it can be performed in aqueous mixtures, and all 
atoms are used without the production of side products. 
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3.3 Biological Evaluation  
The binding affinities of the newly synthesized adenosine derivatives were measured 
at the hA1, hA2A, and hA3ARs expressed in CHO (Chinese hamster ovary) cells as 
previously described, 215  and their relative efficacy to activate the A3AR was 
determined (Table 3.1). The binding affinity of more potent compounds at the ARs 
was evaluated with full competition curves, while the weaker compounds at the hA1 
and hA2A ARs were measured at a fixed concentration of 10 µM. Several compounds 
showed affinity for the A3AR in the low nanomolar range, a very high ratio of A3/A2A 
selectivity, and a moderate-to-high A3/A1 selectivity ratio. The functional A3AR activity 
was measured relative to the full agonist NECA (10 µM) = 100% by a cAMP 
accumulation assay by the method of Nordstet and Fredholm216 or a [35S]GTPγS 
binding assay measured by a variation of the method described by Jacobson et al.217 
The range of efficacies observed depended on the nature of the groups at the 2 and 
N6-positions. 
The 2-azido precursor 3.24 showed high binding affinity at the A3AR (Ki = 10.8 nM) 
and modest selectivity in comparison to the A1AR. The 1,2,3-triazol-1-yl derivatives 
obtained by 1,3-dipolar cycloaddition of azide 3.24 with acetylene (3.1), butyne (3.2), 
and hexyne (3.3) maintained high affinity for the A3AR and increased selectivity. They 
displayed Ki values of 10.4 nM, 13.8 nM, and 11.7 nM, respectively. Also, aromatic 
triazole substituents (3.6, 3.7, 3.9) resulted in similar Ki values of about 10 nM and 
even greater selectivity. Introducing nitrogen or oxygen including substituents at 
position 4 of the 1,2,3-triazole ring (3.4, 3.5, and 3.8) reduced the A3AR affinity. 
Among the investigated analogues, the 4-cyclopentylmethyl derivative 3.10 exhibited 
the highest affinity for the A3AR (Ki = 1.3 nM) and 260-fold selectivity in comparison 
to the A1AR. Replacement of the cyclopentyl ring with a phenyl (3.9) or cyclohexyl 
(3.11) moiety adversely affected A3AR affinity. Remarkably, the 1,2,3-triazol-4-yl 
regiomers (3.12–3.14) showed decreased affinity for the A3AR in comparison to 
similar 1,2,3-triazol-1-yl regiomers. In particular, a comparison of homologous 
compounds 3.12 and 3.9 indicated a 6-fold loss of affinity at the A3AR for the 4-yl 
isomer, approximately the same affinity at the A1AR, and no significant measurable 
gain in affinity at the A2AAR.  
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Replacement of the ribose 4’-hydroxymethyl moiety of the 2-azido derivative 3.24 by 
a 5’-N-ethyluronamide did not appreciably affect affinity at any of the AR subtypes 
(3.32b). However, a similar substitution in the 2-(1,2,3-triazol-1-yl)-substituted series 
provided a modest (2- to 5-fold) increase in A3AR affinity and small or no changes in 
A1AR affinity, as demonstrated for the unsubstituted, 4-butyl, 4-pyridin-2-yl, and 4-
benzyl substituted 1,2,3-triazol-1-yl combinations (3.15b, 3.16b, 3.17b, and 3.18b, in 
comparison to 3.1, 3.3, 3.7, and 3.9, respectively). Curiously, one 5’-N-
ethyluronamide, compound 3.19b, exhibited decreased A3AR affinity (Ki = 11.5 nM) 
compared to its potent 5’-OH analogue 3.10 (Ki = 1.3 nM), while introduction of a 
similar 5’-N-methyluronamide modification was able to partially restore the affinity 
drop (3.19a, Ki = 4.5 nM). This 5’-N-methyluronamide modification also showed 
affinity enhancing effects when applied to the 2-azido derivative 3.24. 2-Azido 5’-N-
methyluronamide derivative 3.32a exhibited enhanced A3AR affinity (Ki = 5.1 nM), 
compared to the corresponding 5’-hydroxymethyl (3.24, Ki = 10.8 nM) and 5’-N-
ethyluronamide (3.32b, Ki = 11.4 nM) analogues.  
For the unsubstituted (3.15a), the 4-benzyl (3.18a) and 4-pyridin-2-yl (3.17a) 
substituted 1,2,3-triazol-1-yl derivatives, the 5’-N-methyluronamide modification 
displayed varying results. The unsubstituted 2-(1,2,3-triazol-1-yl) derivative  3.15a 
exhibited a greatly reduced A3AR affinity (Ki = 76 nM), in comparison to the 
corresponding 5’-hydroxymethyl (3.1, Ki = 10.4 nM) and 5’-N-ethyluronamide (3.15b, 
Ki = 2.1 nM) analogues. For the 4-benzyl substituted 1,2,3-triazol-1-yl derivatives, the 
5’-N-methyluronamide modification (3.18a, Ki = 12.2 nM) did not affect the A3AR 
affinity compared to the corresponding 5’-hydroxymethyl analogue 3.9 (Ki = 9.5 nM), 
while for the 4-pyridin-2-yl substituted analogues, the 5’-N-methyluronamide 
modification yielded better A3AR affinity (3.17a, Ki = 3.6 nM, in comparison to 3.7, Ki 
= 10.3 nM). However, for both the 4-benzyl and 4-pyridin-2-yl substituted analogues, 
the 5’-N-ethyluronamide modification demonstrated the best A3AR affinity.   
Replacement of the N6-methyl substituent of the 2-azido precursor 3.24 by a 
sterically demanding 2-chloro-5-methoxybenzyl group yielded 3.34, which manifested 
very high A3AR affinity (Ki = 1.4 nM). A similar replacement of the N6-methyl group of 
an analogue 3.10, also having a bulky 2-position substituent, to yield 3.20 reduced 
A3AR affinity but not appreciably. This was in accordance with previous observations 
that a simultaneous substitution at the 6- and 2-positions did not improve A3AR 
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affinity.200,40 Thus, the effects of substitution at the 2- and N6-positions were not 
independent; however, it was possible to retain considerable A3AR selectivity (46-fold 
in compound 3.20). This was not representative of findings in a previous study in 
which double substitution greatly diminished the affinity and selectivity at the human 
A3AR.54,200  
Whereas some previously synthesized 2-substituted adenosine derivatives200 
displayed selective A3AR agonist activity, all 2-triazol-1-yl-N6-methyladenosine 
analogues synthesized with an unmodified ribose moiety (3.1-3.11 and 3.20) 
behaved as antagonists or weak partial agonists. Similar findings were reported for 2-
ester derivatives of adenosine, in which a combination of 2 and N6 substitution 
reduced efficacy.218 Direct ring substitution at the 4-position of the 1,2,3-triazole with 
alkyl or aryl groups resulted in weak partial agonists (3.1, 3.2, 3.4-3.8), but subtle 
changes of structure resulted in a loss of efficacy, e.g., the 4-butyl derivative 3.3. 2-
Triazol-1-yl-N6-methyladenosine analogues with a methylene spacer between the 
1,2,3-triazole moiety and a ring system yielded full A3AR antagonists (3.9-3.11, 3.20), 
since they bound to the receptor but did not activate it. The 2-triazol-4-yl-N6-
methyladenosine derivatives (3.12-3.14) also behaved as full A3AR antagonists. Thus, 
the 5’-OH derivatives 3.3, 3.9-3.14, and 3.20 appeared to be A3AR antagonists with 
the following order of decreasing selectivity for the A3AR in comparison to the A1AR: 
4-cyclopentylmethyl-N6-methyl 3.10 (260-fold) >4-butyl-N6-methyl 3.3 (72-fold), 4-
cyclohexylmethyl-N6-methyl 3.11 (67-fold) >4-cyclopentylmethyl-N6-(5-chloro-2-
methoxybenzyl) 3.20. Interestingly, the 5’-N-ethyluronamide modification was able to 
reestablish the A3AR agonist activity in analogues with sterically bulky substitution at 
the 2-position. This is consistent with previous findings that similar 5’-uronamides 
overcome the efficacy-reducing activity of substitution at the adenine 2- and N6-
positions but not at the ribose 3’-position. 199,219,220 Indeed, all 5’-N-ethyluronamide 
analogues studied here (3.15b-3.19b) proved to be full agonists at the A3AR. Among 
them are highly selective A3AR agonists, N6-methyladenosine-5’-N-ethyluronamide 2-
(1,2,3-triazol-1-yl) derivatives: pyridin-2-yl 3.17b (910-fold) > unsubstituted 3.15b 
(280-fold) > benzyl 3.18b (180-fold). Remarkebly, in the 5’-N-methyluronamide series 
only 4-pyridin-2-yl substituted 1,2,3-triazol-1-yl derivative 3.17a was able to 
completely restore the agonist activity, while the other derivatives (3.15a, 3.18a, 
3.19a) exhibited only partial agonist activity. 
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The 2-azido-N6-methyl precursors 3.24, 3.32a and 3.32b showed full agonist activity, 
whereas azide 3.34 having a bulky N6 group showed partial agonist activity. The only 
2-pyrazolyl derivative of which the relative efficacy to activate the A3AR was 
investigated exhibited full agonist activity at the A3AR,55 which highlights the 
remarkably antagonist or weak partial agonist activity of the structurally related 2-
triazolyl adenosine analogues. Although previously reported 2-alkynyl compounds 
were claimed to be adenosine A3AR agonists,54 there are no supporting data 
reported on their A3AR efficacy. In order to be able to compare our observations with 
the efficacy results of the 2-alkynyl adenosine derivatives, we evaluated the A3AR 
efficacy of a few 2-alkynyl substituted adenosine analogues (see 2.2.2). In contrast to 
what the authors presumed, these 2-alkynyl derivatives exhibited full antagonist 
activity (results not shown). Consequently, the introduction of an acetylene or 1,2,3-
triazolyl spacer resulted in A3AR antagonists or partial agonists, whereas a similar 
pyrazolyl spacer probably yielded full A3AR agonists. These observations showed 
that subtle changes or small modifications could influence the A3AR efficacy 
dramatically, which illustrates the difficultty to predict A3AR receptor affinity and 
efficacy. However, the fast and easy preparation of the 1,2,3-triazole series and the 
commercial availability of a large amount of alkynes, permitted us to explore the 2- 
position profoundly, including the effects of the different substituents on the A3AR 
efficacy of all the compounds, which was hardly studied in the previously reported 
studies exploring the 2-position.54,55  
Selected potent agonists in this series were measured in a functional assay of the 
human A2BAR. At a concentration of 10 µM, compounds 3.3-3.7, 3.15, and 3.16 did 
not significantly stimulate adenyate cyclase in human A2BAR-expressing CHO cells 
(<10% of the effect of 10 µM NECA, as a full agonist). Compounds 3.2, 3.8-3.14, 
3.17b, 3.19b, and 3.24 at 10 µM, stimulated adenylate cyclase by <50%. 
Compounds 3.18b and 3.32b produced approximately 50% stimulation at 10 µM. 
Thus, selectivity for the A3AR was demonstrated; these nucleosides that activate the 
A3AR at low nanomolar concentrations activated the A2BAR only at substantial 
micromolar concentrations. On the basis of previous findings, it is predicted that only 
the analogues containing the substituted N6-benzyl group (5-chloro-2-methoxy), i.e., 
full agonist 3.20 and partial agonist 3.34, would be expected to bind in the nanomolar 
range to the rat A3AR. Small alkyl groups at the N6-position, such as methyl and ethyl, 
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although conducive to high affinity at the human A3AR, led to negligible affinity at the 
rat homologue of the receptor. Selected compounds were measured in binding to the 
rat A3AR expressed in CHO cell membranes using [125I]I-AB-MECA. The Ki values 
determined were as follows: compounds 3.5, 3.7, and 3.8, Ki > 10 µM; compound 3.9, 
Ki = 1.79 µM; compound 3.10, Ki = 0.312 µM.  
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  R1 R2 R3 Ki (nM) or (% inhibition) at 10µM %Efficacyb  
        hA1 hA2A hA3 hA3 
3.1 CH2OH H CH3 1000±30 (13±3%) 10.4±0.2 41±6 
3.2 CH2OH ethyl CH3 2920±910 (18%) 13.8±3.3 23d 
3.3 CH2OH butyl CH3 848±76 (23%) 11.7±3.1 3±8 
3.4 CH2OH 2-hydroxyethyl CH3 1270±260 (14%) 45.0±4.4 25d 
3.5 CH2OH dimethylaminomethyl CH3 3800±600 (6%) 117±25 8d 
3.6 CH2OH phenyl CH3 (36%) (5%) 14.9±1.7 14±8 
3.7 CH2OH pyridin-2-yl CH3 1970±210 (40%) 10.3±1.5 11±4 
3.8 CH2OH 4-propoxyphenyl CH3 (49%) (14%) 25.2±2.6 31d 
3.9 CH2OH benzyl CH3 589±55 (20%) 9.5±0.7 -1±5 
3.10 CH2OH cyclopentylmethyl CH3 335±13 (39%) 1.3±0.4 -5±7 
3.11 CH2OH cyclohexylmethyl CH3 1430±60 (16±1%) 21.3±8.1 2±5 
3.12 CH2OH benzyl CH3 770±210 (21±5%) 53.9±6.6 2±3 
3.13 CH2OH 3-methoxybenzyl CH3 957±65 (43±10%) 86.1±3.8 -1±3 
3.14 CH2OH 3-Cl-benzyl CH3 956±6 (39±10%) 81.1±5.0 0±5 
3.15a MeNHCO H CH3 1000±250 (9±7%) 76±10 64.5±0.5c 
3.15b EtNHCO H CH3 590±70 (18±3%) 2.1±0.1 102±5 
3.16 EtNHCO butyl CH3 750±110 (43±1%) 5.6±0.2 89±3 
3.17a MeNHCO pyridin-2yl CH3 (38±4%) (26±6%) 3.6±1.4 95.5±2.6c 
3.17b EtNHCO pyridin-2-yl CH3 1640±90 (45±12%) 1.8±0.6 90±7 
3.18a MeNHCO benzyl CH3 590±80 (30±16%) 12.2±2.8 53.3±1.2c 
3.18b EtNHCO benzyl CH3 510±50 (33±2%) 2.8±1.3 86±5 
3.19a MeNHCO cyclopentylmethyl CH3 1680±620 (26±2%) 4.5±1.2 39.0±1.4c 
3.19b EtNHCO cyclopentylmethyl CH3 1250±150 (36±7%) 11.5±1.4 83d 
3.20 CH2OH cyclopentylmethyl 2-Cl-5-MeO-Bn  830±40 6000 18±11 -6±3 
3.24 CH2OH  CH3 230±10 (23%) 10.8±3.1 84±9 
3.32a MeHCO  CH3 1180±630 (32±1%) 5.1 ±1.7  91.5±6.0c 
3.32b EtNHCO  CH3 429±55 (18±3%) 11.4±4.2 112d 
3.34 CH2OH  2-Cl-5-MeO-Bn 60±10 1800±500 1.4±0.1 44±5 
Table 3.1 
Binding affinities of adenosine derivatives at human A1, A2A and A3ARs expressed in CHO cells and relative 
efficacy at the A3AR.a 
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(a)  All A3AR experiments were performed using cells stably transfected with cDNA encoding one of the human 
ARs. Binding at human A1, A2A, and A3ARs in this study was carried out as described in Methods using [3H]CCPA, 
[3H]CGS 21680 or [125I]AB-MECA as radioligand. Values from the present study are expressed as Ki values 
(mean±s.e.m., n = 3, unless noted), or as percent displacement of radioligand.  
(b)  % Activation at 10 µM, relative to cyclic AMP inhibitory effect of 10 µM NECA = 100%. Cl-IB-MECA was also 
a full agonist (100%) in this assay. 
(c) Activity of nucleoside derivatives tested in a functional assay consisting of guanine nucleotide binding 
([35S]GTPγS) in membranes of CHO cells expressing the human A3AR. The effect of 10 µM NECA is considered 
100%.   
(d) n = 2. 
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3.4 Molecular Modeling  
To explain the structural basis for the high binding affinity of the nucleoside 2-(4-
cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(β-D-ribofuranosyl)adenine 3.10 at 
hA3AR, we performed a computational study of ligand docking in a previously derived 
A3AR model based on the high-resolution structure of bovine rhodopsin. 221 , 222 
Various bound conformations of the C2-substituent and c1 angles for the adenine 
ring were generated for an energetically favorable binding location and orientation, 
and the resulting conformations were compared energetically in the putative binding 
site. The result of docking 3.10 in the putative binding site of the A3AR is shown in 
Figure 3.7. The purine ring was surrounded by a hydrophobic pocket, defined by L91 
(3.33) and L246 (6.51). In addition, the H-bonds formed between the exocyclic amine 
and the hydroxyl group of S247 (6.52) and between the purine N1 atom and the side 
chain of N250 (6.55). The 2’-OH group of the ribose moiety formed a H-bond with the 
side chain of Q167 (EL2), and the 3’-OH group formed an intramolecular H-bond with 
the 5’-OH group. Unlike the previously reported docking models of N6-substituted 
adenosines,221 here the 5’-OH group H-bonded with the side chain of H272 (7.43) 
and the backbone carbonyl group of S271 (7.42). The cyclopentyl moiety interacted 
with aliphatic hydrophobic residues, M177 (5.38) and V178 (5.39), through a 
hydrophobic interaction and were situated in proximity to F168 (EL2) F182 (5.43), 
consistent with the optimized binding affinity of compound 3.10. A comparison of the 
docking modes of Cl-IB-MECA (1.9, Figure 1.8) and compound 3.10 in the putative 
binding domain showed considerable overlap of the ribose rings and of the adenine 
moieties, although in compound 3.10 both were situated a little closer to extracellular 
loop 2 (Figure 3.8). Previously, it was noted that 5’-uronamide analogues, typically of 
derivatives having bulky N6-subsitituents, generally gain affinity in comparison to the 
corresponding 5’-hydroxyl analogue. Here, the 5’-uronamide analogue 3.19 (agonist) 
of the most potent 5’-hydroxyl analogue 3.10 (antagonist) displayed a lower binding 
affinity, which could be explained by the shift of the ribose position in adenosine 
analogue having a bulky 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl) substituent in 
comparison to those having N6 bulky substituents. The binding of the 
cyclopentylmethyl group in 3.10 was directed more toward the upper part of TM5, 
partially overlapping with the binding site of the 3-iodophenyl ring in Cl-IB-MECA. 
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Curiously, other closely related triazoloderivatives displayed a higher potency of the 
5’-uronamide analogues; thus, the compound 3.10 must bind to the receptor in a very 
distinct manner. There was a subtle difference in orientation between the 2-
cyclopentyl group and bulkier groups like benzyl (3.9) or cyclohexylmethyl (3.11), 
which were associated with unfavorable van derWaals interactions and resulted in a 
decrease of binding affinity of 7- and 16-fold, respectively. In addition, the same 
preferred c1 angles of the energetically favorable bound conformation, common to 
Cl-IB-MECA and compound 3.10, were consistent with the empirical finding that the 
combination of bulky N6 and C2 substituents was unfavorable for A3AR selectivity 
because of competitive interaction of these bulky substituents. Thus, the modeling 
has demonstrated that the human A3AR preference of 2-(4-cyclopentylmethyl-1,2,3-
triazol-1-yl) derivatives in the 5’-OH series might be explained by optimal van der 
Waals interactions. 
 
 
Figure 3.7 
Docking complexes of analogue 3.10 
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Figure 3.8 
Superimposition of Cl-IB-MECA in red and compound 3.10 in color by atom type. 
 
Figure 3.7 and Figure 3.8. Molecular docking of compound 3.10 performed under the guidance of prof. dr. 
Kenneth A. Jacobson (see Experimental Section). Residues that were within 5 Å proximity to the ligand in this 
putative binding site were: L91 (3.33), T94 (3.36), H95 (3.37), Q167 (EL2), F168 (EL2), M172 (EL2), S181 (5.42), 
M177 (5.38), V178 (5.39), F182 (5.43), W243 (6.48), L246 (6.51), S247 (6.52), N250 (6.55), C251 (6.56), I268 
(7.39), S271 (7.42), and H272 (7.43). All ligands are represented by ball-and-stick models. The H-bonds are 
indicated with yellow dots. Using MOLCAD ribbon surface program, the A3AR is shown in a ribbon model with 
different colors for each TM (TM1: red, TM2: orange, TM3: yellow, TM4: green, TM5: cyan, TM6: blue, TM7: 
purple, H8: violet). 
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3.5 Conclusions 
Several 2-(1,2,3-triazol-1-yl)-N6-methyl-substituted adenosine derivatives described 
in the present study displayed A3AR affinities in the low nanomolar range, showed 
very high A3/A2A, and a moderate to high A3/A1 selectivity. Contrary to what we 
expected, the 2-triazole analogues with an unmodified ribose moiety (3.1-3.14) 
showed antagonist or weak partial agonist activity at the A3AR. A 2-[4-
cyclopentylmethyl-(1,2,3-triazol-1-yl)]-N6-methyl derivative 3.10 was 260-fold 
selective in binding in comparison to the A1AR. The binding of the 4-
cyclopentylmethyl group in 3.10, in distinction to the binding of closely related bulky 
groups pendent on the triazole ring, was directed more toward the upper part of TM5 
partially overlapping with the binding site of the 3-iodophenyl ring in Cl-IB-MECA. The 
5’-N-ethyluronamide modification was dominant over the efficacy reducing effects at 
the 2-position and was capable of fully re-establishing the A3AR agonist activity, 
resulting in highly potent and selective A3AR agonists 3.15b-3.19b. The most 
selective agonist derivative was compound 3.17b, 9-(5-ethylcarbamoyl-β-D-
ribofuranosyl)-N6-methyl-2-(4-pyridin-2-yl-1,2,3-triazol-1-yl) adenine, which was 910-
fold selective in binding to the A3AR in comparison to the A1AR. Its 5’-N-
methylcarbamoyl analogue (3.17a) also demonstrated highly selective full agonist 
activity at the A3AR, while other 5’-N-methylcarbamoyl derivatives (3.15a, 3.18a, 
3.19a) showed partial agonist activity. The retention of high human A3AR affinity in 
compound 3.20 was not typical of previous findings that double bulky substitution at 
the 2- and N6-positions tended to reduce A3AR affinity markedly. Our observations 
and the comparison with previous findings showed that subtle changes or small 
modifications could influence the A3AR efficacy dramatically, which illustrates the 
difficultty to predict A3AR receptor affinity and efficacy. 
The 2-triazol-1-yl-N6-methyladenosine analogues 3.1-3.11 and 3.15-3.20 constitute a 
novel class of highly potent and selective nucleoside-based A3AR partial agonists 
and antagonists (all of which maintain an intact ribose in the molecular structure) and 
agonists. Since the reported analogues show excellent affinity for the A3AR and span 
the full intrinsic activity range, they might be useful as pharmacological tools or as 
leads for further optimization.  
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4 PYRIMIDINE NUCLEOTIDE ANALOGUES 
 
4.1 Synthesis And Evaluation of 2-Thio UTP 
Derivatives 4.1-4.5 
4.1.1  Introduction 
A recent investigation by Jacobson et al. (results are shown in Table 1.1, Chapter 1) 
showed that distinct modifications of the natural, non-specific P2Y2 receptor agonist 
UTP influenced the P2Y2 receptor affinity and selectivity.123,125 2-Thiouracil 
modification, or replacement of the β-D-ribose part by 2-amino-2-deoxy ribose or by 
β-D-arabinofuranose enhanced both P2Y2 receptor affinity and selectivity relative to 
UTP, while a 4-thio modification enhanced the P2Y2 receptor affinity, but decreased 
P2Y2 receptor selectivity.125  
Based on these results, we combined the 2-thiouracil modification with, respectively, 
a β-D-2’-amino-2’-deoxy ribose and β-D-arabinofuranose to investigate the effect on 
P2Y2 receptor affinity and selectivity. We also envisaged to combine the 2-thio and 4-
thio modification to overcome the selectivity drop caused by 4-thionation. 5’-
Phosphorylation of the synthesized 2-thio derivatives should gain access to new 
possible P2Y2 receptor agonists. Figure 4.1 represents an overview of the 
synthesized compounds. 
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Figure 4.1 
Overview of the synthesized compounds 4.1-4.5 
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4.1.2  Chemistry 
4.1.2.1 Synthesis of 2-Thiouridine 4.12 
The different Vorbrüggen reaction conditions performed for the coupling of silylated 
2-thiouracil with 1-O-acetyl 2,3,5-tri-O-benzoyl β-D-Ribofuranose are summarized in 
Scheme 4.1. We first explored conditions a-c to avoid the use of toxic stannic 
chloride and circumvent the difficulty in isolation of the desired product because of 
inseparable emulsion during extraction. Therefore, we used trimethylsilyltrifluoro- 
methanesulfonate (TMSOTf) as a catalyst. However, in the one-pot coupling reaction, 
using N,O-bis(trimethylsilyl)acetamide (BSA) as a silylating agent, the persistent 
turbidity of the mixture already indicated an unsuccessful silylation. After treatment 
with TMSOTf, sugar degradation occured. 
Alternatively, distinct silylation with hexamethyldisilazane (HMDS) and (NH4)2SO4 
resulted in a clear solution after 6 h. Subsequent addition of the silylated base and 
TMSOTf to a solution of the ribose sugar should result in N1-glycosylation of the base. 
However, when performing the latter step in dichloroethane sugar degradation was 
observed. Acetonitrile as coupling solvent yielded S-glycosylation, which was 
confirmed by the HMBC (Heteronuclear Multiple Bond Connectivity) NMR data: a 
3J(1H-13C) long range coupling between H-1’ and C-2  was observed, while the 
expected H-1’-C-6 or H-1’-C-4 3J(1H-13C) long range couplings (typically for N1- or N3-
glycosylation, respectively) were abscent. Earlier reported S-riboside formation223,224 
generally occurred because of sterical hindrance of the N1-position by 6-substituents. 
The S-nucleoside was instable under ammonia debenzoylation conditions and 
degraded during silica gel purification. Therefore, sodium methoxide in methanol or 
potassium carbonate in methanol/THF was used for deprotection and the purification 
was executed by extraction of the resulting benzoic acid methyl esters with 
diethylether and lyofilisation of the water layer.  
Despite our efforts to explore alternative coupling procedures, we were forced to 
apply the described coupling methods using stannic chloride as a catalyst.225,226 The 
best yield (79%) was obtained using 1.1 equivalents sugar, 1 equivalent silylated 
base and 1.3 equivalents SnCl4. We preferred to use the benzoylated sugar for the 
coupling, which allowed easy work-up after sodium methoxide deprotection. The 
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benzoic methyl esters were extracted with diethylether and subsequent lyophilisation 
of the water layer yielded 2-thiouridine without silica gel purification. 
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Scheme 4.1  
Overview of the different Vörbruggen coupling attempts. Reagents and conditions: (a) BSA, TMSOTf, CH3CN; (b) 
(i) HMDS, (NH4)2SO4; (ii) TMSOTf, C2H4Cl2; (c) (i) HMDS, (NH4)2SO4; (ii) TMSOTf, CH3CN (51%); (d) (i) HMDS, 
(NH4)2SO4; (ii) SnCl4, C2H4Cl2 (79%); (e) K2CO3, MeOH:THF (97%); (f) NaOMe, MeOH (96%). 
 
Alternatively, we started from 2’,3’-O-isopropylidene-uridine (4.14) and adapted the 
method of Manoharan 227  or the synthesis of 2-thiouridine (Scheme 4.2). In this 
procedure, 5’-mesylation of 2’,3’-O-isopropylidene-uridine (4.14) was followed by in 
situ generation of 2,5’-O-anhydrouridine and subsequently opening of the anhydro 
bridge with ethoxide. Isopropylidene deprotection of compound 4.16 with 80% TFA in 
water yielded 2-O-ethyluridine (4.17), that was treated with H2S in anhydrous pyridine 
to allow 2-thionation, resulting in 2-thiouridine (4.12).  
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Scheme 4.2  
Alternative synthetic route for 2-thiouridine (4.12). Reagents and conditions:  (a) 2,2-dimethoxypropane, p-toluene 
sulfonic acid, acetone, 4h (77%); (b) methanesulfonyl chloride, pyridine, 0 °C, 2h (91%); (c) DBU, dry  EtOH, reflux, 
10h (91%); (d) 80% trifluoroacetic acid aq., 2h (86%); (e) H2S, pyridine, 250 psi, 48h (86%). 
 
2’,3’-O-Isopropylidene protection of uridine was performed because the selective 5’-
mesylation of uridine resulted in an unseparable mixture (4.18 a,b,c, 61%, 23% and 
16%, resp.). The attempt to perform selective 5’-tosylation resulted in 2’-tosyluridine 
(4.19) as the major product. (Scheme 4.3) 
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Scheme 4.3 
Unsuccessful selective 5’-mesylation and 5’-tosylation. Reagents and conditions: (a) methane sulfonyl chloride, 
pyridine; (b) p-toluene sulfonyl chloride, pyridine (51%). 
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4.1.2.2 Synthesis of 2’-Amino-2’-deoxy 2-thiouridine 4.33 
Our first attempt for the synthesis of 4.33 (Scheme 4.6) started from 2-thiouridine 
(4.12) (Scheme 4.4). After the synthesis of 2,2’-S-anhydro-1-β-D-arabinofuranosyl-2-
thiouracil (4.22) from 2-thiouridine (4.12), we intended to open the anhydro ring with 
NaN3  and to subsequently reduce the resulting 2'-azido-2’-deoxy-2-thiouridine to the 
corresponding 2’-amine. We planned to follow a similar route to gain access to 2’-
chloro-2’-deoxy-2-thiouridine. Compound 4.22 was synthesized starting from 2-
thiouridine. Selective 2’-mesylation was performed after tetraisopropyl 
disiloxanylidene (TIPDS) protection of the 3’- and 5’-hydroxyl groups. Under basic 
conditions, intramolecular nucleophilic attack of the 2-thio group resulted in the 2,2’-
S-anhydro bridge formation (4.21). After TIPDS deprotection, we obtained 2,2’-S-
anhydro-1-β-D-arabinofuranosyl-2-thiouracil (4.22), which was treated with, 
respectively, NaN3 and HCl to afford the desired 2’-substituted 2-thiouridine 
derivatives. Unfortunately, both attempts to open the 2,2’-S-anhydro bridge resulted 
in degradation of the starting material (see experimental section).  
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Scheme 4.4 
First attempt for the synthesis of 2’-modified 2-thiouridine. Reagents and conditions: (a) TIPDSCl2, imidazole, 
DMF, 0 °C  30 °C, overnight (77%); (b) (i) MsCl, pyridine, 4h  (ii) DBU, CH3CN (62%); (c) TBAF, THF, 2h (74%); 
(d) R = N3: NaN3, benzoic acid, DMF; R = Cl: HCl in dioxane, 75 °C,  overnight or R = Cl: (i) (Ac)2O, pyridine, 
overnight (ii) AcCl, benzoic acid, CH3CN. 
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Consequently, we started to investigate an alternative synthetic procedure (Scheme 
4.5), starting from 2,2’-O-anhydrouridine (4.23), which is commercially available. 2,2’-
O-Anhydrouridine (4.23) was treated with H2S and triethylamine in anhydrous DMF to 
yield arabino analogue 4.24. TIPDS protection of the 3’- and 5’- hydroxyl groups was 
followed by 2’-triflation with triflic chloride and DMAP. Nucleophilic substitution of the 
resulting triflate 4.26 with N,N,N’,N’-tetramethylguanidiniumazide gave in a very low 
yield (10%) 2’-azide 4.27, which again forced us to investigate an alternative 
synthetic route to obtain 2’-amino-2’-deoxy-2-thiouridine (4.33). 
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Scheme 4.5 
Second attempt for the synthesis of 2’-amino-2’-deoxy-2-thiouridine. Reagents and conditions: (a) H2S, 
triethylamine, DMF, 240 psi, 48 h (70%); (b) TIPDSCl2, imidazole, DMF (81%); (c) TfCl, DMAP, CH2Cl2; (d)  
N,N,N’,N’-tetramethylguanidiniumazide, DMF (10% from 4.25).  
 
To get round these difficulties, we adapted Manoharan’s synthesis procedure227 for 
the synthesis of 2’-amino-2’-deoxy-2-thiouridine (4.33) (Scheme 4.6). 2’-Azido-2’-
deoxyuridine (4.30) was obtained via opening of 2,2’-anhydrouridine (4.23) with NaN3 
in DMF.228 After selective mesylation of the 5’-hydroxyl group of 4.30, the resulting 5’-
methanesulfonate ester 4.31 was converted to 2’-azido-2’-deoxy-2-O-ethyluridine 
(4.32). Treatment of 4.32 with H2S in anhydrous pyridine allowed simultaneous 2-
thionation and reduction of the 2’-azido group, resulting in 2’-amino-2’-deoxy-2-
thiouridine (4.33). The 2-thionation was confirmed by the 13C NMR resonance signal 
of C-2, which shifts to low magnetic field (177.66 ppm) compared to uridine (150.66 
ppm). 
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Scheme 4.6 
Synthesis of 2’-amino-2’-deoxy 2-thiouridine 4.33. Reagents and conditions (a) NaN3, DMF, 150 °C, 15h (52%); (b) 
MsCl, pyridine, 0 °C (61%); (c) NaHCO 3/EtOH, reflux, 36h (57%); (d) H2S, pyridine, 50 °C, 250 psi, 24h (77%). 
4.1.2.3  Attempts to Synthesize Other 2’-Substituted 2-Thiouridine 
Derivatives 
Introduction of a 2’-fluorine is described to lock the sugar pucker in the North 
conformation. The anomeric effect of the 2’-fluorine favours the pseudoaxial position 
of the electronegative ligand at the C-1’-position, which forces the sugar to adopt the 
North conformation. 229 In search for a general synthetic method for 2’-substituted 2-
thiouridine to investigate the influence of electronegative ligands such as 2’-F and 2’-
Cl on the 2-thioUTP conformation and receptor binding and to obtain an alternative 
route to synthesize 2’-amino derivative 4.33, we decided to explore the use of 
Lawesson’s reagent227 (Scheme 4.8 and Scheme 4.9).  Lawesson’s reagent has 
been generally used for the conversion of the carbonyl group of nucleobases to a 
thiocarbonyl group. For uracil and thymine, the reactivity of the 4-carbonyl group is 
much higher than that of the 2-carbonyl group. Therefore, 4-O-protection is 
necessary for selective 2-thionation. 
  . 
4.1.2.3.1 Lawesson’s Reagent230 
Lawesson’s reagent (LR) or 2,4-bis(p-methoxyphenyl)-1,3-dithiaphosphetane-2,4-
disulfide can be prepared easily and safely by the reaction of phosphorous 
pentasulfide with refluxing anisole, but is also commercially available. The usual 
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method of thionation is performed in refluxing benzene, toluene, or xylene, in which 
the suggested mechanism involves dissociation equilibriums, which yield II (Scheme 
4.7). These decomposition products can then react with a carbonyl functional group 
to form a four-membered ring (III), which decomposes to the corresponding 
thioketones in a Wittig-like reaction. The formation of thionated products is promoted 
by the thermodynamic stability of the resulting strong P=O bond.  
Thionation of nucleosides, purines, and pyrimidines with LR is widely applied to 
obtain sulfur analogues. To avoid side reactions, the hydroxyl groups are properly 
protected as ethers or esters. Unprotected hydroxyl groups are transformed to thiols 
with 0.5 equivalents of LR, while higher equivalents lead to alkenes as elimination 
products and in some cases rearrangement products are observed. When two 
carbonyl groups are present at the 2- and 4-positions of the pyrimidine, LR is used for 
selective thionation of the 4-carbonyl group. An excess of LR helps for thionation of 
both carbonyl groups.  
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Scheme 4.7 
Suggested mechanism of thionation using Lawesson’s reagent (P = protective group) 
 
 
4.1.2.3.2 Attempted Synthesis of 2’-Chloro-2’-deoxythiouridine and 2’-Azido-2’-
deoxythiouridine 
2’-Chloro-2’-deoxyuridine (4.34) was obtained by treatment of 2,2’-O-anhydrouridine 
(4.23) with saturated HCl in dioxane.231 After protection of the 3’ and 5’ hydroxyl 
groups as a cyclic TIPDS ether (4.35a), 4-O-protection is necessary given the much 
higher reactivity of the 4-carbonyl group in comparison to the 2-carbonyl group. 
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Based on Sekine’s comparison of different possible 4-O-protective groups in 
thionation reactions with Lawesson’s reagent, we have chosen 2,6-dimethylphenyl 
ether protection. 232  Treatment of 4-O-protected 4.36a with Lawesson’s reagent 
resulted in 2-thionation in concert with unexpected 1’,2’-elimination (4.37, 20% yield). 
The low yield was due to degradation of the starting material during the reaction with 
Lawesson’s reagent. Similarly, the attempted synthesis of 2’-azido-2’-deoxy-2-
thiouridine started with the 3’,5’-O-TIPDS-protection and 4-O-protection of compound 
4.30. Subsequent reaction with Lawesson’s reagent only resulted in degradation of 
the starting material. 
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Scheme 4.8 
Attempted synthesis of 2’-chloro-2’-deoxy-2-thiouridine and 2’-azido-2’-deoxy-2-thiouridine. Reagents and 
conditions. (a) 4.30: NaN3, DMF, 150 °C, 15h (52%, Scheme 4.6); 4.34: HCl in dioxane (69%); (b) TIPDSCl2, 
imidazole, DMF (78%); (c) (i) Na2CO3, tetrabutylammonium bromide, 2,4,6-triisopropylbenzene sulfonylchloride, 
CH2Cl2; (ii) 2,6-dimethylphenol, DABCO, Et3N, CH3CN (84-88%); (d) Lawesson’s reagent, toluene. 
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4.1.2.3.3 Attempted Synthesis of 2’-Deoxy-2’-fluoro-2-thiouridine 
For the synthesis of 2’-deoxy-2’-fluorouridine (4.41), the 3’- and 5’-hydroxyl groups of 
2,2’-O-anhydrouridine (4.23) were protected with tetrahydropyran groups. 
Subsequently opening of the anhydro bridge with sodium hydroxide yielded arabino 
nucleoside 4.39. After treatment with diethylamino sulphur trifluoride (DAST) to 
introduce the 2’-fluoro group, deprotection of the tetrahydropyran groups with p-
toluene sulfonic acid was performed to obtain 2’-fluoro analogue 4.41. 
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Scheme 4.9 
Attempted synthesis of 2’-deoxy-2’-fluoro-2-thiouridine. Reagents and conditions: (a) 3,4-dihydro-2H-pyrane, p-
toluene sulfonic acid, DMF; (b) NaOH, EtOH:H2O (89% from 4.23); (c) DAST, pyridine, CH2Cl2; (d) p-toluene 
sulfonic acid, MeOH (71% from 4.39); (e) TBDMSCl, imidazole, DMF (61%); (f) (i) Na2CO3, tetrabutylammonium 
bromide, 2,4,6-triisopropylbenzene sulfonylchloride, CH2Cl2; (ii) 2,6-dimethylphenol, DABCO, Et3N, CH3CN (82%); 
(g) Lawesson’s reagent, toluene. 
        
After protection of the 3’ and 5’-OH as TBDMS ether, followed by 4-O-protection, 
attempted 2-thionation with Lawesson’s reagent also resulted in degradation of the 
starting material.  
Alternatively, we attempted to apply the procedure we used for the synthesis of 2’-
amino-2’-deoxyuridine (Scheme 4.6), starting from 2’-deoxy-2’-fluorouridine (4.41). 
Therefore, selective 5’-mesylation or 5’-tosylation was necessary to allow the 2,5’-O-
anhydro bridge formation. Unfortunately, 3’,5’-O-dimesylation was obtained, while no 
reaction was observed under 5’-tosylation conditions. 
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4.1.2.4 5’-Phosphorylation of 2-Thio Uridine Derivatives 4.1-4.4 
Triphosphate 4.1 was prepared by phosphorylation of the corresponding nucleoside 
in two steps (4.24) (Scheme 4.10). The unprotected nucleoside 4.24 was first treated 
with phosphorous oxychloride to yield the 5’-monophosphate, which was isolated, 
activated with 1,1’-carbodiimidazole and treated with bis(tri-n-butylammonium)pyro-
phosphate. 
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Scheme 4.10 
5’-Phosphorylation of 4.24. Reagents and conditions: (a) (i) POCl3, PO(OCH3)3, 4h, 0 °C.; (ii) Bu 3N, CDI, DMF; 
(Bu3NH)2H2P2O7; TEAB 1M (6.6%). 
 
After protection of the 2’-amino group of nucleoside 4.33 by trifluoroacetylation, the 
phosphorylation was performed as shown in Scheme 4.11. During purification by ion 
exchange, partial hydrolysis yielded a mixture of 4.2 and 4.3, which was readily 
separable by HPLC. 
HN
O
S N
O
NH2OH
OP
O
O
OP
O
O
OP
O
O
O
HN
O
S N
O
NH2OH
HO
HN
O
S N
O
NHCOCF3OH
HO
HN
O
S N
O
NHCOCF3OH
OP
O
O
OP
O
O
OP
O
O
O
(HNEt3)4
a b
(HNEt3)44.33 4.46 4.2
4.3
 
Scheme 4.11 
Synthesis of 5’-triphosphates 4.2 and 4.3. Reagents and conditions: (a) DIEA, ethyl trifluoroacetate, DMF, room 
temperature, 13h (88%); (b) (i) POCl3, PO(OCH3)3, Proton Sponge, 0 °C, 2h; (ii) (Bu 3NH)2P2O7H2, Bu3N, DMF, 
10min; (iii) 0.2 M triethylammonium bicarbonate solution, room temperature, 1 h (12% of 4.2; 7% of 4.3). 
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A 2’-acetamido derivative was obtained by direct acetylation of 4.2 (Scheme 4.12). 
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Scheme 4.12 
2’-Acetylation of compound 4.2. Reagents and conditions: (a) acetic anhydride, H2O, room temperature, 6 h 
(57%). 
 
4.1.2.5 Synthesis of 2,4-Dithiouridine and Phosphorylation Attempt: 
Synthesis of 4-Methylthio Analogue 4.5 
 
The synthesis of 4-methylthio analogue 4.5 is depicted in Scheme 4.13. 4-Thionation 
of 2’,3’,5’-O-triacetyl-2-thiouridine (4.10) using Lawesson’s reagent, 230 followed by 
sugar deprotection afforded 2,4-dithiouridine (4.45) in 75% yield  from 4.10. An 
attempt to synthesize the corresponding triphosphate led to isolation only of the 4-
methylthio analogue (4.5). A possible explanation for the observed S-methylation is a 
nucleophilic attack of the 4-S to the trimethylphosphate reagent. Attempts to perform 
the 5’-phosphorylation in the absence of trimethylphosphate or in the absence of 
proton sponge, probably responsible for the nucleophilic character of 4-S, by NH-
deprotonation, were not successful. 
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Scheme 4.13 
Attempted synthesis of 2,4-dithioUTP. Reagents and conditions: (a) Lawesson’s reagent, toluene, 80 °C,  
overnight (83%); (b) NaOMe, MeOH, reflux, 4 h (91%); (c) (i) POCl3, proton sponge, PO(OMe)3, 0 ˚C; (ii) 
(Bu3NH)2H2P2O7, Bu3N, DMF, 0 ˚C (6.4%). 
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4.1.3  Biological Evaluation 
Activation of phospholipase C by a range of concentrations of each nucleotide 
derivative was studied in 1321N1 astrocytoma cells stably expressing the human 
P2Y2, P2Y4, and P2Y6 receptors (Table 4.1), by reported methods.123,125, 233 , 234 
Tritiated inositol phosphates produced from a radiolabeled myo-inositol precursor 
were measured using a standard ion exchange method. 5’-Triphospate 4.1 
demonstrated a moderately potent and a highly selective agonist activity at the P2Y2 
receptor, while 5’-triphosphate 4.2 was 6 times more potent than the natural ligand 
UTP and 300-fold selective in activation of the P2Y2 receptor in comparison with the 
P2Y4 receptor (Table 4.1, Figure 4.2). The potency of 4.2 was greatly reduced upon 
acetylation (4.4) and reduced to a lesser degree upon trifluoroacetylation (4.3). 4-
Methylthio modification (4.5) dramatically affected the potency of 2-thioUTP (1.45). 
The synthesized compounds 4.1-4.5 were nearly inactive at the P2Y6 receptor.  
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 R’ R X Y EC50 EC50 EC50 
     at hP2Y2 (nM)a at hP2Y4 (nM)a At hP2Y6 (nM)a 
UTP H OH O O 49 ± 12 73 ± 2 >10,000 
1.45 H OH S O 35 ± 4 350 ± 10 1,500 
1.42 H NH2 O O 62 ± 8 1200 ± 300 >100,000 
1.43 OH H O O 87 ± 10 710 ± 80 No data 
4.1 OH H S O 140 ± 10 7930 ± 800 NEb 
4.2 H NH2 S O 8 ± 2 2400 ± 800 >10,000 
4.3 H NHCOCF3 S O 470 ± 60  8300 ± 1200 NEb 
4.4 H NHCOCH3 S O 6500 ± 1400 NEb NEb 
4.5 H OH S SMe 2740 ± 520 ~10,000 >10,000c 
Table 4.1 
In vitro pharmacological data for UTP and its analogues in the stimulation of PLC at recombinant P2Y2, P2Y4, and 
P2Y6 receptors expressed in 1321N1 astrocytoma cells. 
(a) Agonist potencies reflect stimulation of PLC determined as reported123,125,126 and were calculated using a four-
parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC50 values (mean 
standard error) represent the concentration at which 50% of the maximal effect is achieved.  
(b) NE - no effect at 10 µM 
(c) ≤50% effect at 10 µM 
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Figure 4.2 
Activation by compound 4.2 of PLC in 1321N1 astrocytoma cells expressing the human P2Y2 receptor or P2Y4 
receptor. 
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4.1.4  Molecular Modeling 
The putative binding modes of the synthesized P2Y2 receptor agonists were studied 
by molecular docking with a Monte Carlo Multiple Minimum (MCMM) conformational 
search analysis on several known nucleotide ligands of this receptor subtype. As 
described in the Experimental Section (5.3.2.3), UTP (1.41) initially was manually 
docked inside the putative binding site of the P2Y2 receptor. The published data of 
site-directed mutagenesis combined with computational studies of P2Y receptors 
were taken into account.123,149,151 Because the Northern (N) conformation of the 
ribose ring of the ligand was proposed to be important for recognition,234 UTP and all 
other studied ligands were sketched and initially docked in their (N)-conformation. In 
addition, the anti-conformation of the ligand base ring was used during the modeling 
studies. Interestingly, in the original rhodopsin-based model of the P2Y2 receptor, the 
side chain of one of the key cationic residues, namely R3.29, was oriented in the 
opposite direction from the putative binding pocket, but during the simulation it shifted 
toward the binding cavity. After MCMM refinement of the initially obtained docking 
complex, the α-phosphate group of the UTP triphosphate chain was bonded to R7.39 
whereas R6.55 could interact with both α- and γ-phosphate groups and R3.29 
interacted with the γ-phosphate group of UTP (Figure 4.3A). In addition, the γ-
phosphate group of the ligand formed H-bonds with H184, located in EL2 directly 
after the conserved cysteine residue, with the backbone nitrogen atom of D185 and 
with the hydroxyl group of Y6.59. Another tyrosine residue, Y3.33, was H-bonded to 
the β-phosphate group. 
In the model obtained after MCMM calculations, the 2’-hydroxyl group of UTP 
appeared near the conserved F6.51 (in the P2Y11 and P2Y14 receptors, this position 
is Y6.51). This observation suggests the possibility of OH/pi H-bonding between the 
2’-hydroxyl group and the aromatic ring of F6.51. Several examples of similar 
interactions seen in protein crystallographic structures were reviewed by Meyer et 
al. 235  The hypothesis of H-bonding of the 2’-hydroxyl group to the receptor is 
consistent with the experimental SAR.149 For example, 2’-deoxy-UTP (EC50 = 1.08 
µM) is 22-fold less potent than UTP (EC50 = 0.049 µM), whereas the replacement of 
the 2’-hydroxyl group by a 2’-methoxy group (EC50 = 14.3 µM) reduced the potency 
further (290-fold weaker than UTP). In the latter case, this model showed that not 
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only was the suggested OH/pi H-bond lost but the 2‘-O-methyl group also interfered 
sterically with the aromatic ring of F6.51. Agonist activities of the ligands, taken 
together with the binding mode obtained, strongly suggest that the hydroxyl group at 
the 2’-position is important as a donor but not as an acceptor of a H-bond.  
The binding mode of 2’-deoxy-2’-amino-UTP (1.42), which was found to maintain 
potency in activation of the P2Y2 receptor,149 was studied with MCMM calculations. 
The 2’-amino group (pKa = 6.2 in a related derivative)128,236 was examined in both 
unprotonated and protonated positively charged forms. Similar to the 2’-hydroxyl 
group of UTP, the 2’-amino group of 1.42 was found near and oriented toward the 
aromatic ring of F6.51. Both protonated and unprotonated forms of the ligands 
interacted with this residue. However, the protonated form of this amino group was 
involved in a stronger cation-pi interaction with F6.51. In addition, the protonated 2’-
NH3+ group acted as a H-bond donor to the hydroxyl of Y3.33 in this model (Figure 
4.3B).  
In the receptor-ligand complexes obtained for all studied agonists, the 3’-hydroxyl 
group of the ligand appeared to be H-bonded to the α-phosphate group of the 
triphosphate chain. This could be an important intramolecular interaction to stabilize 
the ribose ring in its (N)-conformation, to facilitate the interaction of the 2’-hydroxyl 
group with F6.51.  
In this model, the oxygen atom at position 4 of the UTP ring was H-bonded to the 
hydroxyl group of U1.39, and S7.43 accepted a H-bond from the 3-NH group of the 
ligand. In contrast, the oxygen atom at position 2 was not involved in H-bonding with 
the receptor. In addition, F3.22, conserved among all subtypes of P2Y2 receptors, 
was found to be involved in pi-pi interactions with the uracil ring of UTP.  
The binding mode of the potent and selective compound 4.2 was also studied with 
MCMM calculations, and the results were similar to those for 1.42, in which the 2’-
amino group in its protonated form was involved in cation-pi interaction with F6.51 
and as H-bond donor to Y3.33 (Figure 4.3B). The potency of 4.2 was greatly reduced 
upon acetylation (4.4) and reduced to a lesser degree upon trifluoroacetylation (4.3). 
These observations are consistent with the binding modes obtained for compound 
4.4.  In the model of the P2Y2 receptor complex with compound 4.4, the H-bond 
between F6.51 and the NH group of the acetamide moiety was not observed. 
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Moreover, the methyl group of this moiety undesirably apearded near the OH-group 
of Y3.33 and the NH2 group of R6.55.  The oxygen atom of the acetyl group was not 
involved in interactions with the receptor. We speculate that in the case of compound 
4.3, the CF3 group, which is more electronegative than CH3, provides some 
favourable interactions with positively charged R6.55, improving the potency of 
compound 4.4. 
 
 
Figure 4.3 
Molecular modeling of the synthesized P2Y2 receptor agonists performed under the guidance of prof. dr. Kenneth 
A. Jacobson (see experimental section). Binding modes of UTP (A) and 2’-amino-2’-deoxy-2-thioUTP (A) to the 
human P2Y2 receptor following MCMM calculations. The 2’-amino group is shown in its protonated form, which 
can be involved in cation-pi interactions with F6.51 and can form an additional H-bond with Y3.33  
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4.1.5  Conclusions 
The combination of two favourable UTP modifications resulted in the highly potent 
P2Y2 receptor agonist 4.2, which was 300-fold selective in activation of the P2Y2 
receptor in comparison to the P2Y4 receptor. 5’-Triphosphate 4.2 should prove to be 
very useful as a pharmacological probe for studying P2Y2 receptor action. Modeling 
provided an explanation for the general stabilizing effect of the 2’-amino modification 
of UTP in P2Y2 receptor recognition. 
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4.2 Synthesis and Evaluation of Uridine 5’-
Phosphonodiphosphates 4.6 and 4.7 
4.2.1  Introduction 
Even when applied for topical use (cystic fibrosis) the natural P2Y2 receptor ligand 
UTP and its many reported analogues of this messenger are sensitive to degradation 
by ecto-nucleotidase(s) at the airway surface, which reduces the duration of action 
when administered by inhalation. Replacement of the α-phoshate group by an 
isosteric phosphonate group should enhance the metabolic stability, since a 
phosphorous-carbon bond is not susceptible to phosphatase hydrolysis. 
To assess the influence of this isosteric modification on P2Y2 receptor affinity and 
efficacy, we synthesized a 5’-phosphonodiphosphate analogues of UTP (4.6 and 4.7), 
starting from 2’,3’-O-isopropylidene-uridine (4.14) (Scheme 4.14).  
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Figure 4.4 
Synthesized 5’-phosphonodiphosphate analogues of UTP 
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4.2.2  Synthesis  
4.2.2.1  Synthesis of Uridine 5’-Phosphonodiphosphates 4.6 and 4.7 
The synthesis of the target phosphonodiphosphate 4.7 is depicted in scheme 4.14. 
5’,6’-Vinyl phosphonate 4.47 was synthesized by oxidation of 2,3-O-isopropylidene- 
uridine (4.14) to the 5’-aldehyde intermediate, which was immediately reacted with 
freshly prepared [(diethoxyphosphinyl)methylidene] triphenylphosphorane 4.57. 237 
Catalytic hydrogenation of the resulting vinyl phosphonate ester 4.47 in the presence 
of palladium on carbon gave the corresponding saturated phoshonate ester 4.49.  
Simultanous deprotection of the phosphonate diester and the acetonide was 
achieved upon treatment with TMSBr, yielding the corresponding 5’-phosphonate  
4.50. To prepare the diphosphate derivative, 4.50 was activated with CDI in DMF, 
followed by the addition of bis(tri-n-butylammonium)pyrophosphate. The resulting 
diphosphate contained a 2’,3’-cyclic carbonate moiety resulting from a reaction of the 
2’- and 3’-hydroxyl groups with CDI. Hydrolysis of the cyclic carbonate was achieved 
upon treatment with triethylammonium bicarbonate (TEAB) buffer to obtain the 
desired 5’-phosphonodiphosphate 4.7. To assess the influence of a double bond, 
intermediate 4.47 was also converted to the corresponding diphosphate 4.6.   
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Scheme 4.14 
Synthesis of uridine 5’-phosphonodiphosphates 4.6 and 4.7. Reagents and conditions: (a) (i) TFA, DCC, pyridine, 
DMSO or Dess-Martin periodinane, pyridine, CH3CN or IBX, CH3CN; (ii) (EtO)2P(O)C=PPh3 (4.57), DMSO (34-
44%); (b) TMSBr, CH2Cl2 (62%); (c) Bu3N, CDI, DMF; (Bu3NH)2H2P2O7; TEAB 1M (5.4%-22%); (d) H2, Pd/C 
(84%). 
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4.2.2.2  Attempts to Synthesize 2-Thiouridine 5’-
Phosphonodiphosphate 
Based on the P2Y2 receptor affinity and selectivity enhancing effects of 2-thioUTP125 
and 2’-amino-2’-deoxy-2-thioUTP (4.2) compared to the corresponding uracil 
analogues UTP and 2’-amino-2’-deoxy-UTP (1.42) (results are shown in Table 4.1), 
we have chosen to synthesize the 2-thio analogue of 4.7 starting from intermediate 
4.16 (Scheme 4.15). 2’,3’-O-Isopropylidene-2-thiouridine (4.51) was prepared by 
treatment of 4.16 with H2S in pyridine. In an attempt to convert this nucleoside to the 
vinylic phosphonate, we followed the same two-step procedure as described for 4.47. 
Remarkably, the 1H NMR spectrum of the major reaction product indicated the 
absence of a hydrogen at C-4’. Apparently, expected 5’-oxidation followed by 
condensation of the 5’-aldehyde intermediate with phosphor ylide 4.57 occurred in 
concert with an intramolecular S2,4’-anhydro ring formation, resulting in compound 
4.52.  The structural assignement of 4.52 was made from the following observations: 
in the 1H NMR spectrum, H-3’ appeared as a sharp doublet, C-4’ and N-3 were 
devoid of a proton. The absence of the two protons was confirmed by mass 
spectrometry ([M+H]+ calculated for the desired compound: 433.1, [M+H]+ found: 
431.1). The 13C NMR signals for C-4’ and C-2 at 113.68 and 156.33 ppm, 
respectively, were in agreement with the reported signals of a similar earlier reported 
O2,4’-anhydro uridine derivative.238  
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Scheme 4.15 
Unexpected synthesis of S2,4’-anhydro derivative 4.52. Reagents and conditions: (a) H2S, pyridine, 250 psi, 48h 
(88%); (b) (i) DCC, TFA, pyridine, DMSO; (ii) (EtO)2P(O)C=PPh3 (4.57)(56%) 
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The mechanism of the intramolecular ring closing is currently unclear, because we 
were not capable to isolate any reaction intermediate. We suppose nucleophilic 
sulphur attack is involved, as in the hypothetical mechanism in Figure 4.5. A 
participating role of the ylid in the formation of 4.52 is likely, since several attempts to 
produce aldehyde V as such were unsuccessful. In an effort to prevent nucleophilic 
attack of the 2-sulfur atom, we protected N-3 as a benzyloxymethyl ether (BOM).239 
Unfortunately, this BOM-protected analogue failed to undergo the DMSO-mediated 
oxidation reaction, probably through sterical hindrance. Alternative formation of the 
aldehyde with iodoxybenzoic acid (IBX) resulted in complete degradation of the 
starting material. 
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Figure 4.5 
Supposed mechanism of S2,4’-anhydroformation 
 
Consequently, we attempted to convert compound 4.47 to its 2-thio analogue using 
Lawesson’s reagent (Scheme 4.16). For that purpose, previous 4-O-protection as a 
2,6-dimethylphenyl ether was performed (see also 4.1.2.3). Treatment of the 4-O-
protected 4.53 with Lawesson’s reagent resulted in thionation of the phosphonate 
ester as the major reaction product. The structure was confirmed by the 1H NMR 
spectrum, which was devoid of the 2-thionation related shift of the resonance signal 
of H-1’ to lower magnetic field.232 The conversion of phosphonates to thiophosphates 
was earlier reported.240,241  
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Scheme 4.16 
Unexpected synthesis of 5’-thiophosphonate ester 4.54. Reagents and conditions: (a) (i) Na2CO3, 
tetrabutylammonium bromide, 2,4,6-triisopropylbenzenesulfonyl chloride, CH2Cl2; (ii) 2,6-dimethylphenol, DABCO, 
CH3CN; (b) Lawesson’s reagent, toluene. 
 
The introduction of a phosphonate ester group was not possible in the presence of 
the 2-thiocarbonyl moiety, neither was it possible to perform 2-thionation of the 
uridine 5’-phosphonate ester (4.53). Hence, in Scheme 4.17, we propose an 
alternative retrosynthetic route to obtain the desired 5’-phosphonodiphosphates (R1= 
O or S; R2= O or S). Unfortunately, a shortage of time prevented us to perform this 
reaction pathway, so we suggest this route as a future perspective. 
A key step will be the Vörbruggen coupling of the appropriate silylated pyrimidine with 
a suitably protected 5-deoxy-5-methylphosphonate ribofuranose (III), as reported by 
Mikhailov and coworkers. 242  This sugar intermediate is accessible from the 
commercially available 1,2-O-isopropylidene glucofuranose (V). In case R1= O, this 
method further allows to modify the 2’-OH group by other functionalities. 
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Scheme 4.17 
Proposed retrosynthetic route for the desired 2-thiouridine 5’-phosphonodiphosphates (R1= O or S; R2= O or S)  
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4.2.3 Biological Evaluation 
Activation of phospholipase C by 5’-phosphonodiphosphate 4.7 was studied in 
1321N1 astrocytoma cells stably expressing the human P2Y2, P2Y4, and P2Y6 
receptors, by reported methods.123,125,243,244 Tritiated inositol phosphates produced 
from a radiolabeled myo-inositol precursor were measured using a standard ion 
exchange method. The investigated compound exhibited weak partial P2Y2 agonist 
activity, which was surprising, given the P2Y2 receptor full agonist activities of the 
previously synthesized 5’-triphosphates and 5’-triphosphate isosteres (see 1.3.3.1 
and 4.1.3). However, HPLC and mass screening of the 200 mM Hepes (N-(2-
hydroxyethyl)-piperazine-N’-2-ethanesulfonic acid) storage solution containing 4.7, 
showed nearly quantitative hydrolysis of 5’-phosphonodiphosphate 4.7 to the 
corresponding 5’-phosphonate 4.50. This was in contrast to an earlier reported higher 
chemical stability of a similar 5’-γ-phosphonate group in comparison to the 
corresponding 5’-γ-phosphate.245 The presumption that the partial agonist activity 
was caused by the hydrolysis product 4.50 was confirmed by the repetition of the 
PLC activation assay with pure 5’-phosphonate 4.50, yielding the same PLC 
activation curves for both 4.50 and 4.7 (hydrolysed) (Figure 4.6A).  
5'-Phosphonate 4.50 caused a P2Y2 receptor-dependent increase in phospholipase 
C activity that does not occur in wild type 1321N1 cells or in 1321N1 cells expressing 
the P2Y4 or P2Y6 receptors, which is presented as fold stimulation of [3H]inositol 
phosphate accumulation over background [3H]inositol phosphate accumulation  
(Figure 4.6B). So far, we assumed 4.50 to be a P2Y2 receptor- selective partial 
agonist. However, experiments to determine the antagonist potency with up to 10 µM 
of the 5’-phosphonate did not illustrate an inhibition of the effect of UTP. Therefore, a 
higher concentration of 4.50 may be needed or 4.50 may exhibit some other action, 
for example through an allosteric interaction, to cause an enhancement of the effect 
of UTP, that is always in the medium in low concentrations because of basal release 
of cellular UTP. The latter presumption is supported by the P2Y2 receptor-dependent 
increase in inositol phosphate accumulation in the absence of added UTP (Figure 
4.6B) and the reduction of the basal activity by adding a nucleotide-hydrolyzing 
enzyme (apyrase) to the medium. Additional tests would be necessary to determine 
the role of 4.50 unambiguously. The additional amount of the 5’-phosponate needed 
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for these tests was not possible to provide during the period of this work due to a lack 
of time and is suggested as a future perspective.  
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Figure 4.6 
Partial agonist activity of 5’-phosphonate 4.50 at the P2Y2 Receptor. A) Concentration effect curves were 
generated for UTP or uridine 5’-phosponate (4.50) in the presence of 10 mM LiCl in P2Y2-R-1321N1 cells 
prelabeled with [3H]inositol. B) The capacity of 10 µM uridine phosphonate to stimulate [3H]inositol phosphate 
accumulation was measured in the presence of 10 mM LiCl in wild-type 1321N1 cells or in 1321N1 cells stably 
expressing the human P2Y2-R, P2Y4-R, or P2Y6-R. The data are presented as fold stimulation of [3H]inositol 
phosphate accumulation over background [3H]inositol phosphate accumulation. The data are the mean ± SEM of 
six (A) or three (B) independent experiments. 
 
The chemical stability and the biological data of vinyl analogue 4.6 are currently 
under investigation by prof. K. Harden and its group, Department of Pharmacology, 
University of North Carolina, USA. 
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4.2.4 Conclusions  
Uridine 5’-phophonodiphosphate 4.7 exhibited nearly quantitative hydrolysis to the 
corresponding 5'-phosphonate 4.50 in the 200 mM Hepes buffer storage solution. 
Uridine 5’-phosphonate 4.50 exhibited weak partial P2Y2 agonist activity and caused 
a P2Y2 receptor-selective increase in phospholipase C activity. Therefore, uridine 5'-
phosphonate may be a selective partial agonist at the P2Y2 receptor but we have not 
proven this unambiguously. Uridine 5'-phosphonate may exhibit some other action, 
for example through an allosteric interaction, to cause P2Y2 receptor-dependent 
increases in PLC activity. Additional tests would be necessary to further determine 
the role of 4.50. 
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5 EXPERIMENTAL SECTION 
 
5.1 Synthesis 
5.1.1 General 
All reagents were from standard commercial sources and of analytic grade, except 
for the benzylic azides, which were prepared by treating the corresponding benzylic 
bromides with NaN3 in DMF. Precoated Merck silica gel F254 plates were used for 
TLC, and spots were examined under UV light at 254 nm and further visualized by 
sulfuric acid–anisaldehyde spray. Column chromatography was performed on ICN 
silica gel (63–200 µm, 60 Å, ICN Biochemicals, Eschwege, Germany). NMR spectra 
were obtained with a Varian Mercury 300 MHz spectrometer. Chemical shifts are 
given in ppm (δ) relative to the residual solvent signals, which in the case of DMSO-d6 
were 2.54 ppm for 1H and 40.5 ppm for 13C, in the case of CDCl3 7.26 ppm for 1H and 
77.23 ppm for 13C and in the case of D2O 4.79 ppm for 1H. Structural assignment was 
confirmed with COSY and HSQC. All signals assigned to amino, amide hydrogen 
and hydroxyl groups were exchangeable with D2O. Exact mass measurements were 
performed on a quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem 
mass spectrometer (qToF 2, Micromass, Manchester, U.K.) equipped with a standard 
electrospray ionization (ESI) interface. Samples were infused in a 2-propanol/water 
(1:1) mixture at 3 µL/min.  
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5.1.2  Hypermodified Adenosine Analogues 
9-(3-Amino-3-deoxy-β-D-ribofuranosyl)-2-iodo-N6-
methyladenine (2.1) 
This compound was synthesized from 30 mg (0.069 mmol) of 2.34 
by the procedure described for the synthesis of 2.7; yield: 26 mg 
(92%).  
 
1H NMR (300 MHz, DMSO-d6) : δ 1.66 (br s, 2H, NH2), 2.87 (d, 3H, J = 4 Hz, N6-CH3), 
3.41 (app t, 1H, J = 6.0 Hz, H-3’), 3.54-3.71 (m, 3H, H-4’ and H-5’A and H-5’B), 4.10 
(br s, 1H, 2’-OH), 4.19 (dd, 1H, J = 2.6 and 4.4 Hz , H-2’), 4.98 (br s, 1H, 5’-OH),  
5.82 (d, 1H, J = 2.6 Hz, H-1’), 8.11 (d, 1H, J = 4 Hz, N6-H), 8.30 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C11H16N6O3I [M+H]+: 407.0330, found 
407.0332.     
 
 
9-(3-Amino-3-deoxy-β-D-ribofuranosyl)- 2-amino-N6-
methyladenine (2.2) 
This compound was synthesized from 2.36 (35 mg, 0.11 mmol) by 
the procedure described for the synthesis of 2.7; yield: 30 mg 
(93%).  
 
1H NMR (300 MHz, DMSO-d6) : δ 1.70 (br s, 2H, 3’-NH2), 2.86 (s, 3H, N6-CH3), 3.34 
(app t, 1H, J = 6.0 Hz, H-3’), 3.52-3.70 (m, 3H, H-4’ and H-5’A and H-5’B), 4.16 (br s, 
2H, 2’-OH and H-2’), 5.16 (br s, 1H, 5’-OH),  5.74 (d, 1H, J = 2.8 Hz, H-1’), 5.83 (s, 
2H, 2-NH2), 7.24 (br s, 1H, N6-H), 7.91 (s, 1H, H-8);  
HRMS (ESI-MS, iPrOH:H2O): calculated for C12H18N7O3 [M+H]+: 296.1471, found 
296.1470.       
 
 
General procedure for the synthesis of alkynes 2.3, 2.4 and 2.5 from 2.1 
Compound 2.1 (50 mg, 0.12 mmol) was dissolved in Et3N (1.5 mL) and DMF (1mL). 
After purging the solution with N2, (PPh3)2PdCl2 (8.6 mg, 0.012 mmol) and CuI (2.3 
mg, 0.012 mmol) were added. The appropriate alkyne (2 equiv.) was subsequently 
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added dropwise and the mixture was stirred at room temperature for 3h. The solvents 
were removed under reduced pressure, the residue was taken up in ethyl acetate, 
and the solution filtered over a celite pad. The residue remaining after solvent 
evaporation was purified on silica gel column (CH2Cl2:MeOH, 90:10).  
 
 
 9-(3-Amino-3-deoxy-β-D-ribofuranosyl)-N6-methyl-2-
phenylethynyladenine (2.3) 
The reaction of 2.1 (50 mg, 0.12 mmol) with 
phenylacetylene (27 µL, 0.24 mmol) gave compound 2.3 
in 81% yield.  
 
1H NMR (300 MHz, DMSO-d6) δ 2.07 (br s, 2H, 3’-NH2), 2.94 (s, 3H, N6-CH3), 3.44 
(app t, 1H, J = 5.3 Hz, H-3’), 3.56-3.75 (m, 3H, H-4’ and H-5’A and H-5’B), 4.09 (br s, 
1H, 2’-OH), 4.24 (dd, 1H, J = 2.6 and 4.4 Hz, H-2’), 5.11 (br s, 1H, 5’-OH),  5.94 (d, 
1H, J = 2.3 Hz, H-1’), 7.46 (m, 3H, Ph), 7.61 (m, 2H, Ph), 7.95 (br s, 1H, N6-H), 8.47 
(s, 1H, H-8). 
HRMS (ESI-MS, iPrOH:H2O): calculated for C19H21N6O3 [M+H]+: 381.1675, found 
381.1675.     
   
 
9-(3-Amino-3-deoxy-β-D-ribofuranosyl)-N6-methyl-2-
(4-methyl-phenyl) ethynyladenine (2.4) 
The reaction of 2.1 (50 mg, 0.12 mmol) with 4-methyl-
phenylacetylene (31 µL, 0.24 mmol) gave compound 
2.4 in 82% yield.  
 
1H NMR (300 MHz, DMSO-d6) δ 2.33 (s, 3H, CH3Ph), 2.94 (s, 3H, N6-CH3), 3.50-3.79 
(m, 4H, H-3’, H-4’, H-5’A and H-5’B), 4.31 (dd, 1H, J = 2.4 and 4.5 Hz, H-2’), 5.15 (br 
s, 1H, 5’-OH),  5.74 (s, 1H, 2’-OH), 5.96 (d, 1H, J = 2.4 Hz,  H-1’), 7.25 (m, 2H, Ph), 
7.50 (m, 2H, Ph), 7.95 (br s, 1H, N6-H), 8.46 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C20H23N6O3 [M+H]+: 395.1831, found 
395.1823.   
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9-(3-Amino-3-deoxy-β-D-ribofuranosyl)-N6-methyl-2-(1-
hexyn-1-yl)adenine (2.5) 
The reaction of 2.1 (50 mg, 0.12 mmol) with 1-hexyn (28 µL, 
0.24 mmol) gave compound 2.5 in 80% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.90 (t, 3H, J = 7.03 Hz, CH2CH3), 1.37-1.54 (m, 4H, 
CH2CH2CH3), 2.41 (t, 2H, J = 7.04 Hz, C≡CCH2), 2.88 (s, 3H, N6-CH3), 3.48-3.73 (m, 
4H, H-3’, H-4’, H-5’A and H-5’B), 4.10-4.23 (m, 2H, H-2’ and 2’-OH), 5.10 (br s, 1H, 
5’-OH), 5.90 (d, 1H, J = 2.5 Hz, H-1’), 7.83 (br s, 1H, N6-H), 8.41 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C17H25N6O3 [M+H]+: 361.1988, found 
361.1982.   
    
 
9-(3-Amino-3-deoxy-5-methylcarbamoyl-β-D-ribofuranosyl)-
N6-methyl-2-iodoadenine (2.7) 
Compound 2.19 (50 mg, 0.11 mmol) and PPh3 (57 mg, 0.21 mmol) 
were dissolved in THF (2mL). After stirring for 10 minutes, H2O 
was added (270 µL, 15 µmol) and the reaction was stirred for 2 days. The residue 
obtained after solvent evaporation was purified by column chromatography 
(CH2Cl2:MeOH 95:5) to yield 82% of compound 2.7.  
 
1H NMR (300 MHz, DMSO-d6) : δ 1.79 (s, 2H, 3’-NH2), 2.69 (d, 3H, J = 4.7 Hz, 
CH3NHCO), 2.88 (d, 3H,  J = 4.1 Hz, N6-CH3), 3.54 (t, 1H, J = 11.1 Hz, H-3’), 4.10 (d, 
1H,  J = 6.2 Hz, H-4’), 4.30 (app  t, 1H, J = 8.8 Hz, H-2’), 5.91 (br s, 1H, 2’-OH), 5.93 
(d, 1H, J = 3.8 Hz, H-1’), 8,03 (d, 1H, J = 4,7 Hz, NHCO), 8.13 (d, 1H, J = 4.1 Hz, N6-
H), 8.48 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C12H17ClIN7O3 [M+H]+: 434.0439, found 
434.0445. 
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9-(3-Amino-3-deoxy-5-methylcarbamoyl-β-D-ribofuranosyl]-
2-amino-N6-methylpurine (2.8) 
Compound 2.37 (40 mg, 0.12 mmol) and PPh3 (66 mg, 0.25 
mmol) were dissolved in THF (2 mL). After stirring for 10 
minutes, H2O was added (310 µL, 17 mmol) and the mixture was stirred for 2 days. 
The residue obtained after solvent evaporation was purified by column 
chromatography (CH2Cl2:MeOH 80:20) to give compound 2.8 in 80% yield.  
 
1H NMR (300 MHz, DMSO-d6) : δ 2.95 (br s, 2H, 3’-NH2), 2.66 (d, 3H, J = 4.7 Hz, 
CH3NHCO), 2.86 (s, 3H, N6-CH3), 3.54 (app t, 1H,  J = 5.4 Hz, H3’), 4.05 (d, 1H, J = 
5.6 Hz, H-4’), 4.37 (app t, 1H, J = 4.7 Hz, H-2’), 5.82 (d, 1H, J = 4.1 Hz, H-1’), 5.88 (s, 
2H, 2-NH2), 7.31 (s, 1H, N6-H), 8.04 (s, 1H, H-8), 8.27 (d, 1H, J = 4.4 Hz, NHCO).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C12H19N8O3 [M+H]+: 323.1580, found 
323.1579.        
 
 
9-(3-Amino-3-Deoxy-5-methylcarbamoyl-β-D-
ribofuranosyl)-N6-methyl-2-phenylethynyladenine (2.9) 
This compound was synthesized by the procedure 
described for the synthesis of 2.7 from 20 mg (0.046 mmol) 
of 2.20 in 96% yield (18 mg).  
 
1H NMR (300 MHz, DMSO-d6) : δ 1.78 (s, 2H, 3’-NH2),  2.71 (d, 3H, J = 4.4 Hz, 
CH3NHCO), 2.94 (s, 3H, N6-CH3), 4.33 (dd, 1H, J =  5.0 and 5.3 Hz, H-3’), 4.13 (d, 
1H,  J = 5.3 Hz, H-4’), 4.36 (br s, 1H, H-2’), 5.94 (s, 1H, 2’-OH), 6.02 (d, 1H, J = 4.40, 
H-1’), 7.46 (m, 3H,  Ph), 7.61 (m, 2H, Ph), 8.04 (d, 1H, J = 4.4 Hz, N6-H), 8.41 (d, 1H, 
J = 4.7 Hz, NHCO), 8.62 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C20H22N7O3 [M+H]+: 408.1784, found 
408.1787.       
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1,2-O-isopropylidene-5-O-(toluoyl)-α-D-xylofuranose (2.11) 
A solution of toluoyl chloride (13.2 mL, 100 mmol) in dry CH2Cl2 (40 
mL) was added dropwise to a solution of 1,2-O-isopropylidene-α-D-
xylofuranose 2.10 (20 g, 105.15 mmol) in dry pyridine (50 mL) and dry CH2Cl2 (150 
mL). After stirring at 0 °C for 2h, the reaction mi xture was quenched with water (250 
mL) and extracted with CH2Cl2. The combined organic phases were evaporated to 
dryness. The residue was dissolved in a minimal amount of EtOAc and crystallized 
upon treatment with hexane to obtain 23g (71%) of compound 2.11.  
 
1H NMR (300 MHz, CDCl3): δ 1.32 (s, 3H, CH3), 1.51 (s, 3H, CH3), 2.42 (s, 3H, Ph-
CH3), 2.78 (d, 1H, J = 4.1 Hz, 3-OH), 4.18 (dd, 1H, J = 2.5 and 5.2 Hz, H-3), 4.24-
4.90 (m, 4H, H-2, H-4, H-5A and H-5B), 5.96 (d, J = 3.6 Hz, H-1), 7.26 (d, 2H, Ph), 
8.00 (d, 2H, Ph). (The 1H NMR spectrum is accordance with the literature report.183) 
HRMS (ESI-MS, iPrOH:H2O): calculated for C16H21O6 [M+H]+ 309.1338, found 
309.1343. 
 
 
3-Azido-3-deoxy-1,2-O-isopropylidene-5-O-(toluoyl)-α-D-
ribofuranose (2.12) 
To a solution of 2.11 (23 g, 74.6 mmol) in CH2Cl2 (250 mL) and 
pyridine (20 mL) trifluoromethanesulfonic anhydride (15 mL, 89.5 mmol) was added 
dropwise and the reaction mixture was stirred at -10 °C for 2h. sat. aq. NaHCO 3 was 
added and stirring continued for 20 min. The organic phase was washed with H2O, 
dried over MgSO4, filtered and evaporated to dryness. The residue was dissolved in 
DMF (250 mL) and NaN3 (34 g, 522 mmol) was added. The reaction mixture was 
stirred overnight at room temperature. DMF was evaporated in vacuo, and sat. aq. 
NaHCO3 (250 mL) and EtOAc (250 mL) were added. The organic phase was dried 
over MgSO4, filtered, evaporated to dryness and purified by column chromatography 
(pentane:EtOAc 95:584:15) to yield 10 g (40%) of compound 2.12.  
 
1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H, CH3), 1.58 (s, 3H, CH3), 2.38 (s, 3H, Ph-
CH3), 3.33 (dd t, 1H, J = 4.2 and 8.6 Hz, H-3), 4.21-4.61  (m, 3H, H-4, H-5A and H-
O
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5B), 4.73 (dd, 1H, J = 4.5 and 8.5 Hz, H-2), 5.79 (d, J = 3.6 Hz, H-1), 7.16 (d, 2H, Ph), 
7.86 (d, 2H, Ph). (The 1H NMR spectrum is accordance with the literature report.183) 
HRMS (ESI-MS, iPrOH:H2O): calculated for C16H19N3O5Na [M+Na]+ 356.1222, found 
356.1235. 
 
Next to the desired compound, 40% of the elimination product was 
obtained. 
1H NMR (300 MHz, CDCl3): δ 1.47 (s, 3H, CH3), 1.50 (s, 3H, CH3), 
2.40 (s, 3H, Ph-CH3), 4.83 (s, 2H, H-5’A and H-5’B), 5.31 (m, 2H, H-2 and H-3), 4.51 
(s, 2H, H-2 and H-3), 6.13 (1H, d, J = 4.1 Hz, H-1), 7.16 (d, 2H, Ph), 7.86 (d, 2H, Ph). 
(The 1H NMR spectrum is accordance with the literature report.183) 
 
 
3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (2.13) 
Compound 2.12 (6g, 15 mmol) was dissolved in 0.1 N NaOCH3 in 
CH3OH (150 mL), stirred for 2h, neutralized with a H2O:CH3COOH 
(9:1) solution, evaporated and purified by column chromatography (CH2Cl2:MeOH 
99:1) to yield 3.4 g (88%) of 2.13.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.28 (s, 3H, CH3), 1.44 (s, 3H, CH3), 3.45-3.52 (m, 
2H, H-3 and H-5A), 3.64 (ddd, 1H, J = 2.9, 5.3 and 12.3 Hz, H-5B), 3.94 (ddd, 1H, J 
= 2.9, 4.3 and 9.8 Hz, H-4), 4.77 (app t, 1H, J = 4.3 Hz, H-2), 4.90 (dd, 1H, J = 5.4 
and 6.0 Hz, 5-OH), 5.77 (d, 1H, J = 3.5 Hz, H-1). (The 1H NMR spectrum is 
accordance with the literature report.246) 
HRMS (ESI-MS, iPrOH:H2O): calculated for C8H13N3O4Na [M+Na]+ 238.0803, found 
238.0801. 
 
 
3-Azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofanuronic acid 
methyl ester (2.14) 
A biphasic mixture of water (30 mL), CHCl3 (20 mL) and CH3CN (20 
mL) containing compound 2.13 (2.03 g, 9.43 mmol), RuCl3 (97 mg, 0.47 mmol) and 
NaIO4 (8.2 g, 38.7 mmol) was vigorously stirred for 4.5 h at room temperature. The 
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reaction mixture was then diluted with 0.05 M HCl (75 mL) and extracted with CH2Cl2 
(2 x 150 mL). The combined organic phase was dried over MgSO4, filtered and 
evaporated. A dark green oily residue was triturated with diethyl ether to precipitate 
the ruthenium salts, which were removed by filtration through celite. Concentration of 
the filtrate in vacuo, resulted in a lightly coloured oil that was used without further 
purification. A mixture of this crude 3-azido-3-deoxy-1,2-O-isopropylidene-α-D-
ribofuronic acid, EDC (4.4 mL, 23.58 mmol) and DMAP (113 mg, 0.92 mmol) in dry 
methanol (40 mL) was stirred at room temperature for 24 h. The reaction mixture was 
partionned between CH2Cl2 (150 mL) and water (75 mL). The aqeous phase was 
extracted with CH2Cl2 (3 x 150 mL) and the combined organic phase was dried over 
MgSO4, filtered, evaporated and purified on a silica gel column (CH2Cl2: MeOH 98:2) 
to yield 2.23 g of compound 2.14 (40%). 
 
1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H, CH3), 1.58 (s, 3H, CH3), 3.69 (dd, 1H, J = 
4.4 and 9.7 Hz, H-3), 3.84 (s, 3H, OCH3), 4.56 (d, 1H, J = 9.7 Hz, H-4), 4.74 (app t, 
1H, J = 4.1 Hz, H-2), 5.91 (d, 1H, J = 3.5 Hz, H-1).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C9H14N3O5 [M+ H]+ 244.0934 , found 
244.0941. 
 
 
3-Azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranuronic acid 
methyl amide (2.15) 
Compound 2.14 (2.2 g, 8.77 mmol) was dissolved in 2 M 
methylamine in THF (20 mL) and was heated for 24h at 55 °C in a sealed tube. After 
cooling, the reaction mixture was concentrated to dryness and purified by silica gel 
chromatography (pentane: EtOAc 90:10) to obtain uronamide 2.15 in 89% yield (1.89 
g).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.29 (s, 3H, CH3), 1.46 (s, 3H, CH3), 2.62 (d, 3H, J 
= 4.7 Hz, CH3-N), 3.75 (dd, 1H, J = 4.5 and 9.5 Hz, H-3), 4.27 (d, 1H, J = 9.7 Hz, H-
4), 4.77 (app t, 1H, J = 4.0 Hz, H-2), 5.85 (d, 1H, J = 3.5 Hz, H-1), 8.12 (d, 1H, J = 
4.4 Hz, N-H). (The 1H NMR spectrum is accordance with the literature report.48) 
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HRMS (ESI-MS, iPrOH:H2O): calculated for C9H14N4O4Na [M+ Na]+ 265.0912 , found 
265.0917. 
 
 
N-Methyl 3-azido-3-deoxy-1,2-di-O-acetyl-D-ribofuronamide 
(2.16) 
A mixture of 2.15 (1.8 g, 7.4 mmol), concentrated sulphuric acid 
(2.2 mL, 41.3 mmol) and acetic anhydride (7.4 mL, 78.6 mmol) in glacial acid (25 mL) 
was stirred for 18h at room temperature. After cooling in an ice bath, a saturated 
NaHCO3 solution (75 mL) and CH2Cl2 (75 mL) were slowly added and the mixture 
was stirred for another 10 min. After separation, the organic phase was extracted 
with saturated NaHCO3 solution and with brine, dried over MgSO4, filtered and 
evaporated to dryness to yield 1.18 g (55%) of crude 2.16 as a yellowish foam.  
 
HRMS (ESI-MS, iPrOH:H2O): calculated for C10H15N4O6 [M+ H]+ 287.0991, found 
287.0987. 
 
 
9-(2-O-Acetyl-3-azido-3-deoxy-5-methylcarbamoyl-β-D-
ribofuranosyl)-2-amino-6-chloropurine (2.17) 
Silylation of the base: 2-Amino-6-chloropurine (462 mg, 2.7 
mmol) was treated with 1,1,1,3,3,3-hexamethyldisilazane 
(HMDS, 40 mL) and  (NH4)2SO4 (0.27 mmol, 36 mg) and refluxed for 20h. The 
silylated compound was evaporated to dryness and used without further purification. 
Vorbrüggen coupling: 3-Azido-3-deoxy-1,2-di-O-acetyl-α-D-ribofuronamide (2.16, 600 
mg, 2.09 mmol) in dry 1,2-dichloroethane (25 mL) was added to the crude silylated 2-
amino-6-chloropurine. The solution was gently refluxed, and after 5 minutes TMSOTf 
(417µL, 2.3 mmol) was added dropwise. After 4 h the mixture was cooled to room 
temperature, quenched with a cold saturated NaHCO3 solution (80 mL) and extracted 
with CH2Cl2 (40 mL). The organic layer was dried with MgSO4, filtered and 
evaporated to dryness. The residue was purified by column chromatography 
(CH2Cl2:MeOH 98:2) to give 650 mg (79%) of compound 2.17.  
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1H NMR (300 MHz, CDCl3): δ 2.15 (s, 3H, CH3CO), 2.90 (d, 3H,  J = 5.0 Hz, CH3N), 
4.53 (d, 1H, J = 3.2 Hz, H-4’), 4.90 (dd, 1H,  J = 3.5 and 5.0 Hz, H-3’), 5.14 (s, 2H, 
NH2), 5.94 (t, 1H, J = 5.3 Hz, H-2’), 5.97 (d, 1H, J = 6.2 Hz, H-1’), 7.09 (br s, 1H, 
NHCO), 7.82 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C13H15ClN9O4 [M+H]+: 396.0935, found 
396.0932. 
 
 
9-(2-O-Acetyl-3-azido-3-deoxy-5-methylcarbamoyl-β-D-
ribofuranosyl)-6-chloro-2-iodopurine (2.18) 
Isoamylnitrite (681 µL, 4.98 mmol) was added to a mixture of 2.17 
(650 mg, 1.65 mmol), I2 (418 mg, 1.65 mmol), CH2I2 (1.37 mL, 16.5 mmol) and CuI 
(330 mg, 1.72 mmol) in 15 mL THF. The mixture was refluxed for 45 minutes and 
then cooled to room temperature. Insoluble materials were removed by filtration, and 
the filtrate was concentrated to dryness. The residue was purified by means of a 
silica gel column, which was washed with CH2Cl2 until the iodine colour disappeared 
and then eluted with CH2Cl2:MeOH (98:2). Compound 2.18 was obtainded in 79% 
yield.  
 
1H NMR (300 MHz, CDCl3): δ 2.13 (s, 3H, CH3CO), 3.06 (d, 3H, J = 4.98 Hz, CH3N), 
4.56 (d, 1H, J = 2.9 Hz, H-4’), 4.80 (dd, 1H, J = 2.9 and 5.6 Hz, H-3’), 5.75 (dd, 1H, J 
= 5.9 and 7.0 Hz, H-2’), 6.06 (d, 1H, J = 7.3 Hz, H-1’), 7.09 (br s, 1H, NHCO), 8.11 (s, 
1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C13H13ClIN8O4 [M+H]+: 506.9794, found 
506.9822. 
 
 
9-(3-Azido-3-deoxy-5-methylcarbamoyl-β-D-ribofuranosyl)-
N6-methyl-2-iodoadenine (2.19) 
Compound 2.18 (460 mg, 0.91 mmol) was dissolved in EtOH (10 
mL). Methylammonium chloride (92 mg, 1.36 mmol) and Et3N 
(158 µL,1.13 mmol) were added, and the solution was refluxed overnight. The 
mixture was concentrated to dryness, dissolved in 7N NH3 in methanol and stirred at 
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room temperature for 2 h to deprotect the 2’-hydroxyl group. The volatiles were 
removed under reduced pressure, and the residue was purified by silica gel column 
(CH2Cl2:MeOH 98:2). The product, 2.19, was realized, in 77% yield.  
 
1H NMR (300 MHz, DMSO-d6 ): δ 2.71 (d, 3H, J = 4.7 Hz, CH3NHCO), 2.89 (d, 3H,  J 
= 4.4 Hz, N6-CH3), 4.33 (d, 1H, J = 3.5 Hz, H-4’), 4.47 (dd, 1H,  J = 3.5 and 5.0 Hz, 
H-3’), 4.92 (dd, 1H, J = 5.6 and 11.4 Hz, H-2’), 5.89 (d, 1H, J = 6.5 Hz, H-1’), 6.33 ( d, 
1H, J = 5.6 Hz, 2’-OH), 8.10 (d, 1H, J = 4,7 Hz, NHCO), 8.17 (d, 1H, J = 4.7 Hz, N6-
H), 8.36 (s, 1H, H-8). 
HRMS (ESI-MS, iPrOH:H2O): calculated for C12H15IN9O3 [M+H]+: 460.0344, found 
460.0350. 
 
 
9-(3-Azido-3-deoxy-5-methylcarbamoyl-β-D-
ribofuranosyl)-N6-methyl-2-phenylethynyladenine (2.20) 
A solution of compound 2.29 (30 mg, 0.06 mmol) and 10 
mL 7N NH3 in methanol was kept at room temperature for 
2h to allow deprotection of  the 2’-hydroxyl group. The mixture was concentrated to 
dryness and purified on a silica gel column (CH2Cl2:MeOH 97:3). A 91% yield of 
compound 2.20 was obtained.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.73 (d, 3H, J = 3.5  Hz, CH3NHCO), 2.96 (s, 3H, 
N6-CH3), 4.33 (d, 1H, J =  2.6 Hz, H-4’), 4.51 (dd, 1H,  J = 3.0 and 5.27 Hz, H-3’), 
4.96 (app t, 1H, J = 5.3 Hz, H-2’), 5.98 (d, 1H, J = 6.7 Hz, H-1’), 7.46 (m, 3H, Ph), 
7.64 (m, 2H, Ph), 8.12 (s, 1H, N6-H), 8.51 (s, 1H, H-8), 8.53 (d, 1H, J = 4.4 Hz, 
NHCO).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C20H20N9O3 [M+H]+: 434.1688, found 
434.1686.        
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Attempted synthesis of compound 2.20: Synthesis of 
2.21 
Attempted conversion of 2.19 to 2.20 using the procedure as 
described for 2.3, 2.4 and 2.5 failed to give 2.20, but 
resulted in the formation of triazole 2.21 as sole reaction 
product (41% yield).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.78 (d, 3H, J= 4.6 Hz, N6-CH3), 3.0 (br s, 3H, 
CH3NHCO), 5.15 (app q, 1H, J = 6.3 Hz, H-2’), 5.17 (d, 1H, J = 3.4 Hz, H-4’),  5.61 
(dd, 1H, J = 3.6 and 6.3 Hz, H-3’), 6.26 (d, 1H, J = 5.4 Hz, 2’-OH), 6.27 (d, 1H, J= 6.3 
Hz, H-1’), 7.36 (t, 1H, J = 7.3 Hz,  4’’-Ph), 7.46-7.51 (m, 2H, 4’’-Ph and 3H, C≡CPh), 
7.65 (br d, 2H, J = 6.8 Hz, C≡CPh), 7.90 (d, 2H, J = 7.6 Hz , 4’’-Ph), 8.59 (s, 1H, H-8), 
8.71 (m, 2H, H-5’’ and NHCO).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C28H25N9O3 [M+H]+: 536.2158, found 
536.2166. 
 
 
6-chloro-9-(tetrahydropyran-2-yl)-9H-purine (2.23) 
To a solution of 6-chloropurine (2.22, 6 g, 38.8 mmol) and p-toluene 
sulfonic acid (100 mg, 0.53 mmol) in dry THF (60 mL), 2,3-dihydro-4H-
pyran (4 mL, 43.74 mmol) was added and the reaction mixture was 
heated at 80 °C for 15h. After dropwise addition of  concentrated ammonia (3.5 mL), 
the reaction was cooled to room temperature, and evaporated to dryness. The 
yellowish oil was dissolved in ethyl acetate (150 mL), washedwith brine (75 mL), 
water (2x 75 mL), and then dried over MgSO4. The organic phase was evaporated to 
dryness and boiling petroleum ether (60-80 °C) was added. The ether extract was 
cooled in a fridge overnight to precipitate a colourless powder that was recrystallised 
from petroleum ether 60-80 °C to afford 2.23 (6.3 g, 69%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.58 (m, 3H, THP), 2.00 (m, 2H, THP), 2.30 (m, 1H, 
THP), 3.70 (m, 1H, THP H-3’), 4.00 (d, J = 10.8 Hz, 1H, THP H-2’), 5.76 (dd, J =  2.3 
and 11.0 Hz, 1H, THP H-1’), 8.79 (s, 1H, H-8), 8.90 (s, 1H, H-2). (The 1H NMR 
spectrum is accordance with the literature report.188 ) 
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6-Chloro-9-(tetrahydro-pyran-2-yl)-2-(tributylstannyl)-9H-
purine (2.24) 
To a stirred solution of 2,2,6,6-tetramethylpiperidine (19.5 mL, 
115.5 mmol) in THF (15 mL) and dry THF (30 mL) was added 
dropwise at  -78 °C n-butyllithium (48.5 mL, 2.6 M solution in hexane, 121.3 mmol) 
over 30 minutes. Following stirring at the same temperature for 1 h, a solution of 
compound 2.23 (5.5 g, 23.1 mmol) in dry THF (30 mL) was added dropwise. After 30 
minutes of stirring at -78 °C tributylstannyl chlor ide (31.3 mL, 115.5 mmol) was added 
dropwise to the dark mixture and stirring at the same temperature was continued for 
1 hour. The resulting dark solution was quenched by dropwise addition of a saturated 
aqueous ammonium chloride solution (50 mL). Following overnight warming to room 
temperature with stirring, saturated aqueous NaHCO3 (50 mL) was added. Extraction 
with ethyl acetate (2 × 50 mL) and drying of the combined organic phase over MgSO4 
afforded after evaporation to dryness a yellowish oil. Purification by silica gel column 
chromatography (hexane:EtOAc 80:20) afforded the 2-stannylated purine 2.24 (11.6 
g, 95%) as a colourless oil.  
 
1H NMR (300 MHz, CDCl3): δ 0.81 (t, 9H, J= 7.4 Hz, 3 x CH3), 1.13 (t, 6H J= 7.9 Hz, 
3 x CH2), 1.27 (m, 6H, J = 7.7 Hz, 3 x CH2), 1.55 (m, 9H, 3 x CH2 and THP), 1.75 (m, 
2H, THP) 2.10 (m, 2H, THP), 3.72 (td, 1H, J = 3.3 and 11.8 Hz, THP H-3’), 4.13 (m, 
1H, THP H3’), 5.71 (dd, 1H, J = 2.8 and 7.2 Hz, THP H-1’), 8.15 (s, 1H, H-8). (The 1H 
NMR spectrum is accordance with the literature report.188) 
HRMS (ESI-MS, iPrOH:H2O): calculated for C22H38N4OClSn [M+H]+: 539.1751, found 
529.1746.  
 
 
6-Chloro-2-iodo-9-(tetrahydro-pyran-2-yl)-9H-purine (2.25) 
To a stirred solution of 2-stannylated purine 2.24 (11.5 g, 21.9 mmol) in 
dry THF (190 mL) iodine (8.55 g, 33.5 mmol) was added portionwise. 
Stirring was continued for 24 hours under N2 atmosphere. Following 
treatment of the remaining iodine with saturated sodium metabisulfite, and 
subsequent stirring for one hour, the solution was extracted with dichloromethane (3 
× 100 mL). The combined organic layers were washed with brine (100 mL), water 
(100 mL), dried over magnesium sulfate, and evaporated to full dryness. Trituration 
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with n-hexane (75 mL) precipitated the 2-iodopurine 2.25, which was isolated as a 
pale yellow solid (6 g, 75%).  
 
1H NMR (300 MHz, CDCl3): δ 1.46 (m, 3H, THP), 1.78 (m, 2H, THP), 2.01 (m, 1H, 
THP), 3.72 (td, J =  3.6 and 11.5 Hz, 1H, THP H3’), 4.10 (m, 1H, THP H-2’), 5.70 (dd, 
1H, J = 2.3 and 10.5 Hz, THP H-1’), 8.22 (s, 1H, H-8). (The 1H NMR spectrum is 
accordance with the literature report.188)   
HRMS (ESI-MS, iPrOH:H2O): calculated for C10H11ClN4OI [M+H]+: 364.9661, found: 
364.9665. 
 
 
2-Iodo-N6-methyl-9-(tetrahydropyran-2-yl)adenine (2.26) 
Methylammonium chloride (28 mg, 0.41 mmol) and DMAP (67 mg, 0.54 
mmol) were added to 100 mg (0.27 mmol) of compound 2.25 in EtOH (6 
mL), and the solution was refluxed overnight. The mixture was 
concentrated to dryness and the residue purified on a silica gel column (pentane: 
EtOAc 50:50). The title compound was obtained in 81% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.52 (m, 6H, H-2A’ and H-2B’, H-3A’ and H-3B’, H-
4A’ and H-4B’), 2.87 (s, 3H, NHCH3), 3.68 (t, 1H, J= 11.4 Hz, H-5’A), 3.96 (app d, 1H, 
J = 11.4 Hz, H-5’B), 5.43 (dd, 1H, J = 2.3 and 10.9 Hz, H-1’), 7.26 (br s, 1H, NHCH3), 
7.87 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C11H15N5O3I [M+H]+: 360.0323, found 
360.0333.     
 
 
N6-Methyl-2-phenylethynyl-9-(tetrahydropyran-2-yl)adenine 
(2.27) 
Compound 2.26 (200 mg, 0.557 mmol) was dissolved in a mixture 
of Et3N (3 mL) and DMF (1mL) and the solution was purged with N2. 
(PPh3)2PdCl2 (39 mg, 0.056 mmol) and CuI (10.6 mg, 0.056 mmol) were added. 
Phenyl acetylene (112 µL, 1.11 mmol) was subsequently added dropwise, and the 
mixture was stirred at room temperature for 3h. The solvents were removed under 
reduced pressure, the residue was taken up in ethyl acetate and the resulting 
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solution filtered over a pad of celite. After solvent evaporation, the residue was 
purified on a silica gel column (pentane:EtOAc 50:50) to give compound 2.27 in 91% 
yield.  
 
1H NMR (300 MHz, CDCl3): δ 1.18-2.25 (m, 6H, H-2A’ and H-2B’, H-3A’ and H-3B’, 
H-4A’ and H-4B’), 3.21 (s, 3H, NHCH3), 3.72 (app t, 1H, J = 11.4 Hz, H-5’A), 3.96 
(app d, 1H, J = 10.3 Hz, H-5’B), 5.79 (d, 1H, J = 9.1 Hz, H-1’), 7.20 (s, 1H, H-8), 7.30 
(d, 3H, J = 5.3 Hz, H-Ph), 7.61 (m, 2H, H-Ph). 
HRMS (ESI-MS, iPrOH:H2O): calculated for C19H20N5O [M+H]+: 334.1667, found 
334.1671.   
 
 
N6-Methyl-2-phenylethynylpurine (2.28) 
To a solution of 2.27 (170 mg, 0.510 mmol) in 10 mL of CH2Cl2 
was added slowly a solution of 0.78 mL TFA (10.2 mmol) and 0.78 
mL CH2Cl2. After stirring at room temperature for 1h, the solvent 
was evaporated, and the residue was taken up in ethyl acetate, and the solution 
washed with 7% NaHCO3. After silica gel chromatography (CH2Cl2:MeOH 97:3) pure 
2.28 was obtained in a 72% yield.  
 
1H NMR (300 MHz, DMSO): δ 2.97 (s, 3H, NHCH3), 7.30 (m, 3H, H-Ph), 7.61 (m, 2H, 
H-Ph), 7.88 (br s, 1H, NHCH3), 8.24 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C14H12N5 [M+H]+: 250.1092, found 
250.1073.       
  
 
9-(2-Acetyl-3-azido-3-deoxy-5-methylcarbamoyl-β-D-
ribofuranosyl)-N6-methyl-2-phenylethynyladenine (2.29) 
To a mixture of 2.28 (150 mg, 0.602 mmol) and methyl 3-
azido-3-deoxy-1,2-di-O-acetyl-α-D-ribofuronamide (2.16) 
(207 mg, 0.722 mmol) in 3 mL CH3CN was successively added 223 µL (0.903 mmol) 
of N,O-bis(trimethylsilyl)-acetamide (BSA) and 131 µL (0.722 mmol) of TMSOTf. The 
suspension was refluxed for 10 h. After being cooled to room temperature, the 
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reaction was quenched with 7% NaHCO3 and extracted with CH2Cl2. The organic 
layer was washed with brine, filtered through a short pad of celite and evaporated to 
dryness. The crude material was purified by column chromatography (CH2Cl2:MeOH, 
99:1), and compound 2.29 was obtained in 24.5% yield (70 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.12 (s, 3H, CH3CO), 3.02 (d, 3H, J= 4.69  Hz, 
CH3NHCO), 3.25 (s, 3H, N6-CH3 ), 4.58 (d, 1H, J =  2.6 Hz, H-4’), 4.78 (dd, 1H,  J = 
2.1 and 5.3 Hz, H-3’), 5.78 (dd, 1H, J = 7.3 and 12.9 Hz, H-2’), 5.92 (s, 1H, N6H) 6.02 
(d, 1H, J = 7.6 Hz, H-1’), 7.40 (app d, 3H, J = 7.0 Hz  H-Ph), 7.63 (app d, 2H, J = 9.1 
Hz, H-Ph), 7.81 (s, 1H, H-8), 8.83 (s, 1H, NHCO).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C22H22N9O4 [M+H]+: 476.1794, found 
476.1800.       
 
 
 3-Azido-3-deoxy-1,2-di-O-acetyl-5-O-Toluoyl)-D-ribofuranose 
(2.30) 
The azido derivative 2.12 (5g, 15 mmol) was added to a 75% 
HCOOH solution (150 mL). The mixture was heated to 50 °C for 2h and evaporated 
to dryness. The residue was dissolved in a mixture of acetic anhydride:pyridine (125 
mL, 2:3, v:v) at room temperature. Stirring was continued for 3h and CH2Cl2 (100 mL) 
and sat. aq. NaHCO3 (100 mL) were added. The aqeous phase was washed with 
CH2Cl2 (100 mL) and the combined organic phases were dried over MgSO4, filtered 
and evaporated in vacuo. The residue was precipitated from methanol to give 2.30 as 
a white solid (5.1 g, 90%).  
 
1H NMR (300 MHz, CDCl3): δ 1.90 (s, 3H, CH3CO), 2.15(s, 3H, CH3CO), 2.48 (s, 1H, 
CH3-Ph),  4.10-4.68 (m, 4H, H-3, H-4, H-5A and H-5B), 5.31 (d, 1H, J = 4.6 Hz, H-2), 
6.09 (s, 1H, H-1) 7.16 (d, 2H, J = 8.1 Hz, Ph), 7.88 (d, 1H, J = 8.1 Hz, Ph).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C17H19N3O7Na [M+Na]+: 400.1120, found 
400.1198.    
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 9-(2-Acetyl-3-azido-3-deoxy-5-O-toluoyl-β-D-
ribofuranosyl)-2-amino-6-chloropurine (2.31) 
To a mixture of 2-amino-6-chloropurine (90 mg, 0.53 mmol) 
and compound 2.30 (240 mg, 0.64 mmol) in 3 mL CH3CN was 
successively added 196 µL (0.79 mmol) BSA and 115 µL (0.64 mmol) TMSOTf. The 
suspension was heated at 80 °C for 3 h. After being  cooled to room temperature, the 
reaction was quenched with 7% NaHCO3 and extracted with CH2Cl2. The organic 
layer was washed with brine, filtered through a short celite pad and evaporated to 
dryness. The residue was purified by column chromatography (CH2Cl2:MeOH 99:1) 
to yield 200 mg (65%) of compound 2.31.  
 
1H NMR (300 MHz, CDCl3): δ 2.19 (s, 3H, CH3CO), 2.41(s, 3H, CH3-Ph),  4.40 (m, 
1H, H-4’), 4.52-4.58 (m, 1H, H-5’A’), 4.76-4.82 (m, 2H, H3’ and H-5’B), 5.13 (br s, 2H, 
NH2), 5.94 (d, 1H, J = 3.8 Hz, H-1’), 5.80 (dd, 1H, J = 3.8 and 5.6 Hz, H-2’), 7.23 (d, 
2H, J = 7.63 Hz, Ph ), 7.79 (s, 1H, H-8), 7.86 (d, 2H, J = 8.2 Hz, Ph).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C20H19N8O5Cl [M+H]+: 487.1245, found 
487.1246.        
 
 
9-(2-Acetyl-3-azido-3-deoxy-5-O-toluoyl-β-D-ribofuranosyl)-
6-chloro-2-iodopurine (2.32) 
This compound was prepared by the procedure described for 
the synthesis of 2.18 from 2.31 (200 mg, 0.41 mmol); yield: 200 
mg (81%).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.15 (s, 3H, CH3CO), 2.35 (s, 3H, CH3-Ph), 4.37 (dd, 
1H, J = 4.1 and 7.6 Hz, H-4’), 4.52 (dd, 1H, J = 4.4 and 12.3 Hz, H-5’A’), 4.65 (dd, 1H, 
J = 3.2 and 12.3 Hz, H-5’B), 4.96 (dd, 1H, J = 5.8 and 7.6 Hz, H-3’), 6.03 (dd, 1H, J = 
2.6 and 5.28 Hz, H-2’), 6.29 (d, 1H, J = 2.9 Hz, H-1’), 7.24 (d, 2H, J = 7.9 Hz, Ph ), 
7.68 (d, 2H, J = 8.2 Hz, Ph), 8.74 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C20H17N7O5ClINa [M+Na]+: 619.9924, 
found 619.9920.        
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9-(3-Azido-3-deoxy-2-hydroxyl-5-O-toluoyl-β-D-
ribofuranosyl)-2-iodo-N6-methyladenine (2.33) 
The title compound was prepared as described for the 
synthesis of 2.19 from 2.32 (200 mg, 0.335 mmol); yield: 127 
mg (69%).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.36 (s, 3H, CH3-Ph), 2.87 (d, 3H, J = 3.5 Hz, N6-
CH3), 4.29 (dd, J = 5.3 and 9.7 Hz, H-4’), 4.46-4.60 (m, 3H, H-3’, H5’A and H-5’B), 
5.01 (t, 1H, J = 4.7 Hz, H-2’), 5.87 (d, 1H, J = 4.7 Hz, H-1’), 6.43 (d, 1H, J = 5.3 Hz, 
2’-OH), 7.29 (d, 2H, J = 8.2 Hz, Ph ), 7.78 (d, 2H, J = 8.2 Hz, Ph), 8.17 (d, 1H, J = 4.4 
Hz, N6-H), 8.21 (s, 1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C19H20N8O4I [M+H]+: 551.0653, found 
551.0649.       
  
 
9-(3-Azido-3-deoxy-β-D-ribofuranosyl)- 2-iodo-N6-methyl-
adenine (2.34) 
Ester 2.33 (127 mg, 0.23 mmol) was dissolved in 2.5 mL of 
MeOH. Na° (11.28 mg, 0.32 mmol) was added and the m ixture 
was stirred at room temperature for 1h. The reaction was quenched by adding a 
mixture of CH3COOH:H2O (9:1, v:v) to pH 7. The solution was concentrated to 
dryness, and the residue purified by column chromatography (CH2Cl2:MeOH 98:2) to 
yield 100 mg (95 %) of compound 2.34.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.88 (d, 3H, J = 4 Hz, N6-CH3), 3.52-3.67 (m, 2H, H-
5’A and H-5’B), 3.94 (dd, 1H, J = 7.26 and 3.81 Hz, H-4’), 4.28 (app t, 1H, J = 4.5 Hz, 
H-3’), 4.89 (app t, 1H, J = 5.4 Hz, H-2’), 5.20 (br s, 1H, 5’-OH),  5.80 (d, 1H, J = 6.16 
Hz, H-1’), 6.25 (br s, 1H, 2’-OH), 8.18 (d, 1H, J = 4 Hz, N6-H), 8.28 (s, 1H, H-8). 
HRMS (ESI-MS, iPrOH:H2O): calculated for C11H14N8O3I [M+H]+: 433.0235, found 
433.0237.     
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9-(3-Azido-3-deoxy-5-O-toluoyl-β-D-ribofuranosyl)-2-
amino-N6-methyl-adenine (2.35) 
Derivative 2.31 (100 mg, 0.21 mmol) was solubilized in EtOH 
(5 mL). Methylammonium chloride (35 mg, 0.515 mmol) and 
Et3N (72 µL, 0.515 mmol) were added, and the solution was refluxed overnight. The 
mixture was concentrated to dryness, the residue redissolved in methanolic NH3, and 
the solution stirred at room temperature for 2h to allow deprotection of the 2’-hydroxyl 
group. The mixture was concentrated to dryness and purified on a silica gel column 
(CH2Cl2:MeOH, 97:3). Compound 2.35 was obtained in 68% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ2.36 (s, 3H, CH3-Ph), 2.84 (br s, 3H, N6-CH3), 4.23 
(dd, J = 5.27 and 9.38 Hz, H-4’), 4.43 (dd, 1H, J = 5.6 and 11.6, H-5’A), 4.55 (m, 2H, 
H-3 and H-5’B), 4.48 (app t, 1 H, 4.7 Hz, H-2’), 5.78 (d, 1H, J = 4.7 Hz, H1’), 5.95 (br 
s, 2H, 2-NH2), 6.34 (d, 1H, J = 7.9 Hz, 2’-OH), 7.28 (br s, 1H, N6-H), 7.29 (d, 2H, J = 
7.9 Hz, Ph ), 7.79 (s, 1H, H-8), 7.82 (d, 2H, J = 8.2 Hz, Ph).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C19H22N9O4 [M+H]+: 440.1794, found 
440.1789.     
 
 
9-(3-Azido-3-deoxy-β-D-ribofuranosyl)-2-amino-N6-
methyladenine (2.36) 
The title compound was synthesized from 2.35 (60 mg, 0.013 
mmol) by the procedure described for the synthesis of 2.34; 
yield: 40 mg (91%).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.85 (br s, 3H, N6-CH3), 3.48-3.64 (m, 2H, H-5’A 
and H-5’B), 3.89 (dd, 1H, J = 3.2 and 7.0 Hz, H-4’), 4.25 (dd, 1H, J = 3.2 and 5.6 Hz, 
H-3’), 4.88 (app t, 1H, J = 5.3 Hz, H-2’), 5.58 (t, J = 6.8 Hz, 1H, 5’-OH),  5.71 (d, 1H, J 
= 6.2 Hz, H-1’), 5.85 (s, 2H, NH2), 6.16 (s, 1H, 2’-OH), 7.31 (br s, 1H, N6-H), 7.89 (s, 
1H, H-8).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C11H16N9O3 [M+H]+: 322.1376, found 
322.1365.        
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9-[3-azido-3-deoxy-5-(methylcarbamoyl)-β-D-
ribofuranosyl]-2-amino-6-chloropurine (2.37) 
Derivative 2.17 (120 mg, 0.30 mmol) was dissolved in EtOH 
(6 mL). Methylammonium chloride (30 mg, 0.46 mmol) and 
Et3N (53 µL, 0.38mmol) were added, and the solution was refluxed overnight. The 
mixture was concentrated to dryness, the remaining solid dissolved in 7N NH3 in 
methanol and, the solution stirred at room temperature for 2 h to deprotect the 2’-
hydroxyl group. The mixture was concentrated to dryness and the residue purified on 
a silica gel column (CH2Cl2:MeOH 95:5). Compound 2.37 was obtained in 79% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.68 (d, 3H, J = 4.7 Hz, CH3NHCO), 2.87 (s, 3H, 
N6-CH3), 4.24 (d, 1H, J = 2.9 Hz, H-4’), 4.42 (dd, 1H,  J = 2.9 and 5.3 Hz, H-3’), 4.97 
(dd, 1H, J = 5.6 and 11.7 Hz, H-2’), 5.81 (d, 1H, J = 6.8 Hz, H-1’), 5.91 (s, 2H, NH2), 
6.26 (d, 1H, J = 5.3 Hz, 2’-OH ), 7.31 (s, 1H, N6-H), 7.96 (s, 1H, H-8), 8.35 (d, 1H, J = 
4.7 Hz, NHCO).  
HRMS (ESI-MS, iPrOH:H2O): calculated for C12H17N10O3 [M+H]+: 349.1484, found 
349.1491.       
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5.1.3 2-Triazol-Substituted Adenosine Analogues 
N6-Methyl-9-(β-D-ribofuranosyl)-2-(1,2,3-triazol-1-
yl)adenine (3.1).  
In a pressure tube was added 3.24 (165 mg, 0.51 mmol) 
trimethylsilylacetylene (292 µL, 2.05 mmol) and 4 mL DMF. 
The mixture was stirred at 105 °C for 15h. After so lvent evaporation, the yellowish 
residue was dissolved in 2 mL of a 1.0 solution of tetrabutylammonium fluoride in 
THF and stirred for 5h. The reaction was monitored by NMR After evaporation of the 
solvent, the residue was dissolved in ethyl acetate. Water was added and the triazole 
product precipitated in the water layer. After overnight cooling and filtration, the 
precipitate was further purified on a silica gel column (CH2Cl2:MeOH 92:8) and 
yielded compound 3.1 as a white solid (82 mg, 46 %).  
 
1H NMR (300 MHz, DMSO-d6): δ 3.06 (d, 3H, J = 4.5 Hz, N6-CH3), 3.54-3.61 (m, 1H, 
H-5’A), 3.65-3.72 (m, 1H, H-5’B), 3.96 (dd, 1H, J = 3.8 and 7.9 Hz, H-4’), 4.20 (dd, 
1H, J = 4.7 and 8.2 Hz, H-3’), 4.65 (app q, J = 5.9 Hz, H-2’), 4.98 (t, 1H, J = 5.6 Hz, 
5’-OH), 5.23 (d, 1H, J = 5.0 Hz, 3’-OH), 5.48 (d, 1H, J = 6.2 Hz, 2’-OH), 5.95 (d, 1H, J 
= 5.9 Hz, H-1’), 7.92 (d, 1H, J = 1.2 Hz, H 4”), 8.37 (d, 1H, J = 4.6 Hz, N6-H), 8.46 (s, 
1H, H-8), 8.82 (br s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 27.84 (N6-CH3), 62.19 (C-5’), 71.13 (C-3’), 74.30 (C-
2’), 86.42 (C-4’), 88.01 (C-1’), 119.75 (C-5), 124.67 (C-5”), 134.25 (C-4”), 141.13 (C-
8), 149.56 and 149.85 (C-2 and C-4), 156.082 (C-6).  
HRMS (ESI-MS) C13H17N8O4: [M+H]+: 349.1367  found; 349.1372 calculated.  
 
 
2-(4-Ethyl-1,2,3-triazol-1-yl)-N6-methyl-9-(β-D-
ribofuranosyl)adenine (3.2).  
Compound 3.24 (70 mg, 0.217 mmol), sodium ascorbate 
(8.6 mg, 0.043 mmol) and CuSO4.5H2O (2.2 mg, 0.009 mmol) 
were suspended in 20 mL H2O:t-BuOH (3:1). The mixture was saturated with 1-
butyne and stirred for 4 d at room temperature in a parr apparatus. Purification on a 
preparative silica gel TLC (CH2Cl2:MeOH 90:10) resulted in compound 3.2 as a white 
solid in 40% yield.  
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1H NMR (300 MHz, DMSO-d6): δ 1.27 (t, 3H, J = 7.62 Hz, CH3), 2.75 (q, 2H, J = 7.6 
Hz, CH2), 3.05 (d, 3H, J = 4.4 Hz, N6-CH3), 3.51-3.59 (m, 1H, H-5’A), 3.61-3.70 (m, 
1H, H-5’B), 3.94 (dd, 1H, J = 4.0 en 7.6 Hz, H-4’), 4.15 (dd, 1H, J = 4.4 and 7.9 Hz, 
H-3’), 4.60 (app q,  J = 5.6 Hz, H-2’), 4.97 (t, 1H, J = 5.6 Hz, 5’-OH), 5.22 (d, 1H, J = 
4.7 Hz, 3’-OH), 5.47 (d, 1H, J = 6.2 Hz, 2’-OH), 5.93 (d, 1H, J = 6.2 Hz, H-1’), 8.34 (d, 
1H, J =  4.4 Hz, N6-H), 8.45 (s, 1H, H-8), 8.55 (s, 1H, H-5”). 
13C NMR (75 MHz, DMSO-d6) ): δ 14.32 (CH3), 19.08 (CH2), 27.84 (N6-CH3), 62.13 
(C-5’), 71.15 (C-3’), 74.34 (C-2’), 86.43 (C-4’), 87.84 (C-1’), 119.57 (C-5), 120.962 
(C-5’’), 140.92 (C-8), 149.31, 149.63, 149.88 (C-2, C4 and C-4”), 156.05 (C-6).  
HRMS (ESI-MS) C15H21N8O4 [M+H]+: 377.1682 found; 377.1685 calculated.  
 
 
General procedure for the synthesis of 4”-substituted 2-(1,2,3-triazol-1-
yl)adenosine derivatives 3.3-3.11. Compound 3.24 (70 mg, 0.217 mmol), sodium 
ascorbate (8.6 mg, 0.043 mmol) and CuSO4.5H2O (2.2 mg, 0.009 mmol) were 
suspended in 2 mL H2O:t-BuOH (3:1).  The appropriate alkyne (2 equiv.) was 
subsequently added and the mixture was stirred overnight at room temperature.  The 
2-triazol-1-yl compounds (generally) precipitated from this reaction medium and were 
isolated by filtration with water.  
 
 
2-(4-Butyl-1,2,3-triazol-1-yl)-N6-methyl-9-(β-D-
ribofuranosyl)adenine (3.3). 
The reaction of 3.24 (70 mg, 0.217 mmol) with 1-hexyne 
(50 µL, 0.435 mmol) gave compound 3.3 in 59% yield.†  
 
1H NMR (300 MHz, DMSO-d6): δ 0.93 (t, 3H, J = 7.3 Hz, CH3), 1.38 (m, 2H, CH2), 
1.66 (m, 2H, CH2), 2.71 (t, 2H, J = 7.2 Hz, C4’’-CH2), 3.05 (d, 3H, J = 4.0 Hz, N6-CH3), 
3.52-3.62 (m, 1H, H-5’A), 3.62-3.72 (m, 1H, H-5’B), 3.95 (dd, 1H, J = 3.6 and 7.2 Hz, 
                                            
†
 For the compounds that precipitated from the reaction medium, the yields were calculated from the amount 
obtained after filtration and are lower than the actual yields, since in most cases a considerable amount remained 
in solution. 
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H-4’), 4.18 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.62 (app q, 1H, J = 5.7 Hz, H-2’), 5.01 
(t, 1H, J = 5.2 Hz, 5’-OH), 5.29 (d, 1H, J = 4.0 Hz, 3’-OH), 5.54 (d, 1H, J = 5.6 Hz, 2’-
OH), 5.94 (d, 1H, J = 5.9 Hz, H-1’), 8.36 (d, 1H, J = 4.1 Hz, N6-H), 8.45 (s, 1H, H-8), 
8.56 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 14.37 (CH3), 22.37 (CH2), 25.21 (CH2), 27.83 (N6-
CH3), 31.68 (CH2), 62.14 (C-5’), 71.15 (C-3’), 74.36 (C-2’), 86.43 (C-4’), 87.88 (C-1’), 
119.56 (C-5), 121.33 (C-5”), 140.96 (C-8), 147.88 and 149.90 (C-2, C-4 and C4”), 
156.07 (C-6).  
HRMS (ESI-MS) C17H25N8O4 [M+H]+: 405.1992 found, 405.1998 calculated.  
 
 
2-[4-(2-Hydroxyethyl)-1,2,3-triazol-1-yl]-N6-methyl-9-(β-
D-ribofuranosyl)adenine (3.4).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 3-butyn-1-
ol (33 µL, 0.435 mmol) afforded compound 3.4 without 
precipitation. After solvent evaporation, the mixture was purified on a silica gel 
column (CH2Cl2:MeOH 90:10 + 1% 7N NH3 in MeOH) yielding compound 3.11 as a 
white solid in 68% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.85 (t, 2H, J = 6.9 Hz, CH2), 3.03 (d, 3H, J = 4.7 Hz, 
N6-CH3), 3.52-3.59 (m, 1H, H-5’A), 3.63-3.72 (m, 3H, H-5’B and CH2), 3.94 (dd, 1H, J 
= 3.5 and 7.3 Hz, H-4’), 4.16 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.59 (app q, 1H, J = 
5.4 Hz, H-2’), 4.74 (t, 1H, J = 5.8 Hz, CH2-OH), 4.97 (app t, 1H, J = 5.6 Hz, 5’-OH), 
5.24 (d, 1H, J = 5.0 Hz, 3’-OH), 5.50 (d, 1H, J = 6.2 Hz, 2’-OH), 5.93 (d, 1H, J = 6.2 
Hz, H-1’), 8.31 (d, 1H, J = 4.7 Hz, N6-H), 8.43 (s, 1H, H-8), 8.54 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 27.83 (N6-CH3), 29.70 (CH2), 60.85 (CH2-OH), 62.13 
(C-5’), 71.15 (C-3’), 74.35 (C-2’), 86.43 (C-4’) 87.81 (C-1’), 119.56 (C-5), 122.02 (C-
5”), 140.49 (C-8), 145.49, 149.88 and 149.65 (C-2, C-4 and C4”), 156.05 (C-6).  
HRMS (ESI-MS) C15H21N8O5 [M+H]+: 393.1630 found, 393.1634 calculated.  
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2-(4-Dimethylaminomethyl-1,2,3-triazol-1-yl)-N6-methyl-
9-(β-D-ribofuranosyl) adenine (3.5).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 1-
dimethylamino-2-propyne (47 µL, 0.435 mmol) gave 
compound 3.5 without precipitation. The volatiles were removed under reduced 
pressure, and the residue purified on a silica gel column (CH2Cl2:MeOH 80:10 + 1% 
7N NH3 in MeOH). Compound 3.5 was obtained as a white solid in 67% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.20 (s, 6H, 2 x CH3), 3.05 (d, 3H, J = 4.4 Hz, N6-
CH3), 3.54-3.62 (m, 3H, H-5’A and CH2), 3.65-3.72 (m, 1H, H-5’B), 3.95 (dd, 1H, J = 
4.1 and 7.6 Hz, H-4’), 4.18 (dd, 1H, J = 5.0 and 8.2 Hz, H-3’), 4.62 (app q, 1H, J = 5.4 
Hz, H-2’), 4.98 (t, 1H, J = 5.6 Hz, 5’-OH), 5.23 (d, 1H, J = 5.0 Hz, 3’-OH), 5.49 (d, 1H, 
J = 6.2 Hz, 2’-OH), 5.95 (d, 1H, J = 6.2 Hz, H-1’), 8.38 (d, 1H, J = 4.4 Hz, N6-H), 8.45 
(s, 1H, H-8), 8.64 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6) ): δ 27.85 (N6-CH3), 45.18 (N(CH3)2), 53.85 (CH2), 
62.10 (C-5’), 71.12 (C-3’), 74.38 (C-2’), 86.41 (C-4’), 87.84 (C-1’), 119.64 (C-5), 
123.328 (C-5’’), 140.97 (C-8), 144.41, 149.59, 149.79 (C-2, C4 and C-4”), 156.05 (C-
6).  
HRMS (ESI-MS) C16H24N9O4 [M+H]+: 406.1944 found,  406.1951 calculated.  
 
 
N6-Methyl-2-(4-phenyl-1,2,3-triazol-1-yl)-9-(β-D-
ribofuranosyl)adenine (3.6).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 
phenylacetylene (48 µL, 0.435 mmol) yielded compound 
3.6 (54%) as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 3.11 (d, 3H, J = 4.5 Hz, N6-CH3), 3.55- 3.63 (m, 1H, 
H-5’A), 3.67-3.74 (m, 1H, H-5’B), 3.97 (dd, J = 3.6 and 7.2 Hz, H-4’), 4.21 (dd, J = 4.8 
and 8.1 Hz, H-3’), 4.66 (app q, J = 5.4 Hz, H-2’), 5.03 (app t, 1H, J = 5.6 Hz, 5’-OH), 
5.29 (d, 1H, J = 5.0 Hz, 3’-OH), 5.54 (d, 1H, J = 6.2 Hz, 2’-OH), 5.99 (d, 1H, J = 5.9 
Hz, H-1’), 7.4 (t, 1H, J = 7.3 Hz, Ph), 7.50 (t, 2H, J = 7.5 Hz, Ph), 8.06 (d, 2H, J = 7.3 
Hz, Ph), 8.44 (d, 1H, J = 4.5 Hz, N6-H), 8.49 (s, 1H, H-8), 9.31 (s, 1H, H-5”).  
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13C NMR (75 MHz, DMSO-d6): δ 27.92 (N6-CH3), 62.16 (C-5’), 71.17 (C-3’), 74,39 (C-
2’), 86.48 (C-4’), 87.94 (C-1’), 119.85 (C-5), 120.68 (C-5”), 126.27, 128.95, 129.61 
and 130.85 (Ph), 141.082 (C-8), 147.02 and 149.77 (C-2, C-4 and C-4”), 156.10 (C-
6).  
HRMS (ESI-MS) C19H21N8O4 [M+H]+: 425.1689 found,  425.1685 calculated. 
 
 
N6-Methyl-2-[4-pyridin-2-yl-1,2,3-triazol-1-yl]-9-(β-D-
ribofuranosyl)adenine (3.7).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 2-
ethynylpyridine (44 µL, 0.435 mmol) afforded compound 
3.7 as a white solid in 55% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 3.09 (d, 3H, J = 4.1 Hz, N6-CH3), 3.57-3.66 (m, 1H, 
H-5’A), 3.67-3.76 (m, 1H, H-5’B), 3.97 (dd, 1H, J = 3.9 and 7.5 Hz, H-4’), 4.19 (dd, 
1H, J = 4.8 and 8.1 Hz, H-3’), 4.64 (app q, 1H, J = 6.0 Hz, H-2’), 4.99 (t, 1H, J = 5.6 
Hz, 5’-OH), 5.26 (d, 1H, J = 5.0 Hz, 3’-OH), 5.54 (d, 1H, J = 6.2 Hz, 2’-OH), 5.99 (d, 
1H, J = 5.9 Hz, H-1’), 7.42 (m, 1H, pyridin-2-yl) , 7.96 (m, 1H, pyridin-2-yl), 8.16 (d, 
1H, J = 7.3 Hz, pyridin-2-yl), 8.42 (d, 1H, J = 4.1 Hz, 1H, N6-H), 8.49 (s, 1H, H-8), 
8.68 (d, 1H, J = 4.1 Hz, pyridin-2-yl), 9.16 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 27.92 (N6-CH3), 62.13 (C-5’), 71.14 (C-3’), 74.49 (C-
2’), 86.47 (C-4’), 88.16 (C-1’), 119.92 (C-5), 120.53 (C-5’’), 121.07 (pyridin-2-yl), 
122.25 (pyridin-2-yl), 137.79 (pyridin-2-yl), 141.28 (C-8), 148.47, 150.45 and 150.56 
(C-2, C-4, C-4”and pyridin-2-yl), 156.28 (C-6).  
HRMS (ESI-MS) C18H19N9O4Na [M+Na]+: 448.1458 found,  448.1457 calculated. 
 
 
N6-Methyl-2-[4-(4-propoxyphenyl)-1,2,3-triazol-1-
yl]-9-(β-D-ribofuranosyl)adenine (3.8).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 1-
ethynyl-4-propoxybenzene (57 µL, 0.435 mmol) 
afforded compound 3.8 as a white solid in 36% yield.  
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1H NMR (300 MHz, DMSO-d6): δ 0.99 (t, 3H, J = 7.3 Hz, CH3), 1.71-1.78 (m, 2H, 
CH2), 3.10 (d, 3H, J = 4.1 Hz, N6-CH3), 3.54-3.62 (m, 1H, H-5’A), 3.64-3.72 (m, 1H, 
H-5’B), 3.98 (m, 3H, H-4’and CH2), 4.18 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.64 (app 
q, 1H, J = 5.4 Hz, H-2’), 4.99 (t, 1H, J = 5, 7 Hz, 5’-OH), 5.25 (d, 1H, J = 4.1 Hz, 3’-
OH), 5.50 (d, 1H, J = 5.9 Hz, 2’-OH), 5.97 (d, 1H, J = 6.2 Hz, H-1’), 7.03 (d, 2H, J = 
8.8 Hz, Ph), 7.94 (d, 2H, J = 8.8 Hz, Ph), 8.36 (d, 1H, J = 4.1 Hz, 1H, N6-H), 8.45 (s, 
1H, H-8), 9.15 (s, 1H, H-5”).  
13C NMR (300 MHz, DMSO-d6): δ 11.08 (CH3), 22.73 (CH2), 27.90 (N6-CH3), 62.16 
(C-5’), 69.71 (OCH2), 71.18 (C-3’), 74.38 (C-2’), 86.46 (C-4’), 87.91 (C-1’), 115.50 
(Ph), 119.60 (C-5), 123.28 (C-5’’), 127.66 (Ph), 140.01 (C-8), 147.01, 149.82, 150.45 
(C-4, C-2 and C-4”), 156.10 (C-6).  
HRMS (ESI-MS) C22H27N8O4 [M+H]+: 483.2109 found,  483.2104 calculated. 
 
 
N6-Methyl-2-(4-benzyl-1,2,3-triazol-1-yl)-9-(β-D-
ribofuranosyl)adenine (3.9).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 3-
phenyl-1-propyne (54 µL, 0.435 mmol) gave compound 
3.9 as a white solid in 43% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 3.03 (d, 3H, J = 3.8 Hz, N6-CH3), 3.53-3.62 (m, 1H, 
H-5’A), 3.64-3.71 (m, 1H, H-5’B), 3.95 (dd, 1H, J = 3.7 and 7.2 Hz, H-4’), 4.11 (s, 2H, 
CH2), 4.17 (dd, 1H, J = 4.8 and 8.1 Hz, H-3’), 4.61 (app q, 1H, J = 5.7 Hz, H-2’), 4.97 
(app t, 1H, J = 5.3 Hz, 5’-OH), 5.22 (d, 1H, J = 4.7 Hz, 3’-OH), 5.47 (d, 1H, J = 5.9 Hz, 
2’-OH), 5.94 (d, 1H, J = 5.9 Hz, H-1’), 7.23 (m, 1H, Ph), 7.32 (d, 4H, J = 4.4 Hz, Ph), 
8.34 (d, 1H, J = 3.8 Hz, N6-H), 8.45 (s, 1H, H-8), 8.59 (s, 1H, H-5”). 
13C NMR (75 MHz, DMSO-d6): δ 25.32 (N6-CH3), 32.51 (CH2), 62.11 (C-5’), 71.13 (C-
3’), 74.43 (C-2’), 86.41 (C-4’), 87.96 (C-1’), 121.42 (C-5), 121.97 (C-5”), 126.91, 
129.12, 129.21 and 140.02 (Ph), 140.88 (C-8), 147.42, 149.58 and 149.81 (C-4, C-2 
and C-4”), 156.09 (C-6).  
HRMS (ESI-MS) C20H23N8O4 [M+H]+: 439.1846 found, 439.1842 calculated.  
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2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-N6-methyl-
9-(β-D-ribofuranosyl)adenine (3.10).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 3-
cyclopentyl-1-propyne (57 µL, 0.435 mmol) yielded 
compound 3.10 (32%) as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.23-1.28 (m, 2H, cyclopentyl), 1.48-1.62 (m, 4H, 
cyclopentyl), 1.71-1.75 (m, 2H, cyclopentyl), 2.19-2.25 (m, 1H, cyclopentyl), 2.72 (d, 
2H, J = 7.3 Hz, CH2-cyclopentyl), 3.05 (d, 3H, J = 3.9 Hz, N6-CH3), 3.53-3.61 (m, 1H, 
H-5’A), 3.63-3.72 (m, 1H, H-5’B), 3.96 (dd, 1H, J = 3.6 and 7.2 Hz, H-4’), 4.19 (dd, 
1H, J = 4.8 and 8.1 Hz, H-3’), 4.62 (app q, 1H, J = 5.9 Hz, H-2’), 4.98 (t, 1H, J = 5.3 
Hz, 5’-OH), 5.23 (d, 1H, J = 4.7 Hz, 3’-OH), 5.49 (d, 1H, J = 6.5 Hz, 2’-OH), 5.95 (d, 
1H, J = 5.9 Hz, H-1’), 8.34 (d, 1H, J = 3.9 Hz, N6-H), 8.45 (s, 1H, H-8), 8.55 (s, 1H, H-
5”).  
13C NMR (75 MHz, DMSO-d6): δ 25.37 (cyclopentyl), 27.83 (N6-CH3), 31.56 (CH2), 
32.55 (cyclopentyl), 62.15 (C-5’), 71.15 (C-3’), 74.34 (C-2’), 86.43 (C-4’), 87.87 (C-1’), 
119.60 (C-5), 121.58 (C-5”), 140.92 (C-8), 147.33, 149.89 (C-4, C-2 and C4”), 156.07 
(C-6).  
HRMS (ESI-MS) C19H27N8O4 [M+H]+: 431.2153 found, 431.2155 calculated.  
 
 
2-(4-Cyclohexylmethyl-1,2,3-triazol-1-yl)-N6-methyl-
9-(β-D-ribofuranosyl)adenine (3.11).  
The reaction of 3.24 (70 mg, 0.217 mmol) with 3-
cyclohexyl-1-propyne (63 µL, 0.435 mmol) gave 
compound 3.11 in 82 % yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.86-1.28 (br m, 6H, cyclohexyl), 1.54-1.72 ( br m, 
5H, cylcohexyl), 2.58 (d, 2H, J = 6.9 Hz, CH2), 3.03 (d, 3H, J = 3.9 Hz, N6-CH3), 3.51-
3.59 (m, 1H, H-5’A), 3.63-3.70 (m, 1H, H-5’B), 3.94 (dd, 1H, J =  4.2 and 7.5 Hz, H-
4’),  4.16 (dd, 1H, J =  4.8 and 8.1 Hz, H-3’), 4.59 (app q, 1H, J = 6.3 Hz, H-2’), 4.97 
(t, 1H, J = 5.5 Hz, 5’-OH), 5.22 (d, 1H, J = 4.8 Hz, 3’-OH), 5.47 (d, 1H, J = 6.3 Hz, 2’-
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OH), 5.93 (d, 1H, J =  6.0 Hz, H-1’), 8.30 (d, 1H, J = 3.9 Hz, N6-H), 8.43 (s, 1H, H-8), 
8.51 (s, 1H, H-5”).   
13C NMR (300 MHz, DMSO-d6): δ 26.31 (cyclohexyl), 26.66 (cyclohexyl), 27.84 (N6-
CH3), 33.16 (cyclohexyl), 38.22 (CH2), 62.14 (C-5’), 71.15 (C-3’), 74.35 (C-2’), 86.44 
(C-4’), 87.86 (C-1’), 119.60 (C-5), 121.93 (C-5”), 140.92 (C-8), 146.45, 149.92 (C-4, 
C-2 and C-4”), 153.51 (C-6).  
HRMS (ESI-MS) C20H29N8O4 [M+H]+: 445.2305 found, 445.2311 calculated.  
 
 
General procedure for the synthesis of 4”-substituted 2-(1,2,3-triazol-4-
yl)adenosine derivatives 3.12-3.14. Compound 3.26 (100 mg, 0.32 mmol), sodium 
ascorbate (13 mg, 0.06 mmol mmol) and CuSO4.5H2O (3 mg, 0. 013 mmol) were 
suspended in 30 mL H2O:t-BuOH (3:1).  The appropriate azide ‡  (2 equiv.) was 
subsequently added and the mixture was stirred overnight at room temperature.  The 
2-triazol-4-yl compounds (generally) precipitated from this reaction medium and were 
isolated by filtration with water. 
 
 
2-(1-Benzyl-1,2,3-triazol-4-yl)-N6-methyl-9-(β-D-
ribofuranosyl)adenine (3.12).  
The reaction of 3.26 (100 mg, 0.32 mmol) with 85 mg 
(0.64 mmol) benzylazide gave compound 3.12 in 78 % 
yield (110 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 3.03 (br s, 3H, N6-CH3), 3.52-3.58 (m, 1H, H-5’A), 
3.60-3.66 (m, 1H, H-5’B), 3.92 (app d, H-4’, J = 2.9 Hz, H-4’), 4.15 (dd, 1H, J = 4.7 
and 7.6 Hz, H-3’), 4.60 (app q, 1H, J = 5.9 Hz, H-2’), 5.08 (t, 1H, J = 5.4 Hz, 5’-OH), 
5.19 (d, 1H, J = 3.5 Hz, 3’-OH), 5.44 (d, 1H, J = 5.6 Hz, 2’-OH), 5.68 (s, 2H, CH2), 
5.97 (d, 6.2 Hz, H-1’), 7.38 (br s, 5H, Ph), 7.82 (br s, 1H, N6-H), 8.36 (s, 1H, H-8), 
8.66 (s, 1H, H-5”). 
13C NMR (75 MHz, DMSO-d6): δ 27.54 (N6-CH3), 53.62 (CH2), 62.29 (C-5’), 71.30 (C-
3’), 74.30 (C-2’), 86.41 (C-4’), 87.77 (C-1’), 119.52 (C-5), 126.41 (C-5”), 128.63, 
                                            
‡
 The benzylic azides were prepared by treating the corresponding benzylic bromides with NaN3 in 
DMF. 
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128.86, 129.48 and 136.71 (Ph), 140.27 (C-8), 148.22, 153.56, 153.72 (C-2, C-4 and 
C-4’), 155.69 (C-6).  
HRMS (ESI-MS) C20H23N8O4  [M+H]+: 439.1834 found, 439.1842 calculated. 
 
 
2-[1-(3-Methoxybenzyl)-1,2,3-triazol-4-yl)-N6-
methyl-9-(β-D-ribofuranosyl) adenine (3.13).  
The reaction of 3.26 (100 mg, 0.32 mmol) with 104 
mg (0.64 mmol) 3-methoxybenzylazide gave 
compound 3.13 in 80 % yield (120 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 3.03 (br s, 3H, N6-CH3), 3.52-3.60 (m, 1H, H-5’A), 
3.64-3.72 (m, 1H, H-5’B), 3.95 (app d, H-4’, J = 2.9 Hz, H-4’), 4.15 (dd, 1H, J = 4.7 
and 7.6 Hz, H-3’), 4.60 (app q, 1H, J = 6.4 Hz, H-2’), 5.07 (t, 1H, J = 5.1 Hz, 5’-OH), 
5.21 (d, 1H, J = 4.2 Hz, 3’-OH), 5.46 (d, 1H, J = 6.3 Hz, 2’-OH), 5.62 (s, 2H, CH2), 
5.95 (d, 1H, J = 6.6 Hz, H-1’), 6.91 (m, 3H, Ph), 7.29 (t, 1H, J = 7.9 Hz, Ph), 7.79 (br 
s, 1H, N6-H), 8.34 (s, 1H, H-8), 8.63 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 27.59 (N6-CH3), 53.45 (CH2), 55.82 (OCH3), 62.30 
(C-5’), 71.33 (C-3’), 74.25 (C-2’), 86.42 (C-4’), 87.70 (C-1’), 114.44 and 114.20 (Ph), 
119.51 (C-5), 120.72 (Ph), 130.65 (C-5”), 138.21 (C-8), 148.22, 153.56, 153.64 (C-2, 
C-4 and C-4’), 155.69 (C-6), 160.14 (Ph).  
HRMS (ESI-MS) C21H25N8O5  [M+H]+: 469.1938 found, 469.1947 calculated.  
 
 
2-[1-(3-Chlorobenzyl)-1,2,3-triazol-4-yl)-N6-methyl-
9-(β-D-ribofuranosyl)adenine (3.14). 
The reaction of 3.26 (100 mg, 0.32 mmol) with 107 
mg (0.64 mmol) 3-chlorobenzylazide gave compound 
3.14 in 73 % yield (110 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 3.04 (br s, 3H, N6-CH3), 3.53-3.60 (m, 1H, H-5’A), 
3.64-3.71 (m, 1H, H-5’B), 3.96 (app d, H-4’, J = 2.9 Hz, H-4’), 4.17 (dd, 1H, J = 4.7 
and 7.6 Hz, H-3’), 4.64 (app q, 1H, J = 5.8 Hz, H-2’), 5.09 (t, 1H, J = 5.3 Hz, 5’-OH), 
5.20 (d, 1H, J = 4.4 Hz, 3’-OH), 5.45 (d, 1H, J = 6.2 Hz, 2’-OH), 5.97 (d, 1H, J = 6.2 
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Hz, H-1’), 7.31-7.36 (m, 1H, Ph), 4.41-7.47 (m, 3H, Ph), 7.83 (br s, 1H, N6-H), 8.37 (s, 
1H, H-8), 8.72 (s, 1H, H-5”). 
13C NMR (75 MHz, DMSO-d6): δ 27.54 (N6-CH3), 52.80 (CH2), 62.31 (C-5’), 71.33 (C-
3’), 74.27 (C-2’), 86.43 (C-4’), 87.69 (C-1’), 119.56 (C-5), 126.63 (C-5”), 127.53, 
128.53, 128.84, 131.42, 133.98 and 139.15 (Ph), 140.36 (C-8), 148.22, 150.03 and 
153.43 (C-2, C-4 and C-4’), 155.78 (C-6).  
HRMS (ESI-MS) C20H22N8O4Cl  [M+H]+: 473.1452 found, 473.1452 calculated. 
 
 
9-(5-Methylcarbamoyl-β-D-ribofuranosyl)-N6-methyl-2-
(1,2,3-triazol-1-yl)adenine (3.15a).  
In a pressure tube was added 3.32a (50 mg, 0.14 mmol) 
trimethylsilylacetylene (102 µL, 0.72 mmol) and 2.5 mL 
DMF. The mixture was stirred at 110 °C for 15h. Sol vent evaporation yielded a 
yellowish solid that was dissolved 750 µL THF and 172 µL (0.17 mmol) of a 1.0 M 
solution of tetrabutylammonium fluoride in THF and stirred for 5 h. After solvent 
evaporation, the residue was dissolved in ethyl acetate. Water was added and the 
triazole precipitated in the water layer. After overnight cooling and centrifugation, the 
precipitate was further purified on a silica gel column (CH2Cl2:MeOH 93:7) and 
yielded compound 3.15a as a white solid (23 mg, 42 %).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.60 (d, 3H, J = 4.7 Hz, CONHCH3), 3.06 (d, 3H, J 
= 3.9 Hz, N6-CH3), 4.26 (m, 1H, H-3’), 4.34 (d, 1H, J = 1.8 Hz, H-4’), 4.75 (app q, 1H, 
J = 6.3 Hz, H-2’), 5.60 (d, 1H, J = 6.3 Hz, 2’-OH), 5.72 (d, 1H, J = 4.2 Hz, 3’-OH), 
5.03 (d, 1H, J = 7.2 Hz, H-1’), 7.94 (s, 1H, H-4’’), 8.04 (d, 1H, J = 4.7 Hz, CONH), 
8.45 (d, 1H, J = 4.2 Hz, N6-H), 8.55 (s, 1H, H-8), 8.83 (s, 1H, H-5’’).  
13C NMR (75 MHz, DMSO-d6): δ 26.34 (CONHCH3), 27.86 (N6-CH3), 73.32 (C-3’), 
73.58 (C-2’), 85.03 (C-4’), 88.02 (C-1’), 119.99 (C-5), 124.75 (C-5”), 134.34 (C-4”), 
141.78 (C-8), 149.60 and 149.86 (C-2 and C-4), 156.10 (C-6), 170,42 (CONH).  
HRMS (ESI-MS) C14H17N9O4Na  [M+H]+: 398.12941 found, 398.13013 calculated. 
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9-(5-Ethylcarbamoyl-β-D-ribofuranosyl)-N6-methyl-2-
(1,2,3-triazol-1-yl) adenine (3.15b).  
The reaction of compound 3.32b (110 mg, 0.30 mmol) with 
trimethylsilylacetylene (259 µL, 1.81 mmol) and 
subsequently treatment with 360 µL (0.36 mmol) 1.0 M tetrabutylammoniumfluoride 
was performed as described for the synthesis of compound 3.15a. Compound 3.16b 
was obtained as a white solid in 42% yield (65 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 0.90 (t, 3H, CH3), 3.05-3.21 (m, 2H, N-CH2), 3.05 (d, 
3H, J = 4.2 Hz, N6-CH3), 4.26 (m, 1H, H-3’), 4.33 (d, 1H, J = 2.1 Hz, H-4’), 4.74 (app 
q, 1H, J = 6.5 Hz, H-2’), 5.61 (d, 1H, J = 6.2 Hz, 3’-OH), 5.71 (d, 1H, J = 4.7 Hz, 2’-
OH), 6.04 ( d, 1H, J = 7.2 Hz, H-1’), 7.91 (d, 1H, J = 1.2 Hz, H-4”), 8.07 (t, 1H, J = 5.3 
Hz, NHCO), 8.41 (d, 1H, J = 4.2 Hz, N6-H), 8.54 (s, 1H, H-8), 8.82 (br s, 1H, H-5”). 
13CMR (75 MHz, DMSO-d6): δ 15.16 (CH3), 27.85 (N6-CH3), 34.07 (CH2), 73.64 (C-2’ 
and C-3’), 84.98 (C-4’), 88.02 (C-1’), 119.91 (C-5), 124.70 (C-5”), 134.29 (C-4”), 
141.59 (C-8), 149.69 and 149.90 (C-2 and C-4), 156.14 (C-6), 169.73 (C=O).  
HRMS (ESI-MS) C15H20N9O4  [M+H]+: 390.1676 found, 390.1683 calculated. 
 
 
General procedure for the synthesis of 4”-substituted 2-(1,2,3-triazol-1-yl) 
adenosine derivatives 3.16, 3.17a,b-3.19a,b.  
To a mixture of 3.32a (31b) (100 mg, 0.28 mmol), CuI (5 mg, 0.03 mmol) and 
triethylamine (40 µL, 0.28 mmol) in water:acetonitrile (1:1), the appropriate alkyne (2 
equiv.) was added. The mixture was stirred for 5 d at room temperature. The reaction 
was monitored by 1H-NMR. The product was precipitated with water and cooled 
overnight. After filtration, the yellowish solid was purified on a silica gel column 
(CH2Cl2: MeOH 90:10) to obtain the 1,2,3-triazol-1-yl adenosine derivative as a white 
solid.   
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2-(4-Butyl-1,2,3-triazol-1-yl)-9-(5-ethylcarbamoyl-β-D-
ribofuranosyl)-N6-methyladenine (3.16).  
The reaction of compound 3.32b (100 mg, 0.28 mmol) with 
1-hexyne (64 µL, 0.56 mmol) gave 65 mg (53%) of 
compound 3.16 as a white solid.  
 
1H NMR (300 MHz, DMSO-d6) δ 0.88-0.95 (m, 6H, 2 x CH3), 1.31-1.43 (m, 2H, CH2), 
1.61-1.71 (m, 2H, CH2), 2.72 (t, 2H, J = 7.8 Hz, C4’’-CH2), 3.05-3.22 (m, 2H, N-CH2), 
3.05 (d, 3H, J = 4.1 Hz, N6-CH3), 4.25 (m, 1H, H-3’), 4.33 (d, 1H, J = 2.1 Hz, H-4’), 
4.73 (m, 1H, H-2’), 5.59 (d, 1H, J = 6.3 Hz, 3’-OH), 5.69 (d, 1H, J = 4.5 Hz, 2’-OH), 
6.04 (d, 1H, J = 6.9 Hz, H-1’), 8.09 (t, 1H, J = 5.4 Hz), 8.37 (d, 1H, J = 4.1 Hz, N6-H), 
8.53 (s, 1H, H-8), 8.56 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): 14.36 (CH3), 15.17 (CH3), 22.35 (CH2), 25.21 (CH2), 
27.84 (N6-CH3), 31.70 (CH2), 34.07 (CH2), 73.60 and 73.64 (C-2’ and C-3’), 84.99 (C-
4”), 87.91 ( C-1’), 119.79 (C-5), 121.45 (C-5”), 141.49 (C-8), 147.97, 149, 72 and 
149.93 (C-2, C-4 and C-4”), 156.11 (C-6), 169.73 (C=O).  
HRMS (ESI-MS) C19H28N9O4  [M+H]+: 446.2256 found, 446.2264 calculated. 
 
 
9-(5-Methylcarbamoyl-β-D-ribofuranosyl)-N6-methyl-2-
(4-pyridin-2-yl-1,2,3-triazol-1-yl)adenine (3.17a).  
The reaction of compound 3.32a (70 mg, 0.20 mmol) with 
2-ethynyl-pyridine (41 µL, 0.40 mmol) gave 48 mg (53 %) 
of compound 3.17a as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.64 (d, 3H, J = 4.4 Hz, CONHCH3), 3.10 (d, 3H, J 
= 4.4 Hz, N6-CH3), 4.26 (m, 1H, H-3’), 4.36 (d, 1H, J = 1.8 Hz, H-4’), 4.77 (app q, 1H, 
J = 6.6 Hz, H-2’), 5.63 (d, 1H, J = 6.5 Hz, 2’-OH), 5.74 (d, 1H, J = 4.7 Hz, 3’-OH), 
6.07 (d, 1H, J = 7.0 Hz, H-1’), 7.42 (t, 1H, J = 5.3 Hz, pyridin-2-yl), 7.96 (t, 1H, J = 7.6 
Hz, pyridin-2-yl), 8.06 (d, 1H, J = 4.4 Hz, CONH), 8.16 (d, 1H, J= 7.6 Hz , pyridin-2-yl), 
8.49 (d, 1H, J = 4.4 Hz, N6-H), 8.58 (s, 1H, H-8), 8.67 (d, 1H, J= 4.4 Hz, pyridin-2-yl), 
9.17 (s, 1H, H-5’’).  
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13C NMR (75 MHz, DMSO-d6): δ 26.38 (CH3), 27.95 (N6-CH3), 73.36 and 73.63 (C-2’ 
en C-3’), 85.04 (C-4’), 88.04 (C-1’), 120.68 and 120.18 (C-5 en C-5’’), 122.22 and 
124.16 (pyridin-2-yl), 138.07 (pyridin-2-yl), 141.92 (C-8), 147.96, 149.69 and 150.53 
(C-2, C-4, C-4” and pyridyn-2-yl), 156.13 (C-6), 170.45 (C=O). 
HRMS (ESI-MS) C19H20N10O4Na [M+Na]+: 475.15592 found, 475.15668 calculated. 
 
 
9-(5-Ethylcarbamoyl-β-D-ribofuranosyl)-N6-methyl-2-
(4-pyridin-2-yl-1,2,3-triazol-1-yl)adenine (3.17b).  
The reaction of compound 3.32b (50 mg, 0.14 mmol) with 
2-ethynyl-pyridine (56 µL, 0.56 mmol) gave 35 mg (54 %) 
of compound 3.17b as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.93 (t, 3H,  J = 7.2 Hz, CH3), 3.09-3.21 (m, 2H, N-
CH2), 3.10 (d, 3H, J = 4.2 Hz, N6-CH3), 4.25 (m, 1H, H-3’), 4.35 (d, 1H, J =  2.1 Hz, 
H-4’), 4.74 (m, 1H, H-2’), 5.68 (d, 1H, J = 6.6 Hz, 2’-OH), 5.75 (d, 1H, J = 4.5 Hz, 3’-
OH), 6.08 (d, 1H, J = 6.6 Hz, H-1’), 7.41 (m, 1H, pyridin-2-yl), 7.96 (m, 1H, pyridin-2-
yl), 8.10 (t, 1H, J = 6.0 Hz, NHCO), 8.16 (d, 1H, J = 8.1 Hz, pyridin-2-yl), 8.48 (d, 1H, 
J = 4.1 Hz, 1H, N6-H), 8.60 (s, 1H, H-8), 8.67 (d, H, J = 5.1 Hz, pyridin-2-yl), 9.17 (s, 
1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 15.18 (CH3), 27.94 (N6-CH3), 34.11 (N-CH2), 73.69 
and 73.78 (C-2’ and C-3’), 84.95 (C-4’), 87.98 (C-1’), 120.04 (C-5), 120.65 (C-5”), 
122.20 and 124.11 (pyridin-2-yl), 138.027 (pyridin-2-yl), 141.64 (C-8), 147.95, 149,64, 
149.67 and 149.98 (C-2, C-4, C-4” and pyridin-2-yl), 150.49 (pyridin-2-yl), 156.13 (C-
6), 169.76 (C=O).  
HRMS (ESI-MS) C20H23N10O4 [M+H]+: 467.1899 found, 467.1903 calculated.  
 
 
2-(4-Benzyl-1,2,3-triazol-1-yl)-9-(5-methylcarbamoyl-β-D-
ribofuranosyl)-N6-methyladenine (3.18a).  
The reaction of compound 3.32a (70 mg, 0.20 mmol) with 
3-phenyl-1-propyne (51 µL, 0.40 mmol) gave 37 mg (40 %) 
of compound 3.18a as a white solid.  
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1H NMR (300 MHz, DMSO-d6): δ 2.60 (d, 3H, J = 4.7 Hz, CONHCH3), 3.04 (d, 3H, J 
= 4.3 Hz, N6-CH3), 4.11 (s, 2 H, CH-Ph), 4.22 (m, 1H, H-3’), 4.33 (d, 1H, J = 1.8 Hz, 
H-4’), 4.70 (m, 1H, H-2’), 5.59 (d, 1H, J = 6.5 Hz, 2’-OH), 5.72 (d, J = 4.5 Hz, 1H, 3’-
OH) , 6.01 (d, 1H, J = 7.0 Hz, H-1’), 7.22 (m, 1H, Ph), 7.32 (d, 4H, J = 4.4 Hz, Ph), 
8.03 (d, 1H, J = 4.4 Hz, CONH), 8.41 (d, 1H, J = 4.8 Hz, N6-H), 8.53 (s, 1H, H-8), 
8.60 (s, 1H, H-5”).  
13C NMR (75 MHz, DMSO-d6): δ 26.37 (CH3), 27.85 (N6-CH3), 31.71 (CH2), 73.32 
and 73.58 (C-2’ and C-3’), 85.041 (C-4’), 87.86 (C-1’), 119.88 (C-5), 122.17 (C-5”), 
126.95, 129.16, 129.23 and 140.071 (Ph), 141.66 (C-8), 147.09 (C-4), 149.62 and 
149.84 (C-2 and C-4”), 156.07 (C-6), 170.40 (C=O).  
HRMS (ESI-MS) C21H23N9O4Na [M+Na]+: 488.17631 found, 488.17708 calculated. 
 
 
2-(4-Benzyl-1,2,3-triazol-1-yl)-9-(5-ethylcarbamoyl-β-D-
ribofuranosyl)-N6-methyladenine (3.18b).  
The reaction of compound 3.32b (70 mg, 0.19 mmol) with 
3-phenyl-1-propyne (49 µL, 0.56 mmol) gave 35 mg (38 %) 
of compound 3.18b as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.87 (t, 3H, J = 7.5 Hz, CH3), 3.03-3.20 (m, 2H, N-
CH2), 3.03 (d, 3H, 4.5 Hz, N6-CH3), 4.11 (s, 2H, CH--Ph), 4.24 (m, 1H, H-3’), 4.32 (d, 
1H, J = 2.1 Hz, H4’), 4.72 (m, 1H, H-2’), 5.59 (d, 1H, J = 6.6 Hz, 2’-OH), 5.69 (d, 1H, 
J = 4.5 Hz, 3’-OH), 6.03 (d, 1H, J = 6.9 Hz, H1’), 7.22 (m, 1H, Ph), 7.32 (d, 4H, J = 
4.2 Hz, Ph), 8.06 (t, 1H, J = 5.7 Hz, NHCO), 8.38 (d, 1H, J = 4.1 Hz, N6-H), 8.54 (s, 
1H, H-8), 8.60 (s, 1H, H-5”). 
13C NMR (75 MHz, DMSO-d6): δ 15.16 (CH3), 27.84 (N6-CH3), 31.72 (CH2), 34.07 (N-
CH2), 73.64 (C-2’ and C-3’), 84.98 (C-4’), 87.87 (C-1’), 119.91 (C-5), 122.11 (C-5”), 
126.93, 129.13, 129.22 and 140.07 (Ph), 140.48 (C-8), 147.05, 149.87 (C-4, C-2 and 
C-4”), 156.12 (C-6), 169.71 (C=O). 
HRMS (ESI-MS) C22H26N9O4 [M+H]+: 480.2098 found, 480.2107 calculated.  
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2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(5-
methylcarbamoyl-β-D-ribofuranosyl)-N6-methyladenine 
(3.19a).  
The reaction of compound 3.32a (60 mg, 0.17 mmol) with  
3-cyclopentyl-1-propyn (45 µL, 0.34 mmol) gave 25 mg 
(32%) of compound 3.16a as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.23-1.27 (m, 2H, cyclopentyl), 1.49-1.75 (m, 6H, 
cyclopentyl), 2.20-2.27 (m, 1H, CH, cyclopentyl), 2.62 (d, 3 H, J = 4.7 Hz, N6-CH3), 
2.72 (d, 2H, J = 7.3 Hz, CH2), 3.06 (3H, J = 4.4 Hz, CONHCH3), 4.24 (m, 1H, H-3’), 
4.34 (d, 1H, J = 2.1 Hz, H-4’), 4.72-4.76 (app q, 1H, J = 6.4 Hz, H-2’), 5.59 (d, 1H, J = 
6.4 Hz, 2’-OH), 5.72 (d, 1H, J = 4.4 Hz, 3’-OH), 6.02 (d, 1H, J = 7.0 Hz, H-1’), 8.04 (d, 
1H, J = 4.7 Hz, CONH), 8.40 (d, 1H, J = 4.7 Hz, N6-H), 8.53 (s, 1H, H-8), 8.56 (s, 1H, 
H-5’’).  
13C NMR (75 MHz, DMSO-d6): δ 25.37 (cyclopentyl), 26.36 (CH3), 27.86 (N6-CH3), 
31.55 (cyclopentyl), 32.53 (CH2), 73.27 and 73.58 (C-2’ and C-3’), 85.06 (C-4’), 87.93 
(C-1’), 119.86 (C-5), 121.71 (C-5’’), 141.68 (C-8), 147.49, 149.64 and 149.90 (C-2, 
C-4 and C-4’’), 156.09 (C-6), 170.42 (C=O).  
HRMS (ESI-MS) C20H27N9O4Na [M+Na]+: 480.20778 found, 480.20838 calculated. 
 
 
2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(5-
ethylcarbamoyl-β-D-ribofuranosyl)-N6-methyladenine 
(3.19b).  
Compound 3.32b (60 mg, 0.17 mmol), sodium ascorbate 
(13 mg, 0.066 mmol) and CuSO4.5H2O (3.5 mg, 0.013 
mmol) were suspended in 4 mL t-BuOH:H2O (1:1). 3-cyclopentyl-1-propyne (58 µL, 
0.44 mmol) was subsequently added and the mixture was stirred two d at room 
temperature. The 2-triazol-1-yl compound precipitated from the reaction medium. 
Water was added and the mixture was cooled overnight. The precipitate was filtered 
off and washed with water and hexane to obtain 3.19b as a white solid in 33 % yield. 
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1H NMR (300 MHz, DMSO-d6): δ 0.89 (t, 3H, CH3), 1.19-1.28 (m, 2H, cyclopentyl), 
1.45-1.75 (m, 6H, cyclopentyl), 2.15-2.25 (m, 1H, CH, cyclopentyl), 2.72 (d, 2H, J = 
7.2 Hz, CH2), 3.06 (d, 3H, J = 4.5 Hz, N6-CH3), 3.09-3.22 (m, 2H, N-CH2), 4.24 (dt, 
1H, J = 1.5 and 4.8 Hz, H-3’), 4.33 (d, 1H, J = 2.1 Hz, H-4’), 4.71-4.76 (app q, 1H, J = 
6.6 Hz, H-2’), 5.61 (d, 1H, J = 6.3 Hz, 2’-OH), 5.71 (d, 1H, J = 4.8 Hz, 3’-OH), 6.03 (d, 
1H, J = 6.9 Hz, H-1’), 8.10 (t, 1H, J = 5.7 Hz, NHCO), 8.40 (d, 1H, J = 5.1 Hz, N6-H), 
8.54 (s, 1H, H-8), 8.56 (s, 1H, H-5”). 
13C NMR (75 MHz, DMSO-d6): δ 15.17 (CH3), 25.36 (cyclopentyl), 27.85 (N6-CH3), 
31.53 (cyclopentyl), 31.51 (CH2), 34.07 (CH2), 73.63 and 73.56 (C-2’ and C-3’), 84.99 
(C-4’), 87.93 (C-1’), 119.77 (C-5), 121.69 (C-5”), 141.51 (C-8), 147.48 and 149.92 (C-
2, C-4 and C-4”), 156.10 (C-6), 169.74 (C=O).  
HRMS (ESI-MS) C21H30N9O4 [M+H]+: 472.2415 found, 472.2420 calculated. 
 
 
N6-(5-Chloro-2-methoxybenzyl)-2-(4-cyclopentyl methyl-
1,2,3-triazol-1-yl)-9-(β-D-ribofuranosyl)adenine (3.20).  
Compound 3.34 (100 mg, 0.22 mmol), sodium ascorbate (17 
mg, 0.086 mmol) and CuSO4.5H2O (3.5 mg, 0.017 mmol) 
were suspended in 4 mL H2O:t-BuOH (1:1). 3-Cyclopentyl-1-
propyne (29 µL, 0.44 mmol) was subsequently added and the 
mixture was stirred two d at room temperature. The 2-triazol-
1-yl compound precipitated from the reaction medium. Water was added and the 
mixture was cooled overnight. The precipitate was filtered off and washed with water 
and hexane to obtain 3.20 as a white solid in 59 % yield. 
 
 1H NMR (300 MHz, DMSO-d6): δ 1.23-1.28 (m, 2H, cyclopentyl), 1.48-1.61 (m, 4H, 
cyclopentyl), 1.66-1.73 (m, 2H, cyclopentyl), 2.15-2.25 (m, 1H, cyclopentyl), 2.72 (d, 
2H, J = 7.2 Hz, CH2-cyclopentyl), 3.56-3.61 (m, 1H, H-5’A), 3.66-3.71 (m, 1H, H-5’B), 
3.97 (m, 1H, H-4’), 4.20 (m, 1H, H-3’), 4.64 (m, 1H, H-2’), 4.73 (br s, 2H, N6-CH2), 
4.96 (t, 1H, J = 6.0 Hz, 5’-OH), 5.22 (d, 1H, J = 4.8 Hz, 3’-OH), 5.48 (d, 1H, J = 5.7 
Hz, 2’-OH), 5.95 (d, 1H, J = 6.3 Hz, H-1’), 7.04 (d, 1H, J = 9.0 Hz, Ph), 7.25-7.29 (m, 
2H, Ph), 8.40 (s, 1H, H-8), 8.81 (s, 1H, H-5”), 8.81 (br s, 1H, N6-H);  
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13C NMR (75 MHz, DMSO-d6): δ 25.36 (cyclopentyl), 31.54 (CH2), 32.54 (cyclopentyl), 
38.86 (CH2), 56.57 (OCH3), 62.13 (C-5’), 71.15 (C-3’), 74.37 (C-2’), 86.46 (C-4’), 
88.07 (C-1’), 113.15 (Ph), 119.58 (C-5), 121.37 (C-5”), 124.66, 128.23 and 129.93 
(Ph), 141.37 (C-8), 147.40, 149.66 and 150.12 (C-2,C-4 and C-4”), 155.51 (Ph), 
156.33 (C-6).  
HRMS (ESI-MS) C26H32N8O5Cl [M+H]+: 571.2184 found, 571.2184 calculated.  
 
 
2-Amino-6-chloro-9-(2’,3’,5’-tri-O-acetyl-β-D-
ribofuranosyl)purine (3.21) 
Silylation of the base: 2-Amino-6-chloropurine (500 mg, 2.94 
mmol) was treated with 1,1,1,3,3,3-hexamethyldisilazane 
(HMDS, 40 mL) and  (NH4)2SO4 (0.29 mmol, 39 mg) and refluxed for 20h. The 
silylated compound was concentrated and used without further purification. 
Vorbrüggen coupling: β-D-ribofuranose 1,2,3,5-O-tetraacetate (720  mg, 2.26 mmol) 
in dry 1,2-dichloroethane (25 mL) was added to the silylated 2-amino-6-chloropurine. 
The solution was gently refluxed, and after 5 minutes TMSOTf (584 µL, 3.0 mmol) 
was added dropwise. After 4 h the mixture was cooled to room temperature, 
quenched with a cold saturated NaHCO3 solution (80 mL) and extracted with CH2Cl2 
(40 mL). The organic layer was dried with MgSO4, filtered and evaporated to dryness. 
The residue was purified by column chromatography (CH2Cl2:MeOH 99:1) to give 
705 mg (56%) of compound 2.17.  
 
1H NMR (300 MHz, CDCl3): δ 2.08, 2.10, 2.14 (s, 3H, CH3), 4.3-4.47 (m, 3H, H-4’, H-
5’A and H-5’B), 5.20 (br s, 2H, 2-NH2), 5.74 (app t, 1H, J = 5.0 Hz, H-3’), 5.95 (app t, 
1H, J = 5.0 Hz, H-2’), 6.01 (d, 1H, J = 5.0 Hz, H-1’), 7.87 (s, 1H, H-8). (The 1H-NMR 
is in accordance with the literature report.247) 
 
 
6-chloro-2-iodo-9-(2’,3’,5’-O-triacetyl-β-D-
ribofuranosyl)purine (3.22) 
Isoamylnitrite (1 mL, 7.55 mmol) was added to a mixture of 3.21 
(1.05 g, 2.45 mmol), I2 (620 mg, 2.45 mmol), CH2I2 (2.04 mL, 
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25.2 mmol) and CuI (490 mg, 2.57 mmol) in 20 mL THF. The mixture was refluxed for 
45 minutes and then cooled to room temperature. Insoluble materials were removed 
by filtration, and the filtrate was concentrated to dryness. The residue was purified by 
means of a silica gel column, which was washed with CH2Cl2 until the iodine colour 
disappeared and then eluted with CH2Cl2:MeOH (99:1). Compound 3.22 was 
obtainded in 79% yield.  
 
1H NMR (300 MHz, CDCl3) : δ 2.10, 2.13, 2.17 (s, 3H, CH3), 4.41 (m, 2H, H-5’A and 
H-5’B), 4.48 (dd, 1H, J = 3.2 and 4.4 Hz, H-4’), 5.58 (dd, 1H, J = 5.6 and 4.4 Hz, H-
3’), 5.78 (app t, 1H, J = 5.6 Hz, H-2’), 6.21 (d, 1H, J = 5.3 Hz, H-1’), 8.19 (s, 1H, H-8). 
(The 1H-NMR is in accordance with the literature report.203)  
HRMS (ESI-MS) C16H16N4O7I1Cl1 [M+Na]+: 560.9654 found, 560.9652 calculated.  
 
 
2-iodo-N6-methyl-9-(β-D-ribofuranosyl)adenine (3.23) 
2.22 (280 mg, 0.52 mmol) was dissolved in 3 mL 2.0 M CH3NH2 
in THF and stirred for 2 days. After solvent evaporation and 
purification on a silica gel column (CH2Cl2:MeOH 93:7) 
compound 3.23 was obtained as a white solid (210 mg, 99% yield).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.88 (d, 3H, J = 3.9 Hz, N6-CH3), 3.48-3.55 (m, 1H, 
H-5’A), 3.59-3.66 (m, 1H, H-5’B), 3.91 (dd, 1H, J = 3.8 and 7.3 Hz, H-4’), 4.09 (m, 1H, 
H-3’), 4.51 (app q, 1H, J = 5.7 Hz, H-2’), 5.04 ( t, 1H, J = 5.3 Hz, 5’-OH), 5.23 (d, 1H, 
J = 4.7 Hz, 3’OH), 5.47 (d, 1H, J = 6.2 Hz, 2’-OH), 5.79 (d, 1H, J = 6.2 Hz, H-1’), 8.14 
(d, 1H, J = 3.9 Hz, N6-H), 8.28 (s, 1H, H-8). 
HRMS (ESI-MS) C11H15N5O4I: [M+H]+: 408.0173 found; 408.0170 calculated. 
 
 
2-Azido-N6-methyl-9-(β-D-ribofuranosyl)adenine (3.24). 
Sodium ascorbate (19.4 mg; 0.098 mmol) and CuSO4.5H2O 
(12.2 mg; 0.049 mmol) were added to a mixture of 3.23 (200 mg; 
0.491 mmol), sodium azide (38,3 mg; 0.589 mmol), L-proline 
(11,3 mg; 0.098 mmol) and sodium carbonate (10.4 mg; 0.098 mmol) in 10 mL H2O:t-
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BuOH (1:1).  The reaction was stirred overnight at 65 °C and was monitored by 1H-
NMR. 50 mL dilute NH4OH was added and the crude mixture extracted with ethyl 
acetate (3 x 60 mL). The organic layer was washed with brine (60 mL), dried over 
MgSO4, and purified on a silica gel column (CH2Cl2:MeOH, 95:5) to afford compound 
3.24 as a slightly yellow solid in 66% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.91 (d, 3H, J = 4.4 Hz, N6-CH3), 3.48-3.55 (m, 1H, 
H-5’A), 3.58-3.66 (m, 1H, H-5’B), 3.90 (dd, 1H, J = 3.8 and 7.3 Hz, H-4’), 4.10 (dd, 
1H, J = 4.7 and 9.7 Hz, H3’), 4.53 (app q, 1H, J = 5.9 Hz, H-2’), 5.04 (dd, 1H, J = 5.2 
and 6.2 Hz, 5’-OH), 5.19 (d, 1H, J = 5.0 Hz, 3’-OH), 5.43 (d, 1H, J = 6.2 Hz, 2’-OH), 
5.78 (d, 1H, J = 6.2 Hz, H-1’), 8.12 (d, J = 4.4 Hz, N6-H), 8.27 (s, 1H, H-8), small 
peaks from 1/6 tetrazole tautomeric form: δ 3.15 (d, 3H, J = 5.0 Hz, N6-CH3), 3.95 (d, 
H-4’), 4.15 (d, H-3’), 5.51 (d, 2’-OH), 5.94 (d, H-1’), 8.51(s, H-8). 
13C NMR (75 MHz, DMSO-d6): δ 27.54 (N6-CH3), 62.21 (C-5’), 71.17 (C-3’), 74.12 (C-
2’), 86.35 (C-4’), 88.01 (C-1’), 118.07 (C-5), 139.99 (C-8), 156.06 and 156.20 (C-2 
and C-6), small peaks from 1/6 tetrazole tautomeric form: δ 31.89 (N6-CH3), 61.79 (C-
5’), 70.77 (C-3’), 74.37 (C-4’), 112.30 (C-12), 142.91 (C-11), 147.60 (C-6).  
HRMS (ESI-MS) C11H21N8O4 [M+H]+: 323.1208 found, 323.1216 calculated.  
 
 
N6-Methyl-9-(β-D-ribofuranosyl)-2-[2-trimethylsilylethyn-
1-yl]adenine (3.25).  
Compound 3.23 (500 mg, 1.23 mmol), CuI (12 mg, 0.062 
mmol) and (Ph3P)3PdCl2 were dissolved in 9 mL DMF. 
Triethylamine (205 µL, 1.47 mmol) and trimethylsilylacetylene (210 mg, 1.47 mmol) 
were added and the reaction mixture was stirred overnight. After solvent evaporation, 
the residue was dissolved in CH2Cl2 and filtered through a pad of Celite. Purification 
on a silica gel column (CH2Cl2:MeOH 95:5) yielded 305 mg (66%) of compound 3.25.  
1H NMR (300 MHz, DMSO-d6): δ 0.00 (9H, s, (CH3)3Si), 2.7, 3H, N6-CH3), 3.26-3.34 
(m, 1H, H-5’A), 3.37-3.44 (m, 1H, H-5’B), 3.68 (dd, 1H, J = 3.5 Hz, H-4’), 3.86 (dd, 1H, 
J = 3.4 and 8.2 Hz, H-3’), 4.23 (app q, 1H, J = 5.9 Hz , H-2’), 4.87 (t, 1H, J = 5.0, 5’-
OH), 4.94 (d, 1H, J =  4.99 Hz, 3’-OH), 5.21 (d, 1H, J = 6.2 Hz, 2’-OH), 5.63 (d, 1H, J 
= 6.2 Hz, H-1’), 7.69 (br s, 1H, N6-H), 8.19 (s, 1H, H-8). 
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HRMS (ESI-MS) C16H24N5O4Si: [M+H]+: 378.1586 found; 378.1597 calculated. 
 
 
2-Ethynyl-N6-methyl-9-(β-D-ribofuranosyl)purine (3.26). 
300 mg (0.8 mmol) of compound 3.25 was dissolved in 7N 
ammonia in methanol and stirred for 2 h at 0 °C. Af ter solvent 
evaporation, the residue was purified by silica gel 
chromatography (CH2Cl2:MeOH 95:5) to obtain 160 mg (65%) of derivative 3.26.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.91(s, 3H, N6-CH3), 3.48-3.56 (m, 1H, H-5’A), 3.61-
3.68 (m, 1H, H-5’B), 3.92 (m, 1H, H-4’), 4.02 (s, 1H, C≡CH), 4.11 (dd, 1H, J= 5.0 and 
8.2 Hz, H-3’), 4.53 (app q, 1H, J= 5.9 Hz, H-2’), 5.15 (m, 2H, 3’-OH and 5’-OH), 5.44 
(d, 1H, J= 6.15 Hz, 2’-OH), 5.84 (d, 1H, J= 6.16 Hz, H-1’), 7.95 (br s, 1H, N6-H), 8.40 
(s, 1H, H-8). 
HRMS (ESI-MS) C13H16N5O4: [ M+H]+: 306.1197 found; 306.1202 calculated. 
 
 
2’,3’-O-isopropylidene-2-iodo-N6-methyladenosine (3.27) 
First method: p-Toluene sulfonic acid (213 mg, 1.12 mmol) was 
added to a solution of compound 3.23 (4.55 g, 11.2 mmol) in dry 
acetone (100 mL) and 2,2-dimethoxypropane (6.9 mL, 56 mmol) 
and the reaction was stirred at room temperature for 4h. After 
neutralization with sat. aq. NaHCO3, the mixture was evaporated to dryness and 
purified on a silica gel column (CH2Cl2:MeOH 99:1) to yield 2.2 g (44 %) of 
compound 3.27. The low yield was caused by the formation of an important side 
product (3.27bis), that was treated with 80% trifluoroacetic acid to recuperate the 
starting material 3.23.  
Second method: A mixture of compound 3.23, anhydrous CuSO4 (1.18 g, 7.36 
mmol), and 98% sulfuric acid (49 µL, 0.92 mmol) in dry acetone (45mmL), was stirred 
for 24h, and neutralized with triethylamine. After solvent evaporation, the residue was 
purified by silica gel chromatography to obtain compound 3.27 in 68% yield (1.12 g).  
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1H NMR (300 MHz, DMSO-d6): δ 1.33 (s, 3H, CH3), 1.55 (s, 3H, CH3), 2.90 (d, 3H, J 
= 4.2 Hz, N6-CH3), 3.53 (m, 2H, H-5’A and H-5’B), 4.20 (m, 1H, H-4’), 4.90 (dd, 1H, J 
= 3.0 and 5.0 Hz, H-3’), 5.04 (t, 1H, J = 5.4 Hz, 5’-OH), 5.25 (m, 1H, H-2’), 6.06 (d, 
1H, J = 2.7 Hz, H-1’), 8.14 (d, 1H, J = 4.5 Hz, N6-H), 8.27 (s, 1H, H-8).  
MS (m/z) C14H19IN5O5 [M+H]+: 448.1 found; 448,0 calculated. 
 
 
1H NMR (300 MHz, CDCl3): δ 1.30, 1.33, 1.40, 1.61 (s, 3H, 
CH3), 3.10 (s, 3H, OCH3), 3.16 (d, 3H, J = 4.2 Hz, N6-CH3), 3.63 
(m, 2H, H-5’A and H-5’B), 4.41 (m, 1H, H-4’), 5.09 (dd, 1H, J = 
3.0 and 6.0 Hz, H-3’), 5.25 (dd, 1H, J = 2.2 and 6.0 Hz H-2’), 
6.09 (d, 1H, J = 2.2 Hz, H-1’), 7.80 (s, 1H, H-8), 8.12 (d, 1H, J = 
4.5 Hz, N6-H). MS (m/z) C18H27IN5O5 [M+H]+: 520.1 found; 520,1 calculated. 
 
 
1-Deoxy-1-(6-methylamino-2-iodo-9H-purin-9-yl)-2,3-O-
isopropylidene-β-D-ribufuranuronic acid (3.28).  
First method: To a stirred solution of 3.8 g (8.5 mmol) of 3.27 in 
560 mL H2O were added 1.4 g KOH and, dropwise, a solution of 
4.03 g (25.5 mmol) of KMnO4 in 110 mL of H2O. The mixture 
was stirred in the dark for 20 h, cooled to 0 °C  a nd quenched with 30 mL 7% H2O2. 
The mixture was filtered through Celite, the filtrate was concentrated in vacuo and 
then acidified to pH 4 with 3N HCl. The resulting precipitate was filtered off and 
successively washed with water and ether to give 2.98 g (76%) of 3.27 as a white 
solid. 
Second method: A mixture of compound 3.27 (660 mg, 1.5 mmol), 2,2,6,6-
tetramethylpiperidinoxy (46 mg, 0.3 mmol) and iodosobenzenediacetate (1.046 g, 3.2 
mmol) in 30 ml acetonitrile:water (1:1) was stirred in the dark for 24 h. After solvent 
evaporation, the residue was washed subsequently with acetone and diethylether. 
Isolation of the precipitate by centrifugation resulted in compound 3.28 as a white 
solid in 75% (510 mg).  
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1H NMR (300 MHz, DMSO-d6): δ 1.36 (s, 3H, CH3), 1.51 (s, 3H, CH3), 2.89 (d, 3H, J 
= 3.3 Hz, N6-CH3), 4.68 (d, 1H, J = 1.8 Hz, H-4’), 5.40 (d, 1H, J = 6.0 Hz, H-2’), 5.47 
(dd, 1H, J = 6.0 and 1.8 Hz, H-3’), 6.28 (s, 1H, H-1’), 8.08 (d, 1H, J = 3.3 Hz, N6-H), 
8.16 (s, 1H, H-8).  
HRMS (ESI-MS) C14H16N5O5I: [M+H]+: 462.0273 found; 462.0276 calculated. 
 
 
2-Iodo-9-(5-methylcarbamoyl-β-D-ribofuranosyl)- N6-
methyladenine (3.31a). 
p-Nitrophenol (332 mg, 2.39 mmol) and 1-[3-
(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (420 
mg, 2.15 mmol) were added to a solution of 3.28 (920 mg, 1.99 mmol) in 10 mL dry 
DMF. The reaction mixture was stirred for 3 h at room temperature, cooled to 0 °C 
and 0.7 mL (19.9 mmol) of methylamine was added. The solution turned yellow 
immediately and was further stirred for 30 min at room temperature. After 
evaporating the volatiles, the residue was portioned between ethyl acetate (3 x 100 
mL) and H2O (100 mL). The organic layer was washed with brine (100 mL), dried 
over MgSO4 and concentrated to dryness. The residue was dissolved in 80% aquous 
TFA (20 mL) and stirred for 2 h at room temperature. The mixture was concentrated 
in vacuo, coevaporated several times with EtOH and purified by silica gel 
chromatography (CH2Cl2:MeOH 95:5). Compound 3.31a was obtained as a white 
solid in 63 % yield (547 mg).  
 
1H NMR (300MHz, DMSO- d6): δ 2.77 (d, 3H, J = 4.8 Hz, CONHCH3), 2.91 (d, 3H, J 
= 4.0 Hz, N6-CH3), 4.17 (m, 1H, H-3’), 4.31 (d, 1H, J = 1. 8 Hz, H-4’), 4.58 (app q, J= 
6.7 Hz, 1H, H-2’), 5.57 (d, 1H, J = 6.2 Hz, 2’-OH), 5.71 (d, 1H, J = 4.4 Hz, 3’-OH), 
5.90 (d, 1H, J = 7.3, H-1’), 8.05 (d, 3H, J = 4.8, CONH), 8.19 (d, 3H, J = 4.3, N6-H), 
8.37 (s, 1H, H-8). 
HRMS (ESI-MS) C12H16N6O4I1 [M+H]+: 435.02705 found, 435.02795 calculated. 
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9-(5-Ethylcarbamoyl-β-D-ribofuranosyl)-2-iodo-N6-
methyladenine (3.31b). 
This compound was prepared by the procedure described for 
the synthesis of 3.31a from 3.28 by using EtNH2 instead of 
MeNH2(1.11 g, 2.41 mmol); yield: 840 mg (78%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.2 Hz, CH3), 2.91 (d, 3H, J = 4.4 Hz, 
N6-CH3), 3.19-3.29 (m, 2H, N-CH2), 4.16 (dt, 1H, J = 2.1 and 4.4 Hz, H-3’), 4.31 (d, 
1H, J = 2.1 Hz, H-4’), 4.58 (app q, 1H, J = 5.6 Hz, H-2’), 5.59 (d, 1H, J = 6.5 Hz, 2’-
OH), 5.71 (d, 1H, J = 4.7 Hz, 3’-OH),  5.92 (d, 1H, J = 7.1 Hz, H-1’), 8.12 (t, 1H, J = 
5.5 Hz, NHCO), 8.19 (d, 1H, J = 4.4 Hz, N6-H), 8.38 (s, 1H, H-8). 
HRMS (ESI-MS) C13H18N6O4I [M+H]+: 449.0429 found,  449.0436 calculated.  
 
 
2-Azido-9-(5-methylcarbamoyl-β-D-ribofuranosyl)-N6-
methyladenine (3.32a). 
Sodium ascorbate (61 mg, 0.31 mmol) and CuSO4.5H2O (39 
mg, 0.15 mmol) were added to a mixture of  3.31a (670 mg, 
1.54 mmol), sodium azide (200 mg, 3.08 mmol), L-proline (36 
mg, 0.31 mmol) and sodium carbonate (33 mg, 0.31 mmol) in 20 mL H2O:t-BuOH 
(1:1). The reaction was stirred for 2 d at 65 °C an d monitored by 1H-NMR. 100 mL 
dilute NH4OH was added and the crude mixture extracted with ethyl acetate (5 x 150 
mL) and washed with brine (150 mL). The organic layer was dried over MgSO4 and 
purified on a silica gel column (CH2Cl2:MeOH 93:7) to afford compound 3.32a as a 
white solid in 68 % yield (361 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.73 (d, 3H, J= 4.7 Hz, CONHCH3), 2.96 (d, 3H, J = 
4.6 Hz, N6-CH3), 4.14 (m, 1H, H-3’), 4.30 (d, 1H, J = 1.5 Hz, H-4’), 4.54 (dd, 1H, J= 
6.5 Hz, H-2’), 5.54 (d, 1H, J = 6.45 Hz, 2’-OH), 5.72 (d, 1H, J = 3.52 Hz, 3’-OH), 5.89 
(d, 1H, J = 7.33 Hz H-1’), 8.24 (d, 1H, J = 4.7 Hz, CONH), 8.34 (s, 1H, H-8), 8.55 (d, 
1H, J = 4.8 Hz, N6-CH3) small peaks from 1/5 tetrazole tautomeric form: 2.77 (d, 3H, 
J = 4.7 Hz, CONHCH3), 4.36 (d, 1H, H-4’), 6.02 (d, 1H, J = 7.3 Hz, H-1’).  
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13C NMR (75 MHz, DMSO-d6): δ 22.4 (CH3), 26.74 (N6-CH3), 72.07 and 72.91 (C-2’ 
and C-3’), 84.50 (C-4’), 87.41 (C-1’), 117.65 (C-5), 140.05 (C-8), 156.32 and 156.41  
(C-2 and C-4) 169.67 (C-6). 
HRMS (ESI-MS) C12H16N9O4 [M+H]+: 350.13189 found, 350.13251 calculated. 
 
 
2-Azido-9-(5-ethylcarbamoyl-β-D-ribofuranosyl)-N6-
methyladenine (3.32b).  
This compound was prepared by the procedure described for 
the synthesis of 3.32a. From 3.31b (780 mg, 1.74 mmol), 500 
mg (79%) of 3.32b was obtained.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.06 (t, 3H, J = 7.2 Hz, CH3), 2.96 (d, 3H, J = 4.0 Hz, 
N6-CH3), 3.16-3.29 (m, 2H, N-CH2), 4.14 (dt, 1H, J = 1.8 and 4.8 Hz, H-3’), 4.29 (d, 
1H, J = 1.8, H-4’), 4.53-4.59 (app q, 1H, J = 6.3 Hz, H-2’), 5.52 (d, 1H, J = 6.3 Hz, 2’-
OH), 5.68 (d, 1H, J = 4.8 Hz, 3’-OH), 5.90 (d, 1H, J = 7.2 Hz, H-1’), 8.20 (d, 1H, J = 
4.0 Hz, N6-H), 8.35 (s, 1H, H-8), 8.49 (t, 1H, J = 6.0 Hz, NHCO) small peaks from 1/5 
tetrazole tautomeric form: 1.08-1.12 (t, 3H, J = 7.2 Hz, CH3), 4.34 (d, 1H, J = 2.1 Hz, 
H-4’), 4.67-4.73 (app q, 1H, J = 7.2 Hz, H-2’), 5.54 (d, 1H, J = 4.5 Hz, 2’-OH) 6.00 (d, 
1H, J = 7.2 Hz, H-1’). 
13C NMR (75 MHz, DMSO-d6): δ 15.48 (CH3), 27.52 (N6-CH3), 33.94 (N-CH2), 73.06 
and 73.75 (C-2’ and C-3’), 85.15 (C-4’), 88.09 (C-1’), 118.36 (C-5), 140.69 (C-8), 
156.03 and 156.14 (C-2 and C-4) 169.79 (C-6). 
HRMS (ESI-MS) C13H18N9O4 [M+H]+:  364.1473 found, 364.1481 calculated. 
 
 
N6-(5-Chloro-2-methoxybenzyl)-2-iodo-9-(β-D-
ribofuranosyl)adenine (3.33) 
Compound 3.22 (1 g, 1.86 mmol) was dissolved in EtOH (30 mL). 
5-chloro-2-methoxybenzylammonium chloride (580 mg, 2.79 
mmol) and Et3N (392 µL, 2.79 mmol) were added, and the 
solution was refluxed overnight. The mixture was concentrated to 
dryness, dissolved in 7N NH3 in methanol and stirred at room temperature for 2 h to 
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deprotect the 2’-,3’- and 5’-hydroxyl groups. The volatiles were removed under 
reduced pressure, and the residue was purified by silica gel column (CH2Cl2:MeOH, 
97:3). The product, compound 3.33, was realized in 80 % yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 3.51-3.58 (m, 1H, H-5’A), 3.63-3.68 (m, 1H, H-5’B), 
3.85 (s, 3H, OCH3), 3.94 (m, 1H, H-4’), 4.13 (m, 1H, H-3’), 4.52-4.59 (m, 3H, N6-CH2 
and H-2’), 5.03 (t, 1H, J = 5.6 Hz, 5’-OH), 5.21 (d, 1H, J = 5.0 Hz, 3’-OH), 5.48 (d, 1H, 
J = 5.8 Hz, 2’-OH), 5.83 (d, 1H, J = 6.2 Hz, H-1’), 7.03 (d, 1H, J = 8.8 Hz, Ph), 7.16 (d, 
1H, J = 2.7 Hz, Ph), 7.29 (dd, 1H, J = 2.7 and 8.8 Hz, Ph), 8.35 (s, 1H, H-8), 8.62 (br 
s, 1H, N6-H).  
HRMS (ESI-MS) C18H20N5O5ICl  [M+H]+:  548.0204 found, 548.0199 calculated. 
 
 
2-Azido-N6-(5-chloro-2-methoxybenzyl)-9-(β-D-
ribofuranosyl)adenine (3.34).  
Sodium ascorbate (14 mg, 0.073 mmol) and CuSO4.5H2O (9 
mg, 0.037 mmol) were added to a mixture of 3.33 (200mg, 
0.365 mmol), sodium azide (47 mg, 0.73 mmol), L-proline (8 mg, 
0.073 mmol) and sodium carbonate (8mg, 0.073 mmol) in 4 mL 
H2O:t-BuOH (1:1). The reaction was stirred for 2 d at 65 °C and monitored by 1H-
NMR. 10 mL dilute NH4OH was added and the crude mixture extracted with ethyl 
acetate (5 x 15 mL) and washed with brine (15 mL). The organic layer was dried over 
MgSO4 and purified on a silica gel column (CH2Cl2:MeOH 97:3) to afford compound 
3.34 as a white solid in 82 % yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 3.51-3.56 (m, 1H, H5’-A) , 3.60-3.66 (m, 1H, H5’-B), 
3.93 ( m, 1H, H 4’), 4.13 ( m, 1H, H-3’), 4.56-4.62 (m, 3H, N6-CH2 and H-2’), 5.03 (t, 
1H, J = 5.4 Hz, 5’-OH), 5.17 (d, 1H, J = 4.8 Hz, 3’-OH), 5.41 (d, 1H, J = 6.3 Hz, 2’-
OH), 5.81 (d, 1H, J = 6.0 Hz, H-1’), 7.02 (d, 1H, J = 8.7 Hz, Ph), 7.15 (d, 1H, J = 3.0 
Hz, Ph), 7.28 (dd, 1H, J = 2.7 and 8.7 Hz, Ph), 8.34 (s, 1H, H-8), 8.63 (br s, 1H, N6-
H).  
13C NMR (75 MHz, DMSO-d6): δ 38.59 (CH2), 56.49 (OCH3), 62.19 (C-5’), 71.15 (C-
3’), 74.13 (C-2’), 86.36 (C-4’), 88.13 (C-1’), 113.02 (Ph), 119.58 (C-5), 124.29 (Ph), 
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128.10 (Ph), 129.93 (Ph), 140.43 (C-8), 150.69 (C-4), 155.51 (Ph and C-2), 156.33 
(C-6).  
HRMS (ESI-MS) C18H20N8O5Cl  [M+H]+:  463.1248 found, 463.1245 calculated. 
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5.1.4 Pyrimidine Nucleotide Analogues 
 
1-(β-D-Arabinofuranosyl)-2-thio(1H)pyrimidin-4-one 5’-
triphosphate triethyl ammonium salt (4.1)  
A solution of 4.24 (150 mg, 0.58 mmol) in trimethyl 
phosphate (5.8 mL) was cooled to 0 °C, POCl 3 (342 µL, 
3.8 mmol) was added dropwise and the mixture was 
stirred for 4h at 0 °C and for 30 min at room tempe rature. The mixture was poured 
into ice-water (10 mL), neutralized with concentrated NH4OH and evaporated to 
dryness. The resulting residue was purified by column chromatography 
(iPrOH:NH4OH:H2O 60:30:5). After lyophilisation of the collected pure fractions, the 
5’-monophosphate analogue was obtained as a white solid (124 mg, 60%).  
 
5’-Monophosphate 1H NMR (300 MHz, D2O): δ 3.90-4.01 (m, 3H, H-4’, H-5’A and H-
5’B), 4.12 (app t, 1H, J = 4.8 Hz, H-3’), 4.48 (app t, 1H, J = 4.8 Hz, H-2’), 6.07 (d, 1H, 
J = 8.2 Hz, H-6), 6.78 (d, 1H, J = 5.0 Hz, H-1’), 7.97 (d, 1H, J = 8.2 Hz, H-5).  
31P NMR (121 MHz, D2O-d6): δ 3.42  
HRMS (ESI-MS) C9H12N2O8PSNa: [M+Na]+: 363.0271 found; 363.0281 calculated.  
 
To a solution of the 5’-monophosphate (32 mg, 0.088 mmol) and tributylamine (21 µL, 
0.088 mmol) in DMF (3.2 mL) was added 1,1’-carbonyldiimidazole (71 mg, 0.44 
mmol). After stirring for 3h at room temperature, the reaction was quenched by 
addition of methanol (14 µL). Bis(tri-n-butylammonium)pyrophosphate (228 mg, 0.51 
mmol) was added and the mixture was stirred for 3h and subsequently concentrated 
under reduced pressure. The resulting residue was stirred in 1M triethylammonium 
bicarbonate (TEAB) buffer (6mL, pH = 7.4) for 30 min, lyophilized and purified on a 
source 15 Q column (100% water  100% 1 M TEAB/water in 45 min) to yield 10 
µmol (11%) of compound 4.1.  
 
Compound 4.1. 1H NMR (300 MHz, D2O-d6): δ 1.14 (t, 36H, J = 7.2 Hz, 12 x CH3), 
3.07 (q, 24 H, J = 7.2 Hz, 12 x CH2), 4.03 (m, 1H, H-4’), 4.16 (m, 3H, H-3’, H-5’A and 
H-5’B), 4.48 (app t, 1H, J = 5.0 Hz, H-2’), 6.08 (d, 1H, J = 8.2 Hz, H-6), 6.80 (d, 1H, J 
= 5.2 Hz, H-1’), 7.90 (d, 1H, J = 8.1 Hz, H-5).  
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31P NMR (121 MHz, D2O-d6): δ - 22.19 (t, J = 19.6 Hz), -10.35 (d, J = 19.6 Hz), -9.54 
(d, J = 19.6 Hz).  
HRMS (ESI-MS) C9H14N2O14P3S [M-H]-: 498.9099 found; 498.9384 calculated. 
 
 
2’-Amino-2’-deoxy-2-thiouridine 5’-triphosphate triethylammonium salt (4.2) 
and 2’-trifluoroacetylamino-2’-deoxy-2-thiouridine 5’-triphosphate 
triethylammonium Salt (4.3).  
Phosphorus oxychloride (0.004 mL, 0.04 mmol) was added to a solution of 4.46 (7.2 
mg, 0.020 mmol) and Proton Sponge (4 mg, 0.033 mmol) in trimethyl phosphate (1 
mL) at 0 °C. The reaction mixture was stirred for 2  h at 0 °C. Then a mixture of 
tributylamine (0.02 mL, 0.08 mmol) and tributylammonium pyrophosphate (1.6 mol of 
C12H27N per mol of H4PO7, 62 mg, 0.131 mmol) in DMF (0.3 mL) was added at once. 
After 10 min, 0.2 M triethylammonium bicarbonate solution (2 mL) was added, and 
the clear solution was stirred at room temperature for 1 h. The latter was lyophilized 
overnight, and the resulting residue was purified by ion-exchange column 
chromatography with a Sephadex DEAE A-25 resin with a linear gradient (0.01-0.5 
M) of 0.5 M ammonium bicarbonate as the mobile phase to get a mixture of 4.2 and 
4.3 as the ammonium salts. The mixture was purified by HPLC (10mM TEAA:CH3CN 
from 100:0 to 90:10 in 20 min.) to obtain 4.2 (2.2 mg, 12%) and 4.3 (1.4 mg, 7%) as 
the triethylammonium salts.  
 
 
Compound 4.2. 1H NMR (D2O): δ 1.28 (t, J = 7.5 Hz, 
36H, N(CH2CH3)3), 3.20 (q, J = 7.5 Hz, 24H, 
N(CH2CH3)3), 4.15 (dd, J = 6.9, 5.7 Hz, 1H, H-2’), 4.26 
(m, 1H, H-5’A), 4.37 (m, 1H, H-5’B), 4.48 (m, 1H, H-4’), 
4.86 (m, 1H, H-3’), 6.31 (d, J = 8.1 Hz, 1H, H-6), 7.22 (d, 
J = 7.2 Hz, 1H, H-1’), 8.12 (d, J = 8.1 Hz, 1H, H-5).  
31P NMR (121 MHz, D2O): δ -22.64 (t, J = 20.2 Hz, -11.22 (d, J = 20.2 Hz), -9.63 (d, J 
= 19.6 Hz).  
HRMS (m/z) C9H15N3O13P3S [M - H]-: 497.9529 found; 497.9538 calculated.  
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Compound 4.3. 1H NMR (D2O): δ 1.28 (t,36H, J = 7.5 
Hz, N(CH2CH3)3), 3.20 (q, 24H, J = 7.5 Hz, 
N(CH2CH3)3), 4.32 (m, 2H, H-5’A and H-5’B), 4.58 (m, 
1H, H-4’), 4.68 (m, 1H, H-2’), 4.80 (hidden by the 
water peak, 1H, H-3’), 6.26 (d, 1H, J =  8.1 Hz, H-6), 
6.92 (d,1H, J = 5.4 Hz, H-1’), 8.13 (d, 1H, J = 8.4 Hz, H-5).  
31P NMR (121 MHz, D2O): δ -22.28 (t, J = 19.6 Hz), -11.04 (d, J = 19.6 Hz), -8.54 (m).  
HRMS (m/z) C11H14N3O14P3F3S [M-H]-: 593.9364 found; 593.9361 calculated.  
 
 
2’-Acetylamino-2’-deoxy-2-thiouridine 5’-
triphosphate triethylammonium salt (4.4) 
Acetic anhydride (0.07 mL, 0.74 mmol) was added to 
a solution of 4.2 (0.5 mg, 0.55 µmol) in H2O (0.5 mL) 
at room temperature. After the reaction mixture was 
stirred for 6 h, the solvent was removed in vacuo. The residue was purified by HPLC 
(10mM TEAA:CH3CN from 100:0 to 90:10 in 20 min.) to obtain 4.4 (0.3 mg, 57%) as 
the triethylammonium salt.  
 
1H NMR (D2O): δ 1.28 (t, 36H, J = 7.5 Hz, N(CH2CH3)3), 3.20 (q, 24H, J = 7.5 Hz, 
N(CH2CH3)3), 4.29 (m, 2H, H-5’A and H-5’B), 4.36 (m, 1H, H-4’), 4.53 (m, 2H, H-2’ 
and H-3’), 6.27 (d, 1H, J = 8.1 Hz, H-6), 6.98 (d, 1H, J = 5.6 Hz, H-1’), 8.08 (d, 1H, J 
= 8.1 Hz, H-5). 
31P NMR (121 MHz, D2O): δ -21.31 (t, J = 20.5 Hz), -10.84 (d, J = 20.8 Hz), -7.62 (m).  
HRMS (m/z) C11H17N3O14P3S [M -H]-:  539.9660 found; 539.9644 calculated.  
 
 
 
2-Thio-4-methylthiouridine 5’-triphosphate 
triethylammonium salt (4.5)  
To a solution of 4.45 (15 mg, 0.054mmol) and Proton 
Sponge (23 mg, 0.11 mmol) in trimethyl phosphate (1 
mL) was added phosphorous oxychloride (0.01 mL, 0.11 mmol) at 0 °C. The reaction 
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mixture was stirred for 2 hours at 0°C. Then a mixture of tributylamine (0.03 mL, 0.12 
mmol) and tributylammonium pyrophosphate (1.6 moles C12H27N per mole H4PO7, 
110 mg, 0.23 mmol) in DMF (0.3 mL) was added at once. After 10 min, 0.2 M 
triethylammonium bicarbonate solution (2 mL) was added, and the clear solution was 
stirred at room temperature for 1 h. The latter was lyophilized overnight and the 
resulting residue was purified by ion-exchange column chromatography using a 
Sephadex-DEAE A-25 resin with a linear gradient (0.01-0.5 M) of 0.5 M ammonium 
bicarbonate as the mobile phase to get 4.5 as the ammonium salts. The collected 
portions were purified by HPLC (5 mM TBAP:CH3CN 80:20 to 40 60 in 20 min) to 
obtain 4.5 (3.2 mg, 6.4 %) as the triethylammonium salts.  
 
1H NMR (D2O) δ 1.28 (t, 36H, J = 7.5 Hz, N(CH2CH3)3), 2.60 (s, 3H, SCH3), 3.20 (q, 
24H, J = 7.5 Hz, N(CH2CH3)3), 4.38 (m, 3H, H4’, H-5’A and H-5’B), 4.45 (m, 2H, H-2’ 
and H-3’), 6.53 (br s, 1H, H-1’), 7.15 (d, 1H, J = 7.2 Hz, H-6), 8.51 (d, 1H, J = 7.5 Hz, 
H-5).  
31P NMR (121 MHz, D2O): δ -21.02 (m), -11.00 (t, J = 19.2 Hz). -7.62 (m).  
HRMS (m/z) C10H16N2O13P3S2 [M-H]-: 528.9315 found; 528.9307 calculated. 
 
 
1-[5,6-Dideoxy-6-[(hydroxypyrophosphoroxy) 
phosphonyl]-β-D-ribo-hex-5-enofuranosyl] uracil 
triethylammonium salt (4.6) 
To a solution of compound 4.48 (35 mg, 0.109 mmol) 
and tributylamine (27 µL, 0.109 mmol) in DMF (4mL) was added 1,1’-
carbonyldiimidazole (118 mg, 1.1 mmol). After stirring for 3h at room temperature, 
the reaction was quenched by addition of methanol (40 µL). Bis(tri-n-
butylammonium)pyrophosphate (282 mg, 0.63 mmol) was added, and the mixture 
was stirred and subsequently concentrated under reduced pressure. The resulting 
residue was stirred in 1M triethylammonium bicarbonate (TEAB) buffer (6mL, pH = 
7.4) for 8h, lyofilized and purified on a source 15 Q column (1M TEAB:H2O from  
0:100 to 100:0 in 45 min) to yield 24.27 µmol (22%) of compound 4.6.  
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1H NMR (300 MHz, DMSO-d6) : δ 1.20 (t, 36H, J = 7.3 Hz, 12 x CH3),  3.16 (q, 24H, J 
= 7.3 Hz, 12 x CH2), 4.15 (app t, 1H, J = 5.5 Hz, H-2’), 4.30 (app t, 1H, J = 4.9 Hz, H-
3’), 4.53 (m, 1H, H-4’), 5.84 (d, 1H, J = 7.9 Hz, H-6), 5.88 (d, 1H, J = 3.5 Hz, H-1’), 
6.10-6.23 (dt, 1H, J = 1.3 and 17.3 Hz, H-6’), 6.48-6.63 (ddd, 1H, JH5’-H4’ = 5.6 Hz, 
JH5’-H6’ 17.3 Hz, JH5’-P = 22.6 Hz, H-5’), 7.66 (d, 1H, J = 8.1 Hz, H-5). 
31
 P NMR (D2O) δ -23.3 (t, J = 21.5 Hz), -10.59 (d, J = 20.2 Hz), 3.68 (d, J = 23.0 Hz). 
MS (m/z)  C10H14N2O14P3 [M-H]-: 479.2 found; 479.0 calculated. 
 
 
1-[5,6-Dideoxy-6-[(hydroxypyrophosphoroxy) 
phosphonyl]-β-D-ribo-hexofuranosyl]uracil 
triethylammonium salt (4.7) 
This compound was synthesized by the procedure 
described for the synthesis of 4.6. From compound 4.50 (36 mg, 0.11 mmol), 5’-
triphosphate 4.7 was obtained in 5.4 % yield (5.99 µmol).  
 
1H NMR (300 MHz, DMSO-d6) : δ 1.14 (t, 36H,  J = 7.3 Hz, 12 x CH3), 3.16 (q, 24 H, 
J = 7.3 Hz, 12 x CH2), 1.78-1.97 (m, 4H, H-5’ A-B and H-6’ A-B), 3.98-4.05 (m, 2H, 
H-3’ and H-4’), 4.27 (app t, 1H, J = 5.0 Hz, H-2’), 5.81 (d, 1H, J = 4.8, H-1’), 5.83 (d, 
1H, J = 8.0 Hz, H-6), 7.64 (d, 1H, J = 8.1 Hz, H-5);  
31P NMR (D2O):  δ -23.32 (t, J = 20.5 Hz), -20.50 (d, J = 20.5 Hz), 18.22 (d, J = 26.0 
Hz).  
MS (m/z)  C10H16N2O14P3 [M-H]-: 481.1 found; 481.0 calculated. 
 
 
2-S-(2,3,5-Tri-O-benzoyl-β-D-ribofuranos-1-yl)-2-thio-
pyrimidin-4(3H)-one (4.8)  
Silylation of the base: 300 mg (2.34 mmol) 2-thiouracil was 
treated with 1,1,1,3,3,3-hexamethyldisilazane (20 mL) and some 
(NH4)2SO4 crystals were added. After refluxing overnight, the silylated compound 
was concentrated to dryness and used without further purification.  
Vorbrüggen coupling: 1-O-acetyl 2,3,5-tri-O-benzoyl β-D-Ribofuranose (1.047 g, 2.13 
mmol) in 20 mL dry CH3CN was added to the silylated 2-thiouracil. TMSOTf (461 µL, 
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2.55 mmol) was added after 5 min and the solution was stirred overnight at room 
temperature. The reaction was quenched with cold aquous saturated NaHCO3 and 
extracted with CH2Cl2. The organic layer was washed with brine, dried with MgSO4 
and purified by column chromatography (CH2Cl2:MeOH 99:1). Compound 4.8 was 
obtained in 51 % yield (680 mg). 
 
1H NMR (300 MHz, DMSO-d6): δ  4.52-4.58 (dd, 1H, J = 4.1 and 12.3 Hz, H-5’A), 
4.63-4.68 (dd, 1H, J = 3.8 and 12.3 Hz, H-5’B), 4.79-4.84 (ddd, 1H, J = 3.8, 4.1 and 
5.3 Hz, H-4’), 5.89 (app t, 1H, J = 5.3 Hz, H-3’), 5.99 (app t, 1H, J = 4.7 Hz, H-2’), 
6.24 (d, 1H, J = 5.28 Hz, H-6), 6.42 (d, 1H, J = 4.4 Hz, H-1’), 7.43-7.72 (m, 9H, Ph), 
7.86-8.05 (m, 7H, Ph and H-5), 12.81 (br s, 1H, N-H).   
HRMS (ESI-MS) C30H24N2O8S1: [M+H]+: 572.1249 found;  572.1253 calculated.  
 
 
2-S-(β-D-Ribofuranos-1-yl)-2-thio-pyrimidin-4(3H)-one (4.9) 
Compound 4.8 (229 mg, 0.4 mmol) was dissolved in 10 mL 
MeOH:THF (1:1) and 56 mg K2CO3 (0.4 mmol) was added. The 
mixture was stirred overnight at 35 °C and poured i nto water (10 
mL). Chloroform (10mL) was added to extract the formed methylbenzoate esters. 
The water layer was treated with activated carbon and concentrated to dryness. The 
residue was extracted about 10 times with small portions of acetone and the residual 
salts were discarded. Evaporation to dryness yielded 101 mg (97 %) of compound 
4.9.  
 
1H NMR (500 MHz, DMSO-d6): δ 3.38 (dd, 1H, J = 5.7 and 11.6 Hz, H-5’A), 3.48 (dd, 
1H, J = 3.8 and 11.6 Hz, H-5’B), 3.78 (app q, 1H, J = 4.8 Hz, H-4’), 3.87 (app t , J = 
5.0 Hz, H-3’), 3.97 (app t, J = 4.6 Hz, H-2’), 5.66 (d, 1H, J = 4.5 Hz, H-1’), 5.55 (d, 1H, 
J = 6.0 Hz, H-6), 7.46 (d, 1H,  J = 6.0 Hz, H-5). 
13C NMR (125 MHz, DMSO-d6): δ 62.56 (C-5’), 71.41 (C-3’), 75.82 (C-2’), 84.74 (C4’), 
86.47 (C-1’), 108.22 (C-5), 153.20 (C-6), 167.87 (C-S), 172.55 (C=O).  
HRMS(ESI-MS) C9H12N2O5SK: [M+K]+: 299.0066 found;  299,0104 calculated.   
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2’,3’,5’- Tri-O-acetyl-2-thiouridine (4.10) 
A suspension of 2-thiouracil (2 g, 15.6 mmol) and trimethylsilyl 
chloride (1.8 mL) in hexamethyldisilazane (80 mL) was treated with 
a few crystals of ammonium sulphate and refluxed overnight. The 
clear greenish solution was evaporated and a solution of β-D-ribofuranose 1,2,3,5-
tetraacetate (5.5 g, 17.3 mmol) in 20 mL dry dichloroethane was added. After a few 
minutes, stannic chloride (2.4 mL, 20.8 mmol) was added and after 1h, the mixture 
was poured into a sat. aq. NaHCO3 solution under vigorous stirring and then allowed 
to stand for 1 h. The suspension was filtered over a silica gel pad, which was washed 
with CH2Cl2. The organic layer was separated, dried over MgSO4 and evaporated to 
dryness. Silica gel chromatography (CH2Cl2:MeOH 99:1) yielded 4.75 g (79%) of 
compound 4.10.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.06 (s, 3H, CH3), 2.09 (s, 6H, 2 x CH3), 4.31-4.37 
(dd, 1H, J = 3.2 and 13.5 Hz, H-5’A), 4.41-4.47 (m, 2H, H-5’B and H-4’), 5.20 (app t, 
1H, J = 5.7 Hz, H-3’), 5.45 (dd, 1H, J = 3.8 and 5.6 Hz, H-2’), 6.62 (dd, 1H, J = 2.3 
and 7.9 Hz, H-6), 6.68 (d, 1H, J = 3.8 Hz, H-1’), 7.49 (d, 1H, J = 7.9 Hz, H-5), 10.64 
(br s, 1H, N-H).  
HRMS (ESI-MS) C15H19N2O8S: [M+H]+: 387.08604 found; 387.08620 calculated.  
 
 
2’,3’,5’-Tri-O-benzoyl-2-thiouridine (4.11) 
Vörbruggen coupling of silylated 2-thiouracil with 1-O-acetyl 2,3,5-tri-
O-benzoyl β-D-Ribofuranose was performed as described for the 
synthesis of 4.10. Nucleoside 4.11 was obtained in 79 % yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 4.77 (m, 1H, H-5’A and H-5’B), 4.86 (ddd, 1H, J = 
4.1, 4.7 and 5.9 Hz, H-4’), 5.84 (dd, J = 5.9 and 6.2 Hz, H-3’), 5.90 (dd, 1H, J = 4.7 
and 6.2 Hz, H-2’), 5.99 (d, 1H, J = 7.9 Hz, H-6), 7.22 (d, 1H, J = 4.7 Hz, H-1’), 7.43-
7.72 (m, 9H, Ph), 7.86-8.04 (m, 7H, Ph and H-5), 12.80 (br s, 1H, N-H).  
HRMS (ESI-MS) C30H25N2O8S: [M+H]+: 572.1249 found;  572.1253 calculated.  
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2-Thiouridine (4.12) 
1st Method: Compound 4.11 (2.69 g, 4.7 mmol) was dissolved in a 
mixture of 60 mL dry methanol and 1.3 mL 30% methanolic NaOCH3 
solution. After stirring for 15h at room temp, the solution was 
neutralized by adding DOWEX-50 WX-8 (proton form), previously washed with 
methanol. The resin was filtered off, methanol was evaporated and 200 mL water 
was added. The benzoic methyl ester was extracted twice with 100 mL diethylether 
and the water fraction was lyophilized to obtain 1.1 g of 2-thiouridine (4.12, 96%).   
2nd Method: In a parr apparatus compound 4.17 (430 mg, 1.58 mmol) was dissolved 
in pyridine (60mL). The solution was cooled to -40 °C and saturated with H 2S. The 
reaction mixture was heated at 50 °C for 48h result ing in a pressure of 250 psi. After 
cooling to room temperature, the remaining H2S was released, the solvent 
evaporated and the residue was purified on a silica gel column (CH2Cl2:MeOH 95:5), 
yielding compound 4.12 (354 mg, 86 %) as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 3.56-3.62 (m, 1 H, H-5’A), 3.68-3.74 (m, 1H, H-5’B), 
3.88-4.07 (m, 3H, H-2’, H-3’ and H-4’), 5.11 (d, 1H, J = 5.6 Hz, 3’-OH), 5.26 (t, 1H, J 
= 5.0 Hz, 5’-OH), 5.45 (d, 1H, J = 5.3 Hz, 2’-OH), 5.99 (d, 1H, J = 8.2 Hz, H-6), 6.54 
(d, 1H, J = 3.8 Hz, H-1’), 8.18 (d, 1H, J = 8.2 Hz, H-5), 12.64 (s, 1H, N-H);  
13C NMR (75 MHz, DMSO-d6): δ 60.51 (C-5’), 69.61 (C-3’), 75.23 (C-2’), 85.29 (C-4’), 
93.26 (C-1’), 107.09 (C-5), 141.67 (C-6), 160.28 (C=O), 177.1 (C=S).  
HRMS (ESI-MS) C9H13N2O5S1: [M+H]+:  261.05402 found;  261.05451 calculated.  
 
 
 2’,3’-O-isopropylidene uridine (4.14) 
p-Toluenesulfonic acid (1.6 mmol) was added to a solution of 
uridine (4 g, 16 mmol) in dry aceton (160 mL) and 2,2-
dimethoxypropane (10,6 mL, 80 mmol). The reaction was stirred at 
room temperature for 4h. After neutralization with sat. aq. NaHCO3, 
the mixture was evaporated to dryness and purified on a silica gel column 
(CH2Cl2:MeOH 95:5) to yield 3.5 g (77 %) of compound 4.14.  
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1H NMR (300 MHz, CDCl3): δ 1.36 (s, 3H, CH3), 1.57 (s, 3H, CH3), 3.80 (dd, 1H, J =  
4.5 and 11.9 Hz, H-5’A), 3.91 (dd, 1H, J = 3.6 and 11.9 Hz, H-5’B), 4.26-4.30 (m, 1H, 
H-4’), 4.95 (dd, 1H, J = 3.4 and 6.3 Hz, H-3’), 5.02 (dd, 1H, J = 2.8 and 6.3 Hz, H-2’), 
5.56 (d, 1H, J = 8.0 Hz, H-5), 5.72 (d, 1H, J = 2.8 Hz, H-1’), 7.36 (d, 1H, J = 8.1 Hz, 
H-6). (The 1H NMR spectrum is accordance with the literature report.248183) 
 
HRMS (ESI-MS) C12H17N2O6: [M+H]+: 285.10881 found; 285,10866 calculated.  
 
 
1-(2,3-O-Isopropylidene-5-O-mesyl-β-D-ribofuranosyl)uracil 
(4.15)  
To a cooled solution of 4.14 (1 g, 3.52 mmol) in pyridine (12 mL) 
methanesulfonyl chloride (350 µL, 4.5 mmol) was added. The 
reaction was kept at 0 °C for 2h and then poured in to aquous 
saturated NaHCO3, extracted with CH2Cl2 and dried over MgSO4. The pyridine 
residue was coevaporated with toluene and after silica gel chromatography 
(CH2Cl2:MeOH 98:2) compound 4.15 was obtained in 91% yield (1.143 g).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.30 (s, 3H, CH3), 1.50 (s, 3H, CH3), 3.19 (s, 3H, 
CH3), 4.23-4.28 (m, 1H, H-4’), 4.32-4.38 (dd, 1H, J = 6.9 and 10.8 Hz, H5’-A), 4.41-
4.47 (dd, 1H, J = 4.4 and 10.8 Hz, H-5’B), 4.79-4.83 (dd, 1H, J = 4.1 and 6.5 Hz, H-
3’), 5.08-5.11 (dd, 1H, J = 2.1 and 6.5 Hz, H-2’), 5.65 (d, 1H, J = 8.2 Hz, H-6), 5.82 (d, 
1H, J = 2.1 Hz, H-1’), 7.71 (d, 1H, J = 8.2 Hz, H-5), 11.45 (s, 1H, N-H).  
HRMS (ESI-MS) C13H19N2O8: [M+H]+: 363.0877 found; 3630862 calculated.  
 
 
2’,3’-O-Isopropylidene-2-ethoxyuridine (4.16) 
Compound 4.15 (200 mg, 0.55 mmol) was suspended in ethanol 
(previously dried over 4 Å molecular sieves). After DBU (1.2 mmol, 
181 µL) was added, the solution was boiled with reflux for 10h, 
cooled to room temperature and neutralized with saturated NH4Cl 
solution. The mixture was concentrated in vacuo and the residue was purfied on a 
silica gel column (CH2Cl2: MeOH 95:5) to yield 156 mg (91%) of compound 4.16.  
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1H NMR (300 MHz, DMSO-d6): δ 1.29-134 (6H, s and t, J = 7.0 Hz, 2 x CH3), 1.50 (s, 
3H, CH3), 3.52-3.63 (m, 2H, H-5’A and H-5’B), 4.13-4.17 (dd, 1H, J = 4.1 and 7.6 Hz, 
H-4’), 4.31-4.38 (q, 2H, J = 7.0 Hz, CH2), 4.73 (dd, 1H, J = 3.2 and 6.2 Hz, H-3’), 4.91 
(dd, 1H, J = 2.6 and 6.2, H-2’), 5.15 (t, 5.1 Hz, 5’-OH), 5.81-5.84 (2 x d, J = 2.5 and  
7.8 Hz, H1’ and H-5).  
HRMS (ESI-MS) C14H21N2O6: [M+H]+: 313.1368 found; 313.1399 calculated.  
 
 
2-Ethoxyuridine (4.17)  
Compound 4.16 (150 mg, 0.48 mmol) was dissolved in 80% 
trifluoroacetic acid aquous solution. After stirring for 2h at room 
temperature, the volatiles were removed under reduced pressure. 
The residue was three times dissolved in ethanol and evaporated to dryness. Silica 
gel chromatography (CH2Cl2:MeOH 90:10) yielded 112 mg of compound 4.17 (86%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.31 (t, 3H, J = 7.0 Hz, CH3), 3.54-3.59 (dd, 1H, J = 
2.9 and 12.9 Hz, H-5’A), 3.63-3.68 (dd, 1H, J = 2.9 and 12.0 Hz, H-5’B), 3.88 (dd, 1H, 
J = 3.2 and 6.8 Hz, H-4’), 3.97 (app t, J = 4.5 Hz, H-3’), 4.06 (app t, 1H, J = 5.0 Hz, 
H-2’), 4.32-4.39 (q, 2H, J = 7.0 Hz, CH2), 5.12 (br s, 2H, 3’-OH and 5’-OH), 5.46 (br s, 
1H, 2’-OH), 5.72 (d, 1H, J = 4.8 Hz, H-1’),  5.84 (d, 1H, J = 7.7 Hz, H-6), 7.98 (d, 1H, 
J = 7.7 Hz, H-5).  
HRMS (ESI-MS) C11H16N2O6Na: [M+Na]+: 295.0901 found; 295.0906 calculated.  
 
 
Attempted synthesis of 2,5’-O-anhydrouridine via selective 5’-mesylation or 5’-
tosylation of uridine  
a. Attempted selective 5’-mesylation of uridine: synthesis of 4.18a-c 
Methanesulfonyl chloride (350 µl, 4.5 mmol) was added dropwise to a cooled (- 30 °C) 
solution of uridine (1g, 4.1 mmol) in pyridine (20 mL). After the reaction mixture was 
warmed to 0 °C over 1h, volatiles were removed unde r reduced pressure and the 
residue was purified on a silica gel column (95:5 CH2Cl2: MeOH), yielding 690 mg of 
an unseparable mixture of 5’- (61%), 3’- (16%) and 2’- (23%) mesylated uridine. 
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b. Attempted selective 5’-tosylation of uridine: synthesis of 2’-O-p-toluene 
sulfonyl-uridine (4.19) 
p-Toluenesulfonyl chloride (476 mg, 2.25 mmol) was added to a cooled (-20 °C) 
solution of uridine (500 mg, 2.05 mmol) in pyridine (20 mL) and allowed to warm to 0 
°C. After 4h, the reaction mixture was evaporated t o dryness and the residue was 
dissolved in ethyl acetate. The organic phase was washed with water, dried over 
NaSO4, filtered, evaporated to dryness and purified by column chromatography (95:5 
CH2Cl2:MeOH). Surprisingly, 2’-O-p-toluene sulfonyl-uridine (4.19, 51% yield) was 
isolated as the major reaction product.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.38 (s, 3H, CH3), 3.55 (app t, 2H, J = 4.5 Hz, H5’A 
and H-5’B), 3.93 (dd, 1H, J = 4.8 and 2.4 Hz, H-4’), 4.14 (dt, J = 5.1 and 2.1 Hz, H-3’), 
4.84 (dd, 1H, J = 5.3 and 7.3 Hz, H-2’), 5.27 (t, 1H, J = 4.7 Hz, 5’-OH), 5.46 (d, 1H, J 
= 8.2 Hz, H-6), 5.90 (d, 1H, J = 5.6 Hz, 3’-OH), 6.00 (d, 1H, J = 7.0 Hz, H-1’), 7.36 (d, 
2H, J = 7.8 Hz, 2x H-Ph), 7.55 (d, 1H, J = 8.4 Hz, H-5), 7.67 (d, 2H, J = 8.1 Hz, 2x H-
Ph), 11.2 (br s, 1H, N-H).  
 
 
3’,5’-O-TIPDS-2-thiouridine (4.20) 
To a cooled (0 °C) solution of 2-thiouridine ( 4.12) (500 mg, 1.92 
mmol) and imidazole (653 mg, 9.6 mmol) were dissolved in 10 mL 
DMF, 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (676 µL, 2.11 
mmol) was added. The solution was stirred for 3h at room 
temperature and then overnight at 30 °C. The mixtur e was poured into water and 
extracted twice with ethyl acetate. The organic layers were combined, dried with 
MgSO4, filtered and evaporated to dryness. The residue was purified by column 
chromatography (CH2Cl2:MeOH 99:1) to give compound 4.20 in 77% yield (746 mg).  
 
1H NMR (300 MHz, CDCl3): δ 0.94-1.12 (m, 28H, 4 x isopropyl), 2.77 (d, 1H, J = 1.2 
Hz, H-2’), 4.00 (d, 1H, J = 13.5 Hz, H-5’A), 4.22-4.29 (m, 4H, H-3’, H-4’, 2’-OH and H-
5’B), 5.97 (d, 1H, J = 8.2 Hz, H-6), 6.32 (s, 1H, H-1’), 7.97 (d, 1H, J = 8.2 Hz, H-5), 
10.25 (br s, 1H, N-H).  
HRMS (ESI-MS) C21H38N2O6SSi2Na: [M+Na]+:  525.18864 found;  525.18869 
calculated.  
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1-(2,2’-S-anhydro-3,5-TIPDS-β-D-arabinofuranos-1-yl)-2-
thiouracil (4.21) 
Compound 4.20 (746 mg, 1.48 mmol) was dissolved in 8 mL 
pyridine and methanesulfonyl chloride (138 µL, 1.78 mmol) was 
added. After stirring for 4h at room temperature, the solvent was 
evaporated. The residue was dissolved in ethyl acetate and the organic layer was 
washed with water, dried over MgSO4, filtered and concentrated to dryness. The 
residue was dissolved in CH3CN (12 mL) and DBU (419 µL, 2.96 mmol) was added. 
After 3h, the mixture was cooled to room temperature, taken up in ethyl acetate and 
washed with water. The combined organic layers were dried over MgSO4, filtered and 
concentrated to dryness. After purification on a silica gel column (CH2Cl2:MeOH 97:3), 
447 mg (62 %) of compound 4.21 was obtained.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.96-1.03 (m, 28H, 4 x isopropyl), 3.90-4.02 (m, 3H, 
H-4’, H-5’A and H-5’B), 4.40-4.50 (m, 2H, H-2’ and H-3’), 5.92 (dd, 1H, J = 1.2 and 
7.6 Hz, H-6), 6.25 (d, 1H, J =  6.5 Hz, H-1’), 7.76 (d, 1H, J = 7.6 Hz, H-5). 
HRMS (ESI-MS) C21H36N2O5SSi2Na: [M+Na]+:  507.17833 found;  507.17813 
calculated.  
 
 
1-(2,2’-S-anhydro-β-D-arabinofuranosyl)-2-thiouracil (4.22) 
Compound 4.21 (440 mg, 0.91 mmol) was dissolved in 30 mL THF. 
After adding 2.7 mL of a 1.0 M solution of tetrabutylammonium fluoride 
in THF, the mixture was stirred for 2h at room temperature, evaporated 
to dryness and purified on a silica gel column (CH2Cl2:MeOH 90:10). Compound 4.22 
was obtained in 74% yield (162 mg).  
 
1H NMR (300 MHz, DMSO-d6): δ 3.37-3.50 (m, 2H, H-5’A and H-5’B), 3.97 (m, 1H, H-
4’), 4.30 (m, 2H, H-2’ and H-3’), 4.97 (t, 1H, J = 5.3 Hz, 5’-OH), 5.86 (d, 1H, J = 7.6 
Hz, H-6), 5.90 (br s, 1H, 3’-OH), 6.32 (d, 1H, J = 6.5 Hz, H-1’), 7.80 (d, 1H, J = 7.6 Hz, 
H-5).  
HRMS (ESI-MS) C9H11N2O4S: [M+H]+: 243.04322 found; 243.04394 calculated.  
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Attempted synthesis of 2’-azido-2’-deoxy-2-thiouridine 
To a suspension of 4.22 (120 mg, 0.24 mmol) and 96 mg NaN3 (1.49 
mmol) in DMF (5 mL) was added benzoic acid (3 mg, 0.024 mmol). 
The mixture was heated overnight at 150 °C, but no reaction occurred. 
After longer heating, the starting material degraded. 
 
 
First attempted synthesis of 2’-chloro-2’-deoxy-2-thiouridine 
A suspension of 200 mg 4.22 in 5 mL 4.0 M HCl in dioxane was 
heated in a glass cylinder at 75 °C. After overnigh t reaction, the 
product appeared to be degraded. 
 
 
Second attempted synthesis 2’-chloro-2’-deoxy-2-thiouridine  
4.22 (120 mg, 0.50 mmol) was dissolved in 2.5 mL dry pyridine. Acetic anhydride 
(2.62 mmol, 250 µL) was added and the solution was stired overnight. The mixture 
was poured into water (5 mL) and extracted with CH2Cl2. The combined organic 
layers were washed with 1N HCl (2 x 2.5 mL) and water (2 x 2.5 mL) and dried over 
MgSO4. Evaporation of the solvent gave the diacetate quantitatively (163 mg), which 
was dissolved in dry acetonitrile. After adition of 0.8 mL acetyl chloride, the solution 
was refluxed for 5h. Because no reaction was observed, 0.1 equivalent benzoic acid 
was added, but no reaction occurred after overnight refluxing. 
 
 
1-β-D-Arabinofuranosyl)-2-thio(1H)pyrimidin-4-one (4.24) 
A solution of compound 4.23 (2 g, 8.8 mmol) in dry DMF (40mL) and 
triethylamine (6 mL) was transferred to a parr apparatus and saturated 
with H2S at -40 °C and allowed to warm to room temperature  resulting 
in a pressure of 200 psi. After stirring for two days, the remaining H2S was released 
and the solvent evaporated to dryness. The brown residue was purified on a silica gel 
column (CH2Cl2:MeOH 96:4), yielding compound 4.24 (1.6 g, 70%).  
 
1H NMR (300 MHz, DMSO-d6): δ 3.61 (app t, 2H, J = 4.8 Hz, H-5’ A en B), 3.83 (ddd, 
1H, J = 3.0, 2.7 and 5.4 Hz, H-4’), 3.91 (m, 1H, H-3’), 4.18 (m, 1H, H-2’), 5.04 (t, 1H, 
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J = 5.2 Hz, 5’-OH), 5.47 (d, 1H, J = 3.9 Hz, 3’-OH), 5.59 (d, 1H, J = 5.4 Hz, 2’-OH), 
5.93 (d, 1H, J = 8.4 Hz, H-6), 6.73 (d, 1H, J = 3.9 Hz, H-1’), 7.72 (d, 1H, J = 8.4 Hz, 
H-5), 12.59 (br s, 1H, N-H).  
HRMS (ESI-MS) for C9H13N2O5S: [M+H]+: 261.0540 found; 261.0545 calculated. 
 
 
1-(3,5-O-TIPDS-β-D-arabinofuranos-1-yl)-2-thiouracil (4.25)  
To a solution of compound 4.24 (840 mg, 3.0 mmol) and imidazole 
(1.1 g 16.0 mmol) in dry DMF (20 mL), TIPDSCl2 (1.14 mL; 3.6 
mmol) was added at 0 °C. The mixture was allowed to  warm to 30 
°C over 3h.  After overnight stirring, the solution  was poured into 
water, extracted with ethyl acetate, dried over MgSO4, and purified on a silica gel 
column (CH2Cl2:MeOH 98:2) to obtain 1.30 g of 4.25  (81 % yield).  
 
1H NMR (300 MHz, DMSO-d6): δ 0.96-1.03 (m, 28 H, 4x isopropyl), 3.74-3.80 (m, 1H, 
H4’), 3.99 (m, 2H, H-5’A and H-5’B), 4.11 (app t, J = 6.1 Hz, H-3’), 4.34-4.40 (app q, 
1H, J = 6.2 Hz, H-2’), 5.86 (d, 1H, J = 5.9 Hz, 2’-OH), 5.91 (d, 1H, J = 7.9 Hz, H-5), 
6.82 (d, 1H, J = 5.9 Hz, H-1’), 7.57 (d, 1H, J = 8.1 Hz, H-6), 12.65 (br s, 1H, N-H). 
HRMS (ESI-MS) for C21H39N2O6SSi2: [M+H]+: 503.2064 found; 503.2067 calculated. 
 
 
1-(2-Azido-2-deoxy-3, 5-O-TIPDS-β-D-ribofuranos-1-yl)-2-
thiouracil (4.27) 
To a solution of 4.25 (606 mg, 1.2 mmol) and DMAP (586 mg, 4.8 
mmol) in dry dichloromethane (20 mL), trifluoromethanesulfonyl 
chloride (151.8 µl, 1.4 mmol) was added dropwise at 0 °C. After 1 
h, ice water was added. The mixture was subsequently extracted with CH2Cl2, dried 
over MgSO4 and evaporated. The crude residue was dissolved in dry DMF (20 mL) 
and N,N,N’,N’-tetramethylguanidinium azide (949 mg, 6 mmol) was added. After 
overnight reaction and extraction with CH2Cl2, the organic faction was washed with 
sat. aq. NaHCO3 solution and purified by means of silica gel chromatography 
(CH2Cl2:MeOH 95:5) to obtain compound 4.27 in 10% yield (65 mg).  
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1H NMR (300 MHz, CDCl3): δ 0.88-1.05 (m, 28H, 4 x isopropyl), 3.73-3.77 (dd, 1H, J 
= 1.8 and 9.3 Hz, H-2’), 3.91-3.97 (dd, 1H, J = 2.7 and 13.5 Hz, H-5’A), 4.06-4.12 (m, 
2H, H-4’, H-5’B), 4.54-4.64 (m, 1H, H-3’), 5.94 (d, 1H, J = 8.1 Hz, H-6), 6.62 (d, 1H, J 
= 6.0 Hz, H-1’), 7.86 (d, 1H, J = 8.1 Hz, H-5), 9.35 (br s, 1H, N-H). 
HRMS (ESI-MS) for C21H38N5O5SSi2: [M+H]+: 528.2140 found; 528.2132 calculated. 
 
 
2’-Azido-2’-deoxyuridine (4.30) 
To a suspension of 2,2’-anhydrouridine (4.23) (1g, 4.42 mmol) and 
1.72 g NaN3 (26.5 mmol) in DMF (25 mL) was added benzoic acid 
(540 mg, 4.42 mmol). The mixture was heated overnight at 150 °C, 
cooled to room temperature, diluted with water and evaporated to dryness. 
Purification on a silica gel column (CH2Cl2:MeOH 95:5) yielded 617mg (52%) of 
compound 4.30 as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 3.53-3.60 (m, 1H, H-5’A), 3.62-3.69 (m, 1H, H-5’B), 
3.89 (dd, 1H, J = 3.2 and 7.7 Hz, H-4’), 4.05 (app t, 1H, J = 5.4 Hz, H-2’), 4.30 (app q, 
1H, J = 5.1 Hz, H-3’), 5.17 (t, 1H, J = 5.0 Hz, 5’-OH), 5.68 (dd, 1H, J = 7.9 and 2.1 Hz, 
H-6), 5.88 (d, 1H, J = 5.6 Hz, H-1’), 5.95 (d, 1H, J = 5.6 Hz, 3’-OH), 7.86 (d, 1H, J = 
7.9 Hz, H-5), 11.45 (s, 1H, N-H). (The 1H NMR spectrum is accordance with the 
literature report.249) 
HRMS (ESI-MS) for C9H11N5O5Na : [M+Na]+: found, 292.0654; calculated 292.0658. 
 
 
2’-Azido-2’-deoxy-5’-O-methanesulfonyluridine (4.31) 
To a solution of 4.30 (610 mg, 2.3 mmol) in 10 mL pyridine at -78 °C 
was added methanesulfonyl chloride (210 µL, 2.7 mmol). The 
reaction was stirred for 1h at 0 °C, quenched with aqueous saturated 
NaHCO3, extracted with CH2Cl2, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by column chromatography (CH2Cl2:MeOH 96:4) to 
obtain compound 4.31 as a white solid (61%, 472 mg).  
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1H NMR (300 MHz, DMSO-d6): δ 3.23 (s, 3H, CH3), 4.06 (m, 1H, H4’), 4.25-4.48 (m, 
4H, H-2’, H-3’, H-5’A and H-5’B), 5.68 (dd, 1H, J = 7.9 and 2.1 Hz, H-6), 5.82 (d, 1H, 
J = 5.3 Hz, 3’-OH), 6.2 (d, 1H, J = 5.6 Hz, H-1’), 7.62 (d, 1H, J = 8.2 Hz, H-5), 11.47 
(s, 1H, N-H).  
HRMS (ESI-MS) for C10H14N5O7S: [M+H]+: 348.0618 found; 348.0613 calculated. 
 
 
2’-Azido-2’-deoxy-2-O-ethyluridine (4.32) 
Compound 4.31 (465 mg, 1.3 mmol) was refluxed in absolute ethanol 
(60 mL) in the presence of anhydrous sodium bicarbonate (281 mg, 
3.3 mmol) under a nitrogen atmosphere for 36h. After cooling to room 
temperature, the reaction was diluted with ethyl acetate and the precipitated sodium 
salt was removed by filtration. The filtrate was concentrated in vacuo and purified on 
a silica gel column (CH2Cl2:MeOH 95:5) to obtain compound 4.32 (222 mg, 57%) as 
a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.33 (t, 3H, J = 6.9 Hz, CH3), 3.56-3.63 (m, 1H, H-
5’A), 3.67-3.74 (m, 1H, H-5’B), 3.92 (m, 1H, H-4’), 4.12 (app t, 1H, J = 4.8 Hz, H-2’), 
4.27-4.39 (m, 3H, CH2 and H-3’), 5.23 (t, 1H, J = 4.8 Hz, 5’-OH), 5.85 (m, 2H, H-6 
and H-1’), 6.01 (d, 1H, J = 5.4 Hz, 3’-OH), 7.98 (d, 1H, J = 7.8 Hz, H-5).  
HRMS (ESI-MS) for C11H15N5O5Na : [M+Na]+: 320.0974 found;  320.0971 calculated. 
 
 
2’-Amino-2’-deoxy-2-thiouridine (4.33) 
In a parr apparatus compound 4.32 (210 mg, 0.71 mmol) was 
dissolved in pyridine (40mL), cooled to -50 °C and saturated with H2S. 
The mixture was heated at 50 °C for 24h resulting i n a pressure of 250 
psi. After cooling to room temperature, the remaining H2S was 
released, the solvent evaporated and the residue was purified on a silica gel column 
(CH2Cl2:MeOH 90:10), yielding compound 4.33 (141 mg, 77%), after subsequent 
crystallization from MeOH.  
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1H NMR (300 MHz, DMSO-d6): δ 3.32 (dd, 1H, J = 5.0 and 6.1, H-2’), 3.56-3.67 (m, 
2H, H-5’A and H-5’B), 3.94 (m, 2H, H-3’ and H-4’), 5.19 (t, J = 4.7 Hz, 5’-OH), 5.41 
(br s, 1H, 3’-OH), 6.01 (d, 1H, J = 8.2 Hz, H-6), 6.53 (d, 1H, J = 6.0 Hz, H-1’), 8.09 (d, 
1H, J = 8.2 Hz, H-5).  
13C NMR (300 MHz, DMSO-d6): δ 59.74 (C-2’), 61.43 (C-5’), 70.91 (C-3’), 86.50 (C-
4’), 93.49 (C-1’), 107.32 (C-5), 141.66 (C-6), 160.24 (C-4), 177.66 (C-2). 
HRMS (ESI-MS) for C9H14N3O4S: [M+H]+:  260.0692 found; 260.0704 calculated. 
 
 
2’-Chloro-2’-deoxyuridine (4.34) 
A suspension of 2,2’-anhydrouridine (2.0 g, 8.8 mmol) in 4.0 M HCl in 
dioxane (30 mL) was heated in a glass cylinder at 75 °C. After 24 h, a 
white suspension was obtained. Solvent evaporation yielded 2’-chloro-
2’-deoxyuridine 4.34 (1.6 g, 69%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6):  δ 3.55-3.71 (m, 2H, H-5’A and B), 3.94 (app q, 1H, J 
= 3.2 Hz, H-4’), 4.18 (app q,1H, J = 4.8 Hz, H-3’), 4.54 (app t, 1H, J = 5.3 Hz, H-2’), 
5.22 (t, 1H, J = 5.0 Hz, 5-OH’), 5.66 (dd, 1H, J = 2.4 and 8.2 Hz, H-6), 5.84 (d, 1H, J 
= 5.6 Hz, H-1’), 5.99 (d, 1H, J = 8.1 Hz, H-5), 6.0 (d, 1H, J = 5.7 Hz, 3’-OH), 11.42 (br 
s, 1H, N-H). ). (The 1H NMR spectrum is accordance with the literature report.250)  
HRMS (ESI-MS) C9H12N2O5Cl: [M+H]+: 263.04286 found; 263.04346 calculated. 
 
 
1-(2-Chloro-2-deoxy-3, 5-O-TIPDS-β-D-ribofuranos-1-yl)uracil 
(4.35a) 
To a solution of 4.34 (1.6 g, 6.1 mmol) and imidazole (2.1 g, 30.5 
mmol) in DMF (20 mL) was added TIPDSCl2 (2.14 mL, 6.7 mmol) 
at 0 °C. After 3h at room temperature, the reaction  was stirred 
overnight at 30 °C. Water was added and extraction with ethyl acetate was 
performed. The organic layer was dried over MgSO4 and purified by silica gel 
chromatography (CH2Cl2:MeOH 99:1) to obtain compound 4.35a in 78% yield (2.4 g).  
 
1H NMR (300 MHz, DMSO-d6):  δ 0.93-1.04 (m, 28H, 4x isopropyl), 3.91-3.96 (dd, 1H, 
J = 2.4 Hz and 13.5 Hz, H-5’A), 4.12-4.15 (dd, 1H, J = 2.1 Hz and 9.4 Hz, H-2’), 4.18-
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4.27 (m, 2H, H-4’ and H-5’B), 4.35-4.39 (dd, 1H, J = 5.1 en 9.3 Hz, H-3’), 5.62 (dd, 
1H, J = 2.01 en 8.21 Hz, H-6), 5.88 (s, 1H, H-1’), 7.82 (d, 1H, J = 8.2 Hz, H-5), 8.52 
(br s, 1H, N-H).  
HRMS (ESI-MS) C21H38N2O6ClSi2: [M+H]+: 505.1957 found; 505.1956 calculated. 
 
 
1-(2-Azido-2-deoxy-3,5-O-TIPDS-β-D-ribofuranos-1-yl)uracil 
(4.35b) 
Compound 4.35b was prepared as described for the synthesis of 
4.35a from 4.30 (300 mg, 1.1 mmol); yield 720 mg (79%) of 
compound 4.35b. 
 
1H NMR (300 MHz, DMSO-d6):  δ 0.92-1.04 (m, 28H, 4 x isopropyl), 3.90-3.96 (dd, 
1H, J = 2.6 Hz and 13.8 Hz, H-5’A), 4.03-4.07 (m, 2H, H-2’ and H-4’), 4.17 (d, 1H, J = 
13.8 Hz, H-5’B), 4.41-4.45 (dd, 1H, J = 5.3 Hz and 9.4 Hz, H-3’), 5.50 (s, 1H, H-1’), 
5.62 (d, 1H, J = 8.1 Hz, H-6), 7.72 (d, 1H, J = 8.1 Hz, H-5), 8.36 (br s, 1H, N-H).  
HRMS (ESI-MS) C21H37N5O6Si2 [M+H]+: 512.2351 found; 512,23606 calculated. 
 
 
1-(2-Chloro-2-deoxy-3, 5-O-TIPDS-β-D-ribofuranos-1-yl)-4-O-
(2,6-dimethylfenyl)uracil (4.36a) 
Compound 4.35a (300 mg, 0.6 mmol) was dissolved in CH2Cl2 
(12 mL) and a solution of tetrabutylammoniumbromide (77 mg, 
0.24 mmol) and 2,4,6-triisopropylbenzene sulfonylchloride (234 
mg, 0.8 mmol) in 0.2 M Na2CO3 (24 mL) was added. The mixture 
was stirred vigorously for 15 h, the organic fraction was isolated and the aqueous 
fraction was extracted twice with CH2Cl2. After drying over MgSO4 and concentration 
in vacuo, the residue was dissolved in CH3CN. 2,6-Dimethylphenol (73 mg, 0.6 
mmol),  triethylamine (248 µl; 1.8 mmol) and 1,4-diaza-bicyclo[2,2,2]octane (7 mg, 
0.06 mmol) were added to the solution. After stirring at room temperature for 30 min, 
sat. aq. NaHCO3 was added. The mixture was extracted with CH2Cl2, dried over 
MgSO4 and purified by silica gel chromatography (EtOAc:Hex 90:10) to yield 320 mg 
(88 %) of compound 4.36a.  
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1H NMR (300 MHz, DMSO-d6):  δ 0.83-1.05 (m, 28H, 4x isopropyl), 2.05 (s, 6H, 2x 
CH3), 3.91-3.97 (dd, 1H, J = 2.6 Hz and 13.5 Hz, H-5’A), 4.17-4.25 (m, 2H, H-2’ and 
H-4’), 4.32-4.41 (m, 2H, H-3’ and H-5’B), 5.89 (s, 1H, H-1’), 5.97 (d, 1H, J = 7.6 Hz, 
H-6), 6.98 (s, 3H, Ph), 8.20 (d, 1H, J = 7.6 Hz, H-5).  
HRMS (ESI-MS) C29H46N2O6ClSi2: [M+H]+: 609.2585 found; 609.2582 calculated. 
 
 
1-(2-Azido-2-deoxy-3,5-O-TIPDS-β-D-ribofuranos-1-yl)-4-O-
(2,6-dimethylphenyl) uracil (4.36b) 
Compound 4.36b was prepared as described for the synthesis of 
4.36a from 4.35b (218 mg, 0.4 mmol); yield: 226.8 mg (84 %) of 
compound 4.36b.  
   
 
1H NMR (300 MHz, DMSO-d6): δ 0.88-1.05 (m, 28H, 4x isopropyl), 2.05 (s, 6H, 2 x 
CH3), 3.91-3.97 (dd, 1H, J = 13.5 and 2.6 Hz, H-5’A), 4.08-4.12 (dd, 1H, J = 2.4 and 
9.1 Hz, H-2’), 4.16-4.22 (m, 2H, H-5’B and H-4’), 4.22-4.41 (dd, 1H, J = 4.8 and 9.1 
Hz, H-3’), 5.54 (s, 1H, H-1’), 5.99 (d, 1H, J = 7.5 Hz, H-6), 6.98 (s, 3H, H-Ph), 8.11 (d, 
1H, J = 7.5 Hz, H-5).  
HRMS (ESI-MS) C29H46N5O6Si2 [M+H]+: 616.29847 found; 616.29864 calculated. 
 
 
Attempted synthesis of 1-(2-chloro-2-deoxy-3,5-O-TIPDS-
β-D-ribofuranos-1-yl)-4-O-(2,6-dimethylphenyl)-2-
thiouracil: synthesis of compound 4.37 
Lawesson’s reagent (303 mg, 0.8 mmol) was added to a 
solution of 4.36a (300 mg, 0.53 mmol) in dry toluene. The 
mixture was refluxed for 1h and cooled to room temperature. 
Insoluble materials were filtered off and the filtrate was subjected to silica gel 
chromatography (EtOAc:hexane 90:10) to obtain 4.37  in 20 % yield (94 mg).  
1H NMR (300 MHz, DMSO-d6): δ 0.83-1.05 (m, 28 H, 4x isopropyl), 2.05 (s, 6 H, 2x 
CH3), 3.54 (t, 1 H, J = 11.14 Hz, H-5’A), 4.02 (dd, 1 H, J = 4.1 and 10.9 Hz, H-5’B), 
4.43 (ddd, 1 H, J = 11.2, 4.1 and 5.0 Hz, H-4’), 5.20 (dd, 1 H, J = 1.2 and 5.0 Hz, H-
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3’), 6.34 (d, 1 H, J = 6.0 Hz, H-6), 6.54 (d, 1 H, J = 1.2 Hz, H-2’), 7.02 (s, 3H, Ph), 
8.22 (d, 1H, J = 5.7 Hz, H-5).  
MS (m/z) [M + H]+ = 589.3 found; 589.3 calculated.  
 
 
1-[3,5-O-(Tetrahydropyran-2-yl)-β-D-arabinofuranos-1-yl]uracil 
(4.39) 
2,3-Dihydro-4H-pyrane (22.6 mL, 247.5 mmol) and p-toluenesulfonic 
acid (1.8 g, 9.2 mmol) were added to a solution of 2,2’-
anhydrouridine (4.23, 2g, 8.84 mmol)  in dry DMF (40 mL). The suspension was 
stirred at 0 °C and after 4h the obtained clear sol ution was neutralized by adding 
triethylamine. After addition of sat. aq. NaHCO3, an extraction with EtOAc was 
performed and the organic fraction was dried over MgSO4 and concentrated in vacuo. 
The resulting white solid was dissolved in EtOH:H2O (150 mL, 1:1), dioxane (150 mL) 
and 11 mL of a 1.0 M NaOH solution. After stirring for 3h at room temperature, 
diluted acetic acid was added until pH 7 and after solvent evaporation, the residue 
was purified on a silica gel column (EtOAc:hexane, 70:30). Compound 4.39 was 
obtained in 89 % yield (3.3 g).  
 
MS (m/z) C19H28N2O8Na [M+Na]+: 435.8 found; 435.2 calculated. 
 
 
1-(2-Deoxy-2-fluoro-β-D-ribofuranos-1-yl)uracil (4.41) 
Compound 4.39 (3.0 g, 7.9 mmol) was dissolved in CH2Cl2 (45 mL) 
and pyridine (9 mL) and diethylaminosulfur trifluoride (2.9 ml, 24.5 
mmol) was added at -60 °C. The mixture was allowed to warm to 
room temperature and was subsequently heated for 4h at 40 °C. After addition of sat. 
aq. NaHCO3 and extraction with CH2Cl2, the organic layer was dried over MgSO4 and 
concentrated to dryness. The residue was dissolved in methanol (16 mL) and p-
toluenesulfonic acid (1.3 g, 7.0 mmol) was added. After 15 min, the mixture was 
neutralized with triethylamine and evaporated to dryness. Silica gel purification 
(CH2Cl2:MeOH, 97:3 → 95:5) yielded compound 4.41 in 71 % yield (985 mg).  
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1H NMR (300 MHz, CDCl3):  δ 3.53-3.60 (m, 1H, H-5’A), 3.71-3.77 (m, 1H, H-5’B), 
3.85 (m, 1H, H-4’), 4.06-4.20 (m, 1H, H-3’), 4.92-5.11 (ddd, 1H, J = 53.3, 4.4 and 2.1 
Hz, H-2’), 5.17 (t, 1H, J = 5.3 Hz, 5’-OH), 5.60 (m, 1H, 2H, H-6 and 3’-OH), 5.90 (dd, 
1H, J = 2.1 and 17.6 Hz, H-1’), 7.92 (dd, 1H, J = 1.2 and 8.1 Hz, H-5), 11.38 (s, 1H, 
N-H). ). (The 1H NMR spectrum is accordance with the literature report.251) 
HRMS (ESI-MS) C9H11N2O5FNa [M+Na]+: 269.05442 found;  269.05499 calculated. 
 
 
1-(2-Deoxy-2-fluoro-3,5-O-TBDMS-β-D-ribofuranos-1-yl) uracil 
(4.42) 
Compound 4.41 (900 mg, 3.6 mmol) and imidazole (961 mg, 16 
mmol) were dissolved in 35 mL DMF and TBDMSCl (2.3 g, 15 
mmol) was added at 0 °C. After stirring for 24 h at  room temperature, the mixture was 
poured into sat. aq. NaHCO3, extracted with EtOAc, dried over MgSO4 and purified 
on a silica gel column (CH2Cl2: MeOH 99:1) to obtain compound 4.42 in 61% yield.  
 
1H NMR (300 MHz, CDCl3): δ 0.00 (s, 12H, Si-(CH3)2), 0.80 (s, 9H, t-Bu), 0.82 (s, 9H, 
t-Bu), 3.75-3.80 (dd, 1H, J = 1.8 and 11.7 Hz, H-5’A), 4.03-4.09 (m, 2H, H-5’B and H-
4’), 4.23-4.33 (ddd, 1H, J = 4.1, 7.3 and 19.1 Hz, H-3’), 4.67-4.87 (ddd, 1H, J = 53.2, 
4.1 and 1.8 Hz, H-2’), 5.68 (dd, 1H, J = 8.2 Hz, H-6), 6.03-6.08 (dd, 1H, J = 1.8 and 
15.3 Hz, H-1’), 7.93 (d, 1H, J = 8.2 Hz, H-5), 8.67 (br s, 1H, N-H). 
HRMS (ESI-MS) C21H39N2O5FSi2Na [M+Na]+: 497.22754 found; 497.22793 
calculated. 
 
 
1-(2-Deoxy-2-fluoro-3,5-O-TBDMS-β-D-ribofuranos-1-yl)-4-O-
(2,6-dimethylphenyl) uracil (4.43) 
The reaction was performed as described for the synthesis of 
4.36a and 4.36b. 1.03 g of compound 4.42 yielded 1.027 g (82%) 
of compound 4.43.  
1H NMR (300 MHz, CDCl3): δ 0.00 (s, 12H, Si-(CH3)2), 0.80 (s, 9H, t-Bu), 0.82 (s, 9H, 
t-Bu), 2.04 (s, 6H, 2 x CH3-Ph), 3.71-3.75 (dd, 1H, J = 1.5 and 12.3 Hz, H-5’A), 4.03-
4.06 (m, 2H, H-5’B and H-4’), 4.13-425 (ddd, 1H, J = 3.8, 8.5 and 23.2 Hz, H-3’), 
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4.66-4.84 (dd, 1H, J = 3.8 and 51.9 Hz, H-2’), 5.92-5.99 (d, 1H, J = 22.3 Hz, H-1’) 
5.97 (d, 1H, J = 7.2 Hz, H-6), 8.31 (d, 1H, J = 7.3 Hz, H-5). 
HRMS (ESI-MS) C29H47N2O5FSi2Na [M+Na]+: 601.29072 found; 601.29053 
calculated. 
 
 
2’,3’,5’-Tri-O-acetyl-2,4-dithiouridine (4.44) 
To a solution of 4.10 (290 mg, 0.75 mmol) in dry toluene (10 mL), 
Lawesson’s reagent (304 mg, 0.75 mmol) was added. After heating 
the reaction mixture at 80 °C overnight, insoluble materials were 
filtered off and the filtrate was purified by silica gel chromatography (Hex:EtOAc 
65:35) yielding compound 4.44 as a yellow foam  (250 mg, 83%).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.06 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.09 (s, 3H, 
CH3), 4.25-4.30 (dd, 1H, J = 3.5 and 13.5 Hz, H-5’A), 4.34-4.40 (m, 2H, H-5’B and H-
4’), 5.16 (app t, 1H, J = 5.7 Hz, H-3’), 5.37 (dd, 1H, J = 4.1 and 5.6 Hz, H-2’), 5.98 (d, 
1H, J = 8.2 Hz, H-6), 6.76 (d, 1H, J = 4.1 Hz, H-1’), 7.65 (d, 1H, J = 8.2 Hz, H-5) 9.97, 
(br s, 1H, N-H). 
HRMS (ESI-MS) C15H19N2O7S2: [M+H]+: 403.06338 found; 403.06335 calculated.  
 
 
2,4-Dithiouridine (4.45) 
Compound 4.44 (240 mg, 0.60 mmol) was dissolved in dry methanol 
(15 mL) and the warmed solution was treated with 130µL of a solution 
of NaOMe (30% w/w) in methanol. The reaction was refluxed for 4h 
and then treated with diluted acetic acid to pH 5, evaporated to dryness and purified 
on a silica gel column (CH2Cl2:MeOH 93:7) to obtain compound 4.45 as a yellow 
foam (150 mg, 91%). 
 
1H NMR (300 MHz, DMSO-d6): δ 3.58-3.64 (m, 1H, H-5’A), 3.72-3.78 (m, 1H, H-5’B), 
3.93 (m, 2H, H-3’ and H-4’), 4.08 (m, 1H, H-2’), 5.11 (d, 1H, J = 5.9 Hz, 3’-OH), 5.29 
(t, 1H, J = 5.0 Hz, 5’-OH), 5.53 (d, 1H, J = 5.3 Hz, 2’-OH), 6.40 (d, 1H, J = 2.7 Hz, H-
1’), 6.63 (d, 1H, J = 7.7 Hz, H-6), 8.07 (d, 1H, J = 7.7 Hz, H-5), 13.80 (br s, 1H, N-H). 
HRMS (ESI-MS) C9H11N2O4S2: [M-H]-: 275.01637 found; 275.01602 calculated. 
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2’-Trifluoroacetylamino-2’-deoxy-2-thiouridine (4.46) 
N,N-Diisopropylethylamine (0.006 mL, 0.035 mmol) and ethyl 
trifluoroacetate (0.004 mL, 0.035 mmol) were added sequentially to 
a solution of 4.33 (6 mg, 0.023 mmol) in DMF (1 mL). The reaction 
mixture was stirred for 13 h at room temperature. The solvent was removed in vacuo, 
and the residue was purified by preparative thinlayer chromatography 
(CH2Cl2:MeOH, 90:10) to afford 4.46 (7.2 mg, 88%) as a white solid.  
 
1H NMR (CD3OD): δ 3.84 (m, 2H, H-5’A and H-5’B), 4.14 (dd, J = 5.4, 2.7 Hz, 1H, H-
4’), 4.34 (dd, J = 5.7, 3.0 Hz, 1H, H-3’), 4.58 (dd, J = 6.6, 6.3 Hz, 1H, H-2’), 6.01 (d, J 
= 8.1 Hz, 1H, H-6), 7.12 (d, J = 6.9 Hz, 1H, H-1’), 8.25 (d, J= 8.1 Hz, 1H, H-5).  
HRMS (ESI-MS) C11H13N3O5F3S: [M+H]+: 356.0520 found; 356.0528 calculated. 
 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-
isopropylidene-β-D-ribo-hex-5-enofuranosyl]uracil (4.47) 
1st method: Trifluoroacetic acid (18 µL) was added to a 
solution of 4.14 (100 mg, 0.33 mmol), DCC (275 mg, 1.33 
mmol) and pyridine (36 µL) in anhydrous DMSO (2 mL). The mixture was stirred at 
room temperature for 22h and freshly prepared [(diethoxyphosphinyl)methylidene] 
triphenylphosphorane (4.57) in DMSO (2 mL) was added. After stirring for 24h, 
excess carbodiimide was hydrolyzed by a careful addition of a solution of oxalic acid 
(90 mg, 1 mmol) in methanol (365 µL). After 10 min, the volatiles were removed 
under reduced pressure and the formed DCU was removed by centrifugation.  After 
adding water and extraction with EtOAc, the combined organic layers were dried over 
MgSO4, filtered and concentrated to dryness. The residue was lyophilized to remove 
the remaining DMSO and purified on a silica gel column (CH2Cl2:MeOH 95:5 and 
acetone:pentane 50:50) yielding 51 mg (34%) of 4.47. 
2nd method: Compound 4.14 (100 mg, 0.33 mmol) was dissolved in CH3CN (3 mL) 
and dry pyridine (27 µL, 0.33 mmol) was added. The solution was treated dropwise 
with 0.3 M Dess-Martin periodinane in CH2Cl2 (2.7 mL, 0.53 mmol) and stirring was 
continued for 1h at room temperature. The mixture was diluted with CH2Cl2 to 20 mL 
and sat. aq. NaHCO3 (9 mL) and sat. aq. Na2S2O3 (1.8 mL) were added. The organic 
fraction was isolated and the aqueous fraction was extracted with CH2Cl2. The 
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combined organic fractions were dried over MgSO4, filtered and evaporated to 
dryness. The residue was dissolved in anhydrous DMSO (1 mL) and freshly prepared 
4.57 in DMSO (1 mL) was added. After 20h, the mixture was poured into water and 
extracted with CH2Cl2. The combined layers were dried over MgSO4, filtered and 
concentrated to dryness. The residue was lyophilized to remove the remaining 
DMSO and purified on a silica gel column (CH2Cl2:MeOH 95:5 and acetone:pentane 
50:50) yielding 48 mg (35%) of 4.47. 
3rd method: Compound 4.14 (100 mg, 0.33 mmol) was dissolved in CH3CN (3 mL) 
and IBX was added (275 mg 45 % wt, 0.49 mmol). The resulting suspension was 
stirred vigorously open to the atmosphere at 80 °C.  After 4h, the reaction was cooled 
to room temperature and filtered through a medium glass frit. The filter cake was 
washed 3 times with CH3CN (3 mL) and the combined filtrates were concentrated to 
dryness. The residue was dissolved in anhydrous DMSO (1 mL) and freshly prepared 
4.57 in DMSO (1 mL) was added. After 20h, the mixture was poured into water and 
extracted with CH2Cl2. The combined layers were dried over MgSO4, filtered and 
concentrated to dryness. The residue was lyophilized to remove the remaining 
DMSO and purified on a silica gel column (CH2Cl2:MeOH 95:5 and acetone:pentane 
50:50) yielding 60 mg (44%) of 4.47. 
 
1H NMR (DMSO-d6): δ 1.22 (t, 6H, J = 7.1 Hz, 2 x OCH2CH3), 1.30 (s, 3H, CH3), 1.51 
(s, 3H, CH3), 3.93-3.99 (m, 4H, 2 x OCH2CH3), 4.60 (dd, 1H, J = 4.7 and 6.3 Hz, H-
4’), 4.85 (dd, 1H, J = 4.2 and 6.3 Hz, H-3’), 5.13 (ddd, 2H, J = 1.3 and 6.3 Hz, H-2’), 
5.63 (d, 1H, J = 8.1 Hz, H-6), 5.82 (d, 1H, J = 1.6 Hz, H-1’), 5.96-6.02 (dt, 1H, JH6’-H4’ 
= 1.1 Hz, JH6’-H5’ 17.0 Hz, H-6’), 6.66-6.73 (ddd, 1H, JH5’-H4’ = 6.3 Hz, JH5’-H6’ = 17.0 Hz, 
JH5’-P = 21.8 Hz, H-5’), 7.73 (d, 1H, J = 8.1 Hz, H-5), 11.43 (s, 1H, N-H). 
31P NMR (D2O) δ 17.84. 
HRMS (ESI-MS) C17H25N2O8PNa [M+Na]+: 439.12395 found; 439.12463 calculated. 
 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hex-5-
enofuranosyl]uracil (4.48) 
To a solution of 4.47 (150 mg, 0.36 mmol) in CH2Cl2 (10 mL) 
was added TMSBr (480 µL, 3.6 mmol). After stirring overnight, 
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the volatiles were removed in vacuo. The residue was dissolved in water, washed 
with diethylether and lyofilized to give pure product 4.48 in 62 % yield.  
 
1H NMR (D2O): δ 4.03 (app t, 1H, J = 5.5 Hz, H-3’), 4.23 (app t, 1H, J = 5.5 Hz, H-2’), 
4.43 (m, 1H, H-4’), 5.73 (d, 1H, J = 8.2 Hz, H-5), 5.74 (d, 1H, J = 3.8 Hz, H-1’), 5.98-
6.10 (app t, 1H, J = 17.5 Hz, H-6’), 6.48-6.63 (ddd, 1H, JH5’-H4’ = 5.3 Hz, JH5’-H6’ 17.3 
Hz, JH5’-P = 22.3 Hz, H-5’), 7.49 (d, 1H, J = 8.2 Hz, H-5);  
31
 P NMR (D2O) δ 13.80   
HRMS (ESI-MS) C10H14N2O8P [M+H]+: 323.04897 found;  321,04878 calculated.  
 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-
isopropylidene-β-D-ribo-hexofuranosyl]uracil (4.49) 
To a solution of compound 4.47 (100 mg, 0.27 mmol) in 
methanol (5 mL) was added Pd/C (10%wt, 10 mg). The 
reaction mixture was stirred under hydrogen atmosphere. After 
20h, the mixture was filtered through Celite to remove the catalyst and purified on a 
silica gel column (CH2Cl2:MeOH 95:5) yielding 85 mg (84%) of compound 4.49.  
 
1H NMR (DMSO-d6): δ 1.22 (t, 6H, J = 7.1 Hz, 2 x OCH2CH3), 1.29 (s, 3H, CH3), 1.48 
(s, 3H, CH3), 1.72-1.85 (m, 4H, H-5’ A-B and H-6’ A-B), 3.92-4.02 (m, 5H, H-4’ and 2 
x OCH2CH3), 4.64 (dd, 1H, J = 4.7 and 6.5 Hz, H-3’), 5.00 (dd, 1H, J = 2.3 and 6.5 Hz, 
H-2’), 5.64 (dd, 1H, J = 2 and 7.9 Hz, H-6), 5.75 (d, 1H, J = 2.9 Hz, H-1’), 7.70 (d, 1H, 
J = 7.9 Hz, H-5), 11.40 (s, 1H, N-H).  
 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-
hexofuranosyl]uracil (4.50)  
This compound was synthesized by the procedure described for 
the synthesis of 4.48 from 80 mg (0.21 mmol) of 4.50 in 65% 
yield (44 mg).  
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1H NMR (300 MHz, D2O) : δ 1.68-1.87 (m, 4H, H-5’ A-B and H-6’ A-B), 3.86-3.93 (m, 
2H, H-3’ and H-4’), 4.20 (app t, 1H, J = 4.5 Hz, H-2’), 5.67 (d, 1H, J = 4.4 Hz, H-1’), 
5.72 (d, 1H, J = 8.0, H-6), 7.49 (d, 1H, J = 8.2, H-5). 
31P NMR (D2O) δ 30.13. 
HRMS (ESI-MS) C10H16N2O8P [M+H]+: 323.06373 found; 323.04639 calculated. 
 
 
2’,3’-O-Isopropylidene-2-thiouridine (4.51) 
The reaction was performed as described for the synthesis of 2-
thiouridine from 2-ethoxyuridine. 2-Thiouridine (4.12) (5g, 1.6 mmol) 
yielded 4.3 g (88%) of 4.51. 
 
1H NMR (DMSO-d6) δ 1.29 (s, 3H, CH3), 1.51 (s, 3H, CH3), 3.58-3.72 (m, 2H, H-5’A 
and H-5’B), 4.14 (dd, 1H, J = 3.5 and 7.0 Hz, H-4’), 4.75-4.83 (m, 2H, H-2’ and H-3’), 
5.30 (t, 1H, J = 5.0 Hz, 5’-OH), 6.02 (d, 1H, J = 8.2 Hz, H-6), 6.86 (d, 1H, J = 2.6 Hz, 
H-1’), 7.98 (d, 1H, J = 8.2 Hz, H-5), 12.70 (s, 1H, N-H). 
HRMS C12H16N2O5SNa [M+Na]+: 323.06722 found; 323.06778 calculated. 
 
 
Attempted synthesis of 1-[5,6-Dideoxy-6-
(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hex-5-
enofuranosyl]-2-thiouracil, yielding compound 4.52 
This compound was synthesized from 4.51 (380 mg, 1.27 mmol) 
by the 1st method described for the synthesis of 4.47, to afford 
compound 4.52 in 56 % yield (308 mg).  
 
1H NMR (300 MHz, DMSO-d6) : δ 1.22 (t, 6H, J = 7.1 Hz, 2x CH2CH3), 1.29 (s, 3H, 
CH3), 1.36 (s, 3H, CH3), 3.96-4.07 (m, 4H, 2 x CH2CH3), 5.24 (d, 1H, J = 5.3 Hz,  H-
3’), 5.31 (d, 1H, J = 5.6 Hz, H-2’), 5.98 (d, 1H, J = 7.6 Hz, H-6), 6.23-6.34 (t, J = 17.3 
Hz, H-6’), 6.26 (s, 1H, H-1’), 6.80-6.93 (dd, 1H, JH5’-H4’ = 17.0 Hz, JH5’-P = 22.0 Hz, H-
6’), 7.88 (d, 1H, J = 7.9 Hz, H-5);  
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13C NMR (75 MHz, DMSO-d6): δ 16.80, 16.88 (2 x CH2CH3), 25.66, 26.31 (2 x CH3), 
62.45 (2 x CH2CH3), 85.53 (C-3’), 87.88 (C-2’),110.48 (C-6), 113.68 (C-4’), 120.93, 
123.34 (C-5’), 93.34 (C-1’), 142.29 (C-6’), 156.33 (C-2), 166.82 (C=O).  
HRMS  C17H24N2O7PS [M+H]+: 431.0934 found; 431.10418 calculated.  
 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-
isopropylidene-β-D-ribo-hex-5-enofuranosyl]uracil-4-O-(2,6-
dimethylphenyl)uracil (4.53) 
Compound 4.47 (40 mg, 0.106 mmol) was dissolved in CH2Cl2 
(1 mL) and a solution of tetrabutylammoniumbromide (14 mg, 
0.021mmol) and 2,4,6-triisopropylbenzene sulfonyl chloride (40 
mg, 1.32 mmol) in 0.2M Na2CO3 (4 mL) was added. The mixture was stirred 
vigorously for 15 h, the organic fraction was isolated and the aqueous fraction was 
extracted twice with CH2Cl2. After drying over MgSO4 and concentration in vacuo, the 
residue was dissolved in CH3CN. 2,6-Dimethylphenol (13 mg, 0.106 mmol),  
triethylamine (22 µl, 0.34 mmol) and 1,4-diaza-bicyclo[2,2,2]octane (0.6 mg, 0.106 
mmol) were added to the solution. After stirring at room temperature for 30 min, sat. 
aq. NaHCO3 was added. The mixture was extracted with CH2Cl2, dried over MgSO4 
and purified by silica gel chromatography (CH2Cl2 98:2) to yield 40 mg (73 %) of 
compound 4.53.  
 
1H NMR (300 MHz, CDCl3): δ 1.24-1.37 (m, 6H, 2 x CH3 (OEt)), 1.32 and 1.56  (s, 3H, 
CH3 (isopropylidene)), 2.12 (s, 6H, 2 x CH3), 4.00-4.09 (q, 4H, J = 7.0 Hz, 2 x CH2), 
4.64-4.69 (m, 1H, H-4’), 4.89 (dd, 1H, J = 4.4 and 6.4 Hz, H-3’), 5.11 (dd, 1H, J = 1.2 
and 6.2 Hz, H-2’), 5.66 (d, 1H, J = 1.2 Hz, H-1’), 5.82-5.95 (dt, 1H, JH6’-H4’ = 1.7 Hz, 
JH6’-H5’ = 17.2 Hz, H-6’), 6.10 (d, 1H, J = 7.3 Hz, H-6), 6.77-6.92 (ddd, 1H, JH5’-H4’ = 
5.6 Hz, JH5’-H6’ 17.3 Hz, JH5’-P = 22.9 Hz, H-5’), 5.99 (d, 1H, J = 7,5 Hz, H-6), 7.04 (s, 
3H, H-Ph), 7.57 (d, 1H, J = 7,3 Hz, H-5).  
HRMS (ESI-MS) C25H33N2O8PNa: [M+Na]+ 543,18751 found; 543,18722 calculated. 
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Attempted synthesis of 1-[5,6-Dideoxy-6-
(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hex-5-
enofuranosyl]uracil-4-O-(2,6-dimethylphenyl)-2-thiouracil 
(4.53): synthesis of compound 4.54. 
Lawesson’s reagent (27 mg, 0.067 mmol) was added to a 
solution of compound 4.53 (35 mg, 0.067 mmol) in dry toluene 
(1 mL). The mixture was refluxed for 3h, cooled to room temperature, concentrated in 
vacuo and purified by silica gel chromatography (CH2Cl2:MeOH 98:2) to obtain 
compound 4.54 in 20 % yield.  
 
1H NMR (300 MHz, CDCl3): δ 1.23-1.37 (m, 6H, 2 x CH3 (OEt)), 1.33 and 1.57  (s, 3H, 
CH3 (isopropylidene)), 2.13 (s, 6H, 2 x CH3), 4.04-4.14 (q, 4H, J = 7.0 Hz, 2 x CH2), 
4.69 (m, 1H, H-4’), 4.86 (dd, 1H, J = 4.4 and 6.2 Hz, H-3’), 5.11 (dd, 1H, J = 1.3 and 
6.4 Hz, H-2’), 5.68 (d, 1H, J = 1.4 Hz, H-1’), 6.02-6.15 (dt, 1H, JH6’-H4’ = 1.7 Hz, JH6’-H5’ 
16.8 Hz, H-6’), 6.10 (d, 1H, J = 7.3 Hz, H-6), 6.77-6.92 (ddd, 1H, JH5’-H4’ = 4.8 Hz, JH5’-
H6’ = 16.6 Hz, JH5’-P = 22.1 Hz, H-5’), 7.04 (s, 3H, H-Ph), 7.57 (d, 1H, J = 7,2 Hz, H-6). 
31P NMR (CDCl3): δ 15.41 
MS (m/z) C25H34N2O7PS [M+H]+: 537.4 found; 537,2 calculated. 
 
 
(Diethoxyphosphinyl)methyl triflate (4.55) 
To a stirred solution of diethyl(hydroxymethyl)phosphonate (13.6 
mmol, 2.28 g) and 2,6-lutidine (1.9 mL, 16.18 mmol) in anhydrous 
CH2Cl2 (22 mL) at -50 °C was added trifluoromethanesulfon ic anhydride (2.7 mL, 
15.7 mmol) dropwise. The resulting mixture was allowed to warm to 0 °C over 3h and 
diluted with ether. The precipitates formed were removed by filtration and the 
ethereal solution was successively washed with water and 1N HCl and then dried 
over MgSO4. After concentration in vacuo, a yellowish oil (3.5 g, 90%) was obtained, 
which was used in the next step without purification.  
 
1H NMR (300 MHz, CDCl3) : δ 1.38 (t, 6H, J = 7.1 Hz, 2 x OCH2CH3), 4.19-4.29 (m, 
4H, 2 x OCH2 CH3), 4.63 (d, 2H, J = 8.8 Hz, CH2). (The 1H NMR spectrum is 
accordance with the literature report.237) 
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[(Diethoxyphosphinyl)methyl]triphenylphosphonium triflate 
(4.56) 
Compound 4.55 (3.5 g, 12.3 mmol) was added dropwise to a 
stirred solution of triphenylphosphine (3.7 g, 14.1 mmol) in 7 mL anhydrous CH2Cl2 at 
0 °C. The mixture was allowed to warm to room tempe rature and then stirred 
overnight. The solvent was removed under reduced pressure to about one-third of 
the volume and the remaining oil triturated with ether. The white solid formed was 
collected by filtration and crystallized from EtOAc/Hexane (6.1 g, 80%).  
 
1H NMR (300 MHz, CDCl3): δ 1.12 (t, 6H, J = 7.1 Hz, 2 x OCH2CH3), 3.91-4.06 (m, 
4H, 2 x OCH2 CH3), 4.09-4.22 (dd, 2H, J = 16.1 and 20.2 Hz, CH2), 7.65-7.90 (m, 
15H, PPh3). (The 1H NMR spectrum is accordance with the literature report.237) 
 
 
[(Diethoxyphosphinyl)methylidene]triphenylphosphorane (4.57) 
To a stirred suspension of NaH (221 mg, 9 mmol) in anhydrous 
THF (9 mL) was added triphenylphosphonium triflate salt 4.56 (2.26 
g, 4.1 mmol) in anhydrous THF (9 mL) at 0 °C. The r esulting mixture was stirred at 0 
°C for 30 min. The solvent was removed under reduce d pressure and the residue 
was extracted with anhydrous CH2Cl2. After concentration of the extracts, a slightly 
yellow oil was obtained, that was used immediately as reagent for the synthesis of 
α,β-unsaturated phosphonate esters. 
 
1H NMR (300 MHz, CDCl3): δ 1.12 (t, 6H, J = 7.1 Hz, 2 x OCH2CH3), 1.27 (d, 1H, J = 
7.5 Hz, CH), 3.81-3.93 (m, 4H, 2 x OCH2 CH3), 7.40-7.74 (m, 15H, PPh3). (The 1H 
NMR spectrum is accordance with the literature report.237) 
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5.2  Binding Studies 
5.2.1 Binding studies at the A3AR 
The binding studies at the A3AR are performed under the guidance of prof. dr. 
Kenneth A. Jacobson at the Molecular Recognition Section, Laboratory of Bioorganic 
Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, 
National Institutes of Health, Bethesda, Maryland 20892, USA. 
5.2.1.1  Cell Culture and Membrane Preparation  
CHO cells expressing recombinant human ARs or the rat A3AR were cultured in 
DMEM (Dulbecco’s modified Eagle’s medium) and F12 (1:1) supplemented with 10% 
fetal bovine serum, 100 units/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/mL 
glutamine. After harvest and homogenization, the cells were centrifuged at 500g for 
10 min. The pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) containing 10 
mM MgCl2 and 1 mMEDTA. The suspension was homogenized with an electric 
homogenizer for 10 s and was then recentrifuged at 20000g for 20 min at 4 °C. The 
resulting pellets were resuspended in buffer containing 3 units/mL of adenosine 
deaminase, and the suspension was stored at -80 °C prior to the binding 
experiments. The protein concentration was measured using the Bradford assay.252 
 
5.2.1.2  Radioligand Binding Studies  
For the A3AR binding experiments, the procedures were similar to those previously 
described.195 Briefly, each tube contained 100 mL of membrane suspension, 50 mL 
of [125I]I-AB-MECA (final concentration of 0.5 nM), and 50 µL of increasing 
concentrations of compounds in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM 
MgCl2 and 1 mM EDTA. Nonspecific binding was determined using 10 µM NECA. 
The mixtures were incubated at 25 °C for 60 min. Bi nding reactions were terminated 
by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell 
harvester (Brandel, Gaithersburg, MD). Filters were washed three times with ice-cold 
buffer. Radioactivity was determined in a Beckman 5500B γ-counter. The binding of 
[3H]CCPA (2-chloro-N6-cyclopentyladenosine, [3H]1.33, Figure 1.15) to the 
recombinant hA1AR and the binding of [3H]CGS21680 (2-[p-(2-
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carboxyethyl)phenylethylamino]-5’-N-ethylcarbamoyladenosine) to the recombinant 
hA2AAR was performed as previously described.196,253  
 
5.2.1.3  Cyclic AMP Accumulation Assay 
Intracellular levels of 3’,5’-cyclic AMP were measured by the competitive protein 
binding method.216 CHO cells expressing of medium/well. After 24 h the medium was 
removed and cells were washed three times with 1 mL/well of DMEM containing 50 
mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, pH 7.4. Cells were then 
treated with recombinant human ARs 254   were harvested by trypsinization. After 
resuspension in the medium, cells were plated in 24-well plates in 0.5 mL agonists 
and/or test compounds in the presence of rolipram (10 mM) and adenosine 
deaminase (3 units/mL) and incubated at 37 °C. For the A3AR, after 45 min forskolin 
(10 µM) was added to the medium, and incubation was continued for an additional 15 
min. The reaction was terminated upon removal of the medium, and the cells were 
lysed with 200 µL/well of 0.1 M ice-cold HCl. The cell lysate was resuspended and 
stored at –20 °C. For determination of cyclic AMP p roduction, protein kinase A (PKA) 
was incubated with [3H]cyclic AMP (2 nM) in K2HPO4/EDTA buffer (K2HPO4, 150 mM; 
EDTA, 10 mM), 20 µL of the cell lysate, and 30 µL of 0.1 M HCl. Bound radioactivity 
was separated by rapid filtration through Whatman GF/C filters under reduced 
pressure and washed once with cold buffer. Bound radioactivity was subsequently 
measured by scintillation spectrometry. Calculation of the relative maximal efficacy at 
the A3AR was determined at a fixed concentration of the nucleoside analogue (10 
µM) and expressed as a relative percent of the effect of 10 µM NECA determined in 
each experiment, which typically reached ~50% inhibition of the forskolin stimulated 
cyclase. 
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5.2.1.4  [35S]GTPγS binding assay 
[35S]GTPγS binding was measured by a variation of the method described.255 Each 
assay tube consisted of 200 µL buffer containing 50 mM Tris HCl (pH 7.4), 1 mM 
EDTA, 1 mM MgCl2, 1 µM GDP, 1 mM dithiothreitol, 100 mM NaCl, 3 U/ml ADA, 0.2 
nM [35S]GTPγS, 0.004% 3-[(3-cholamidopropyl) dimethylammonio]propanesulfonate 
(CHAPS), and 0.5% bovine serum albumin. Incubations were started upon addition 
of the membrane suspension (CHO cells stably expressing the native human A3AR, 5 
µg protein/tube) to the test tubes, and they were carried out in duplicate for 30 min at 
25°C. The reaction was stopped by rapid filtration through Whatman GF/B filters, pre-
soaked in 50 mM Tris HCl, 5 mM MgCl2 (pH 7.4) containing 0.02% CHAPS. The 
filters were washed twice with 3 mL of the same buffer, and retained radioactivity was 
measured using liquid scintillation counting. Non-specific binding of [35S]GTPγS was 
measured in the presence of 10 µM unlabelled GTPγS. 
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5.2.2 Binding Studies at the P2Y2 Receptor 
The binding studies at the P2Y2 receptor are performed under the guidance of prof. 
dr. Kendall Harden at the Department of Pharmacology, University of North Carolina 
School of Medicine, Chapel Hill, NC 27599, USA. 
5.2.2.1  Assay of PLC Activity Stimulated by P2Y2, P2Y4, and P2Y6 
Receptors 
Stable cell lines expressing the human P2Y2, P2Y4, or P2Y6 receptor in 1321N1 
human astrocytoma cells were generated as described.123 Agonist-induced 
[3H]inositol phosphate production was measured in 1321N1 cells grown to confluence 
on 96-well plates. Twelve hours before the assay, the inositol lipid pool of the cells 
was radiolabeled by incubation in 200 µL of serum-free inositol-free Dulbecco's 
modified Eagle's medium, containing 0.4 µCi of myo-[3H]inositol. No changes of 
medium were made subsequent to the addition of [3H]inositol. On the day of the 
assay, cells were challenged with 50 µL of the five-fold concentrated solution of 
receptor agonists in 200 mM Hepes (N-(2-hydroxyethyl)-piperazine-N’-2-
ethanesulfonic acid), pH 7.3, containing 50 mM LiCl for 20 min at 37 °C. Incubations 
were terminated by aspiration of the drug-containing medium and addition of 450 µL 
of ice-cold 50 mM formic acid. After 15 min at 4 °C, samples were neutralized with 
150 µL of 150 mM NH4OH. [3H]Inositol phosphate accumulation was quantified using 
scintillation proximity assay methodology as previously described in detail.256 
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5.3 Molecular modeling and docking 
5.3.1 Docking Studies of Compound 3.10 
The docking studies of compound 3.10 are performed under the guidance of prof. dr. 
Kenneth A. Jacobson at the Molecular Recognition Section, Laboratory of Bioorganic 
Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, 
National Institutes of Health, Bethesda, Maryland 20892, USA. 
 
All calculations were performed on a Silicon Graphics Octane2 workstation (600 MHz 
IP30 processor, MIPS R14000). Compound 3.10 was constructed with the use of the 
Sketch Molecule of SYBYL 7.1.257,  A grid search was performed in which flexible 
bonds were rotated by 0° and 180° for t1 (C 5–C6–N6–CMe) at the N6-position, t2 
(4’O–4’C–5’C–5’OH) at the 5’-position, and t3 (N3–C2–N1’–N2’) and by 60°, 180°, and 
–60° for t4 (N 3’–C4’–CMe–CCyc) and t5 (C4’–CMe–CCyc–CCyc) at the C2-position. The 
low-energy conformers from the grid search were reoptimized, removing all torsional 
constraints. Merck molecular force field (MMFF)258 and charges were applied with the 
use of distance-dependent dielectric constants and the conjugate gradient method 
until the gradient reached 0.05 kcal·mol–1·Å–1. After clustering the low-energy 
conformers from the result of the grid search were clustered, the representative ones 
from all groups were reoptimized by semiempirical molecular orbital calculations with 
the PM3 method in the MOPAC 6.0 package.259  
 
A human A3AR model (PDB code 1OEA) constructed by homology to the X-
raystructure of bovine rhodopsin with 2.8 Å resolution (PDB codeID 1F88)222 was 
used for the docking study. All atom types were assigned by the Amber7_FF99 force 
field.260 Amber charges for protein and MMFF charges for ligand were calculated. 
The starting geometry of the ligand conformation was chosen from the human A3AR 
complex model with Cl-IB-MECA (1.9),195 which was already validated by point 
mutation. The ribose binding position was fixed, using an atom-by-atom fitting 
method for the carbon atoms of the ribose ring. To determine the binding region of 
the 2-(4-cyclopentylmethyl-1,2,3-triazole) moiety at the adenine 2-position, the 
flexible bond defining a χ1 (O–C1’–N9–C4) angle was searched while docked within 
the putative binding cavity through various low-energy conformers with diverse t1–to 
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t5 angles, rotating by –60°, –110°, and –160°, assu ming an anti conformation. 
Several conformations without any steric bump were selected for further optimization. 
The initial structures of all complexes were optimized using the Amber force field with 
a fixed dielectric constant of 4.0 and a terminating gradient of 0.05 kcal·mol–1·Å–1. 
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5.3.2 Molecular Modeling of the P2Y2 Receptor 
The molecular modeling of the P2Y2 receptor is performed under the guidance of prof. 
dr. Kenneth A. Jacobson at the Laboratory of Biological Modeling, National Institute 
of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 
Bethesda, Maryland 20892, USA. 
 
5.3.2.1  Molecular Modeling 
The published molecular model of the human P2Y2 receptor1 was updated by 
insertion of a part of the C-terminal domain including H8 helix and the N-terminal 
domain. The P2Y2 C-terminal domain (residues Gly310 – Met346) was modeled by 
homology to bovine rhodopsin. Based on the published sequence alignment1, the 
backbone atoms of the TM domain of the P2Y2 receptor were superimposed on the 
corresponding atoms of bovine rhodopsin (PDB ID = 1U19)261 using Sybyl 7.1.257 The 
rhodopsin TM domains and its hydrophilic loops (Ala26 - Met309) as well as Gly310 
of the P2Y2 receptor (last residue in the published model) subsequently were 
removed from the receptor structures. The remaining rhodopsin N-terminal (Met1 – 
Glu25) and C terminal (residues starting from Asn310) domains were connected to 
Gly22 and Ala309 of the P2Y2 receptor, respectively. The residues of the C-terminal 
domain were replaced with the corresponding residues of the P2Y2 receptor (residues 
Gly310 – Met346) using Sybyl 7.1. An attempt to apply the same technique for 
modeling of the NT domain failed due to overlap of the rhodopsin NT domain and the 
extracellular loops (EL) of the P2Y2 receptor. For this reason, the configuration of the 
P2Y2 receptor N-terminal domain (Met1 – Gly22) was predicted using the Loopy 
program from the Jackal package,262 and one thousand initial conformations were 
generated. The option of energy minimization of the generated candidates was used. 
The P2Y2 receptor model was minimized using Sybyl 7.1 in the Amber7 FF99 force 
field. The energy minimization of sidechains of the terminal domains initially was 
performed with constrained positions of all other atoms of the P2Y2 receptor until an 
energy gradient lower than 0.05 kcal·mol-1·Å-1 was reached. The minimization was 
continued without any constraints in the terminal domains, but with constraint of the 
atoms of the TM helices and hydrophilic loops. The structure then was minimized 
fixing only the backbone atoms of the TM α-helices until the energy gradient lower 
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than 0.05 kcal·mol-1·Å-1 was reached. Finally, an unconstrained energy minimization 
of the whole P2Y2 receptor model was performed until an energy gradient was lower 
than 0.05 kcal·mol-1·Å-1. The formal geometry of the model was tested using the 
ProTable command of Sybyl 7.1 as well as the Procheck software.151 
 
5.3.2.2  Molecular Dynamics Simulation of the P2Y2 Receptor 
The molecular dynamics (MD) simulation of the P2Y2 receptor was performed on the 
Biowulf cluster at the NIH (Bethesda, MD) using CHARMM 32a2 software.263 The 
protocol used for the system construction and MD simulation was described 
previously.264,265 The constructed system included the P2Y2 receptor surrounded by 
100 DOPC lipids, 5964 TIP3 water molecules, 107 Cl and K+ ions, for a total of 37,242 
atoms. The MD simulation was performed for 10 ns under conditions of CPT 
(constant pressure and temperature) as previously described.151 A hexagonal unit cell 
(69.3_69.3_85Å) and hexagonal periodic boundary conditions in all directions were 
used. For the first 4.5 ns of MD simulation, nuclear Overhauser effect (NOE) 
restraints were applied within TM7 to the distances between each backbone carbonyl 
oxygen atom of residue n, and the backbone NH-group of the residue n+4. The 
restraints were applied to all residues of TM7 with the exception of prolines and 
residues before and after prolines. MD simulation performed without such restraints 
led to a disordered secondary structure of TM7. Similar findings were described 
previously for the P2Y6 receptor.151 After 4.5 ns the MD simulation was continued 
without any restraints, and the helical structure of the TM7 remained stable until the 
end of the simulation. The typical structure of the P2Y2 receptor calculated from the 
last 100 ps of the MD trajectory was used as final model.  
 
5.3.2.3  Manual Molecular Docking 
The structure of UTP containing all hydrogen atoms initially was sketched using 
Sybyl 7.1. The ligand geometry was optimized in the Tripos force field with 
Gasteiger-Hückel atomic charges.257 Available site-directed mutagenesis data and 
previously published results of molecular modeling123,149,151 were utilized to manually 
preposition UTP, with an anti-conformation of the uracil ring and a (N)-conformation 
of the ribose ring, inside the putative binding site of the P2Y2 receptor using the 
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DOCK command of the Sybyl 7.1 package.257 The triphosphate chain of the ligand 
was placed between the R3.29, R6.55, and R7.39, while the nucleobase ring was 
located near Y1.39, Y2.53, and S7.43. The manual molecular docking procedure 
subsequently was performed in several stages. During the first stage of the molecular 
docking process, only the bonds of the ligand were flexible. When the most 
energetically favorable location and conformation of the ligand was found, the 
molecular docking procedure was repeated with flexible bonds of the receptor. 
During each iteration of the docking process the minimization of the binding site with 
the ligand inside was performed until a RMS of 0.01 kcal·mol-1·Å-1 was reached. 
Finally, the energy of the entire obtained protein-ligand complexes was minimized 
until an energy gradient lower than 0.01 kcal·mol-1·Å-1 was reached. 
 
5.3.2.4  Conformational Analysis of UTP, ATP and Their Derivatives 
The conformational analysis of the studied mononucleotides located in the putative 
binding site of the P2Y2 receptor was performed using the Monte Carlo Multiple 
Minimum (MCMM) and the mixed torsional/low-mode sampling methods 
implemented in MacroModel 9.0 software. 266  MCMM calculations initially were 
performed for UTP and all residues located within 5Å of the ligand, using a shell of 
constrained atoms with a radius of 2Å. The following parameters were used: MMFFs 
force field; water as an implicit solvent; maximum of 1000 iterations of the Polak-
Ribier Conjugate Gradient (PRCG) minimization method with a convergence 
threshold of 0.05 kJ·mol-1·Å-1; number of conformational search steps = 100; energy 
window for saving structures = 1000 kJ·mol-1. The ligand-receptor complex obtained 
after MCMM calculations was subjected to additional 100 steps of the mixed 
torsional/low-mode conformational search. The structure of UTP docked in the 
receptor subsequently was transformed to other studied UTP analogues by 
substitution of functionalities, and MCMM calculations were performed for each 
analogue, setting the number of steps to 100 and the energy window for saving 
structures to 100 kJ·mol-1 
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